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The telomeres of human chromosomes consist of long tracts of the hexanucleotide repeat 
sequence T2AG3 which help to maintain the integrity of the genome. Telomeric DNA is 
gradually lost with cellular proliferation, until the length of any given telomere reaches a 
critical level that triggers cell senescence and death. Telomere dysfunction leading to 
shortened telomeres is now implicated in a range of severe inherited premature ageing 
syndromes with reduced longevity. Average telomere length, usually measured in 
leukocytes from peripheral blood, decreases as humans age and shows considerable 
heterogeneity in the wider population. This variability is in part believed to reflect 
individual lifetime exposure to environmental, genetic and biological stressors that 
impact on telomere maintenance. Previous research suggests that these stressors increase 
the rate of telomere shortening with potential impact on age-related disease and mortality 
later in life. Thus there is interest in the application of telomere length measures as a 
biomarker of general health or “biological age”, and the possibility of using mean 
telomere length to gauge individual disease risk, and to promote lifestyle changes to 
improve health. The principle aim of this thesis was to explore the impact of 
environmental and genetic factors on telomere length, with the additional aim of 
developing improved methods for accurately measuring telomere length. 
 
Establishment of the monochrome multiplex quantitative polymerase chain reaction 
(MMQPCR) assay for measuring average telomere length proved problematic on the 
Roche LightCycler® 480 qPCR platform. Temperature heterogeneity across the Peltier 
block led to severe position effects resulting in high assay variability which impacted on 
the T/S ratio. Therefore, this assay was abandoned. A modified form of the original two-
plate qPCR assay was determined to be more compatible with this platform, with the 
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choice of hot-start Taq polymerase, intercalating dye, and careful attention to quality 
control of the assay revealed as critical factors. This assay was validated by comparison 
with the gold standard, TRF (Terminal restriction fragment) method.  
 
The modified telomere length assay was then applied to two longitudinal cohorts, the 
Christchurch Health and Development Study (CHDS) and the Canterbury Health, Ageing 
and Life Course (CHALICE) study. Extensive phenotypic data were available to 
comprehensively assess the effect of life course stressors on telomere length. No 
associations were found in either cohort between telomere length and life course stress, 
although for the CHDS cohort, Māori and Pacific Island participants were found to have 
a significantly higher average leukocyte telomere length than Caucasians. For the 
CHALICE cohort, the only significant association observed was between telomere length 
and gender, with females having longer telomere length than men.  
 
Whole exome analysis was used to assess the potential impact of rare genetic variation 
on telomere length in six subjects from the CHALICE cohort who had the shortest 
telomeres. The top fifteen variants arising from this analysis were genotyped in the entire 
CHALICE cohort to determine if they were over-represented in individuals with short 
telomeres. Two variants reached statistical significance but were found to be very rare in 
this cohort, and would need to be followed up in a larger cohort before any firm 
conclusion could be drawn about their relevance to telomere length.  
 
Finally, attempts were made to develop a novel method of accurately measuring telomere 
length by directly counting the telomeric repeats from individual chromosomes using the 
MinIONTM nanopore sequencer. Preliminary data demonstrated that some telomere 
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repeats were detectable, but the method was error prone with few perfect consecutive 
repeat sequences obtained. Nanopore sensing holds some potential as an alternate 
approach for measuring telomere length, but further advances in the sequencing 
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Chapter 1: General introduction overview 
Telomeres are complex ribonucleoprotein structures at the end of linear chromosomes 
distinguished by long tracts of the hexanucleotide repeat sequence T2AG3, and the 
presences of specific binding proteins and noncoding RNA (TERRA). These structures 
help to maintain the integrity of the genome by providing protection from DNA damage 
and degradation [Blackburn and Gall 1978, Greider 1996]. Cellular proliferation 
progressively shortens telomeric DNA due to the inability of DNA polymerase to 
replicate the ends of DNA molecules, eventually reducing the telomere to a critical length 
triggering replicative senescence and apoptosis. When telomeres reach a critically short 
length they can no longer provide their protective function, which is thought to have an 
impact on disease states and mortality later in life [Harley et al. 1990]. 
1.1 Ageing 
Ageing and age-associated pathologies are complex, multidimensional processes of 
physical, psychological and social changes. They are associated with an overall decline 
in the functional capacity of tissues and stem cells and are one of the largest known risk 
factors for most human diseases, including cardiovascular disease and cancer. Due to 
their involvement in cellular senescence, telomeres have now been implicated in the 
ageing process [Shay and Wright 2007, López-Otín et al. 2013]. 
1.1.1 Historical view 
Leonard Hayflick demonstrated that cells in vitro have a limited proliferative potential 
before they enter a senescence phase, now known as the Hayflick limit. This suggested 
an ageing mechanism at the cellular level which limits the cell’s replicative ability 
[Hayflick and Moorhead 1961, Hayflick 1965]. Watson proposed that this phenomenon 
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resulted from semi-conservative DNA replication and the ‘end replication problem’ 
(Figure 1.1). DNA synthesis proceeds in a 5’ to 3’ direction and RNA primers are 
required by DNA polymerase for the syntheses of the lagging strand [Watson 1972]. 
RNA primers located close to the ends of DNA molecules, such as at telomeres, are 
removed but cannot be replaced by DNA synthesis, resulting in the loss of around 50-
150 bp on the 5’ end in each successive division [Martens et al. 2000]. Olivnikov further 
suggested that this would progressively shorten the length of the telomere, and that this 
mechanism would result in replicative senescence [Olovnikov 1973]. This was the first 
link between telomeres and ageing, and now telomere shortening is thought to be a major, 
measurable molecular characteristic of ageing cells, reflecting the biological age of an 




Figure 1.1. End replication problem 
DNA synthesis proceeds in a 5’ to 3’ direction where RNA primers are required by DNA 
polymerase for the synthesis of the lagging strand (A). The end replication problem 
occurs due to the inability of DNA polymerase to completely copy the lagging strand of 
DNA. Short sequences of RNA are synthesised to prime lagging strand replication by 
way of Okazaki fragments (B). DNA polymerase converts the RNA (from the primers) 
to DNA, and DNA ligase seals the gaps between the Okazaki fragments, producing an 
intact DNA molecule (C) Eventually the last RNA primer is removed and cannot be 
replaced by DNA, resulting in the loss of around 50-150 bp on the 5’ end of the telomere 
during each cycle of replication (D).  
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1.2 Telomere structure and function 
1.2.1 Sequence characteristics 
Telomere sequences from the ciliated protozoan Tetrahymena thermophila were the first 
to be elucidated, and were found to consist of tandem hexaucleotide repeat sequences 
(T2G4)n, with the length of the telomere varying from 20 to 70 repeats [Blackburn and 
Gall 1978]. The human telomere sequence was identified ten years later and consisted of 
the repeat sequence (T2AG3)n [Moyzis et al. 1988] with an average length of 10-15 kb, 
which is now known to be conserved in all vertebrates [Meyne et al. 1989]. Furthermore, 
the sequence of the sub-telomeric region, which is proximal to the telomere, is 
chromosome-specific. Although the sequence of the telomere differs amongst species, 
they are all located at the ends of chromosomes, consist of tandem repeats of short G-
rich sequences that vary in number, and have a conserved function. Beyond the 
vertebrate, there are some exceptions to the conventional telomere, as many yeast species 
have short complex sequences whereas Drosophila melanogaster have retrotransposable 
elements as their telomeres [Shampay et al. 1984, Pardue and DeBaryshe 2008, Giardini 
et al. 2014]. The telomeric sequence motif alone is not sufficient for the functioning of 
the telomere. 
1.2.2 Structural characteristics 
The double-stranded telomeric DNA ends in a 3’ G-rich single-stranded overhang 
approximately 150-300 nucleotides in length (Figure 1.2, A) [Makarov et al. 1997, 
Wright et al. 1997]. This single-stranded overhang is essential for formation of telomere 
higher order structure, and to enable them to accomplish their protective function. 
Telomeres are highly dynamic, forming both closed and open structures at different 
stages of the cell cycle depending on the requirements of the cell, such as DNA synthesis 
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or telomere extension. Typically, telomeric DNA is maintained in a complex loop 
structure (t-loop) which obscures the vulnerable single-stranded ends of the chromosome 
[Neidle and Parkinson 2003]. The t-loop is a lariat like structure that forms when the 3’ 
single-stranded overhang loops back and invades the upstream telomeric duplex DNA; 
this displaces the duplex DNA forming a triple stranded displacement loop (d-loop) via 
base pairing (Figure 1.2, B) [Griffith et al. 1999]. This specialised structure is stabilised 
by telomere-specific single and double-stranded binding proteins, known as the shelterin 
proteins. The human shelterin complex consists of the six proteins TRF1, TRF2, POT1, 
RAP1, TIN and TPP1 [de Lange 2005]. Not only does the shelterin complex mask 
telomeres to prevent recognition by cellular DNA repair processes but it is also directly 





Figure 1.2. Structure of the telomere 
Telomeres form higher order structures as they are composed of both double and single 
stranded DNA, which can assume different confirmations. A: As a result of the end 
replication problem, the double stranded telomeric DNA ends in a 3’ G-rich single-
stranded overhang approximately 150-300 nucleotides in length. B: The single-stranded 
overhang forms a T-loop lariat-like structure that obscures the vulnerable DNA ends, by 
invading the upstream telomeric duplex DNA, forming a triple stranded displacement 
loop (d-loop) by base pairing. C: G-quadruplex structures can also form at the single-
stranded, guanine rich ends of the chromosomes. This configuration forms between 
groups of four guanine bases that are stabilised by Hoogsteen hydrogen bonding. From 
[Giardini et al. 2014]. Reprinted with permission from Elsevier.  
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1.2.2.1 G-quadruplexes (G4s) 
In addition to those described above, other complex structures have been observed to 
form in the G-rich single-stranded telomeric DNA in vitro and in vivo (Figure 1.2, C) 
[Sen and Gilbert 1988, Sundquist and Klug 1989]. G-quadruplexes (G4) are a type of 
non B-DNA structure which can form at repetitive G-rich motifs through Hoogsteen 
bonds rather than the traditional base pairing. The association of four guanines results 
in a square-planar arrangement (G-tetrad), where multiple G-tetrads then stack above 
each other to form a G4. They are evolutionary conserved structures and can assume 
several conformations. Telomeric G4s appear to have regulatory roles in telomere 
elongation and maintenance by rendering the G-rich single-stranded overhang 
inaccessible to telomerase, thus inhibiting telomere extension [Bochman et al. 2012, 
Pagano et al. 2015]. Furthermore, they may also contribute to t-loop stabilisation and the 
suppression of DNA damage signals when the telomeric proteins have been displaced 








Figure 1.3. Telomere structure 
Structure of the human telomere. A: Telomeric DNA consists of a long double stranded 
DNA tract of tandem repeats, terminating in a single-stranded G-rich overhang. B: 
Telomeric DNA is packaged by histones into chromatin, and is bound by telomeric 
binding proteins (shelterin complex - TRF1, TRF2, Rap1, TIN2, TPP1 and POT1) which 
bind to both single and double stranded DNA. The telomerase complex is also shown, 
which is recruited to the distal end of the telomere. From [Sandin and Rhodes 2014]. 





1.2.3 Telomere function 
Hermann Muller [Muller 1938] and Barbara McClintock [McClintock 1941] provided 
the first insight into the function of telomeres in two different species, Drosophila 
melanogaster and maize respectively. Using X-ray irradiation to generate chromosomal 
rearrangements, they independently established that the ‘natural ends’ of linear 
chromosomes were not only structurally different from the rest of the chromosome, but 
that they also behaved differently. DNA breaks and deletions were observed along the 
chromosomes but not at the ends, which instead fused to each other or to other broken 
chromosomes. Muller concluded that they must have a special protective function and 
thus postulated the first insight into the role of the telomere. He named them telomeres 
from the Greek word end (telos) and part (meros) to highlight their uniqueness and 
distinguish the termini from the rest of the chromosome. 
 
Through the t-loop conformation, the telomeric DNA forms a protective cap which 
allows telomeres to be distinguished from double-stranded breaks and suppresses the two 
major DNA damage-sensing pathways, ATM and ATR, as well as two major DNA repair 
pathways, homologous recombination (HR) and non‐homologous end joining (NHEJ). 
These processes would otherwise cause chromosome breakage upon mitosis, resulting in 
genomic instability [Griffith et al. 1999, Blackburn 2001]. Furthermore, telomeres are 
needed to compensate for the end replication problem and prevent loss of genetic material 
that resides near the ends of the chromosome that would otherwise be lost as a result of 
cellular proliferation [O'Sullivan and Karlseder 2010]. However, extensive telomere 
attrition to a critically short length appears to trigger replicative senescence, and once 
that occurs, telomeres become de-protected and can no longer form specialised structures 
to carry out their protective function [Greider 1996]. This attrition can lead to telomeres 
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as short as 12.5 TTAGGG units before chromosomal fusion occurs [Capper et al. 2007] 
and in telomerase-positive cells, functional telomeres have been detected as short as 
seven repeat units [Xu and Blackburn 2007]. Furthermore, in human fibroblasts it has 
recently been shown that the critical threshold for senescence to occur is five 
dysfunctional telomeres in a single nucleus [Kaul et al. 2012]. 
 
In addition to their protective function, telomeres are involved in several important 
cellular processes including mitosis, meiosis and carcinogenesis. Telomeres enable the 
faithful segregation of genetic material into daughter cells by playing an important role 
in tethering the chromosomes to the nuclear envelope and helping to position the 
chromosomes and promote homologous recognition and pairing [Calderon Mdel et al. 
2014, Ishiguro et al. 2014, Ohishi et al. 2014, Zhang et al. 2014, Viera et al. 2015]. 
Telomeres also act as molecular switches that can rapidly stop cell cycle progression in 
response to a variety of stressors including oncogenic signals, and thus act as tumour 
suppressors by limiting the cell’s capability to divide [Suram and Herbig 2014].  
1.2.4 Telomerase 
In 1985, Carol Greider and Elizabeth Blackburn discovered a compensatory mechanism 
for telomere shortening, and in 2009 they were awarded the Nobel Prize for this research 
[Greider and Blackburn 1985, 1989, Greider 2006]. This process was originally observed 
in experiments whereby native linear DNA from the ciliated protozoan Tetrahymena 
thermophila introduced into yeast was maintained for generations by the addition of yeast 
telomeric DNA (TG1–3) instead of the Tetrahymena (T2G4 or T4G4) telomeric repeat 
[Szostak and Blackburn 1982, Shampay et al. 1984]. These results indicated the existence 
of a mechanism that was able to add de novo telomere repeats to the termini of the 
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chromosome. They identified this enzyme as ‘terminal transferase’ which is now known 
as telomerase [Greider and Blackburn 1985]. 
 
Telomerase is a ribonucleoprotein complex which consists of a catalytic reverse 
transcriptase core protein (TERT), an RNA component (TERC, also referred to as TR), 
which provides the template for repeat synthesis, and the H/ACA snRNP member 
dyskerin (DKC1). Telomerase and its components are conserved amongst different 
eukaryotes. The telomeric 3' G-rich overhang serves as an anchor for telomerase binding 
by pairing with the telomerase RNA subunit. This enables complementary telomeric 
DNA to be added to the 3’ end of the telomere for de novo synthesis and elongation of 
the telomere. Once the telomeres are replicated by telomerase, the 5’ end is synthesised 
by conventional DNA replication machinery [Greider and Blackburn 1985, 1989].   
 
Human TERC (hTERC) is ubiquitously expressed in germ cells and stem cells [Feng et 
al. 1995], and telomerase activity is limited by the expression of hTERT [Wright et al. 
1996] [Takakura et al. 1998, Ducrest et al. 2002]. Telomerase is typically repressed in 
most human somatic tissues shortly after birth [Kim et al. 1994] and as a consequence 
these tissues cannot regenerate telomere length (TL). An exception to this, however, is 
that telomerase is up-regulated in certain highly proliferative cells such as the skin, 
intestine, bone marrow, dividing lymphocytes, ovaries and testes [Wright et al. 1996]. 





1.3 Telomere length 
1.3.1 Maintenance and regulation 
Telomere length maintenance and regulation is a highly coordinated, intricate process in 
homeostatic balance, with TL ultimately determined by the combined effect of elongating 
and shortening processes. Maintenance and regulation is dependent on the telomere’s 
higher order structure and whether it is accessible by telomerase. Two mechanisms are 
known to maintain TL; these are telomerase activity and alternative lengthening of 
telomeres (ALT), which are predominantly regulated by the shelterin proteins and long 
non-coding RNA [Greider 1996, Smogorzewska and de Lange 2004].  
1.3.1.1 Telomere proteins 
Telomerase activity is extensively regulated due to the important role it plays in the 
maintenance of genome integrity. The length of each individual telomere is monitored 
and tightly regulated within a narrow range [Palm and de Lange 2008]. In humans the 
key protein involved is the TTAGGG repeat binding factor 1 (TRF1). TRF1 binds along 
the double-stranded telomeric tract, acting in cis to block telomerase from binding and 
forming part of a negative feedback loop inhibiting telomere elongation. The number of 
TRF1 proteins bound to the telomere is proportional to its length, essentially providing a 
‘protein counting mechanism’ that is presumed to affect chromatin structure by allowing 
the telomeres to switch between telomerase extendible and non-extendible states [van 
Steensel and de Lange 1997, Blackburn 2000, Smogorzewska et al. 2000, Ancelin et al. 
2002, Smogorzewska and de Lange 2004]. As a consequence, only a subset of telomeres 
are elongated during each cell cycle, where telomerase preferentially elongates shorter 




However, not only is the elongation of short telomeres important for proper cellular 
proliferation but the shortening of excessively long telomeres is equally as important. 
Long telomeres are vulnerable to replication slippage, stalled replication forks, and the 
formation of secondary structures which can disturb normal cell cycle progression. In 
both cancer and primary human cells telomere trimming occurs, a process whereby TL 
is rapidly decreased by the cleavage of the entire t-loop (Section 1.2.2) from the end of 
the telomere, generating a t-circle [Lustig 2003, Pickett et al. 2009, Pickett et al. 2011, 
Chang 2012]. To a lesser extent, nucleases (Exo1 and Apollo) can trim the C-rich strand 
of telomeres in order to restore the 3’ overhang [Henderson and Blackburn 1989, Wu et 
al. 2012]. However, telomere trimming can be counteracted by the CST (CTC1-STN1-
TEN1) complex [Miyake et al. 2009, Surovtseva et al. 2009, Chen et al. 2012, Chen and 
Lingner 2013]. In addition, hTERT both shortens excessively long telomeres and 
elongates short telomeres simultaneously in one cell to maintain the optimal TL at each 
chromosomal end for efficient protection [Zheng et al. 2014]. 
1.3.1.2 Alternative lengthening of telomeres (ALT)  
Approximately 10% of cancer cells adopt the non-telomerase mechanism known as 
alternative lengthening of telomeres (ALT) to maintain their telomeres [Bryan et al. 1997, 
Reddel et al. 1997]. ALT positive cells have a characteristic heterogeneous TL phenotype 
ranging from less than 3 kb to over 50 kb, in contrast to telomerase positive cells that 
have a more homogeneous length around 10 kb [Bryan et al. 1995]. Due to the TL 
dynamics seen in these cells, it has been proposed that a recombination-based mechanism 
is involved, whereby these cells use either other telomeres or their own t-loop structure 
as a template [Dunham et al. 2000]. How normal cells repress the ALT pathway is still 
unknown, but the activation of ALT appears to involve the loss of one or more of these 
normal repressor functions [Henson et al. 2002, Cesare and Reddel 2010, Napier et al. 
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2015]. The ALT pathway is most prevalent in sarcomas and glioblastomas [Aeby and 
Lingner 2015]. Both ALT and telomerase pathways can operate within cultured cells and 
tumours, which means that the design of effective anticancer therapeutics targeted at 
telomere maintenance is challenging [Perrem et al. 2001].  
1.3.1.3 Telomere RNA regulation of telomere length (TERRA) 
Originally, telomeres were believed to be transcriptionally silent. However, it was 
recently discovered that telomeric DNA is transcribed into the long non-coding RNA 
Telomeric Repeat-containing RNA (TERRA) which is believed to be another 
telomerase-dependent mechanism of TL regulation. Similar to TL, TERRA RNAs are 
heterogeneous in length and range between 100 and 9000 nucleotides of the repeat 
sequence UUAGGG in mammals [Azzalin et al. 2007]. TERRA plays a key role in 
maintaining telomeric architecture through interaction with several telomeric binding 
proteins: (TRF1, TRF2), origin recognition complex (ORC), HP1, and H3K9me3. The 
transcription of TERRA is dependent on a variety of factors including TL, chromatin 
structure, and cell cycle stage. It is generally accepted that TERRA is transcribed from 
short telomeres, and it recruits telomerase to elongate the telomere from which the 
transcript originated. Once telomeres are elongated, the transcription of TERRA is 
inhibited. Therefore, TERRA represses its own expression by negative feedback upon 
telomere elongation [Azzalin et al. 2007, Wang et al. 2015].  
1.3.2 Telomere length heterogeneity 
The length of the telomere is determined by a combination of inherited and regulatory 
factors and as a consequence shows a substantial amount of heterogeneity [de Lange et 
al. 1990]. To begin with, TL is species specific. Rodents have long telomeres of up to 
150 kb [Kipling and Cooke 1990, Starling et al. 1990, Makarov et al. 1993], and in 
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comparison, human telomeres range in size from 2-30 kb [Cooke and Smith 1986, de 
Lange et al. 1990]. Additionally, there is considerable variation within a given 
population. Sex and ethnicity are contributors, with shorter TL associated with males and 
European ethnicity (longer in Africian-Americans) [Hunt et al. 2008, Zhu et al. 2011, 
Sanders and Newman 2013]. The strength of the assocaition between gender and TL 
varied by the method of TL measurement used [Gardner et al. 2014] and sex-related 
differences have not been observed to be present at birth [Okuda et al. 2002]. Telomere 
length is a highly heritable trait [Slagboom et al. 1994, Nordfjall et al. 2005], with a 
recent meta- analysis of 19,713 subjects estimating the heritability to be 0.7 [Broer et al. 
2013]. Further evidence to support the heritability of TL comes from the disease 
dyskeratosis congenita, whereby the offspring of patients have increasingly short 
telomeres in successive generations [Vulliamy et al. 2004, Bessler et al. 2007].  
 
It has also been suggested that older paternal age at conception is correlated with longer 
leukocyte telomere length (LTL) in offspring [De Meyer et al. 2007, Njajou et al. 2007, 
Kimura et al. 2008a, Aviv and Susser 2013, Hjelmborg et al. 2015a]. This is thought to 
occur as TL is actively elongated by telomerase during spermatogenesis, whereby the 
longer LTL in the offspring is believed to reflect the age-related elongation in the fathers’ 
sperm [Unryn et al. 2005, Kimura et al. 2008a]. 
 
Lastly, at the cellular level, TL differs between tissues and cell types [Dlouha et al. 2014] 
as a result of cell proliferation capacity, cellular environment, epigenetic factors and 
disease state [Shay and Wright 2007]. Telomere length is found to be longest in the 
muscle and shortest in leukocytes [Daniali et al. 2013]. Chromosome-specific TL has 
also been observed within a single cell [Lansdorp et al. 1996, Martens et al. 1998, 
Londono-Vallejo et al. 2001] and TL is positively correlated with chromosomal length. 
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There is also evidence that the telomeres of homologous chromosomes have differing 
lengths, and furthermore, the length is found to differ between the p and q arms within 
the same chromosome [Martens et al. 1998, Graakjaer et al. 2003].  
1.3.3 Telomere dynamics and age dependent erosion 
It is established that TL decreases with age, but instead of a steady decline throughout 
life, it is a dynamic process with age-dependent attrition being observed (Figure 1.4). 
Initially there is a sharp decline in TL between 6 and 7 weeks of gestational age, but it 
then stabilises until birth [Cheng et al. 2013]. A rapid decline in TL of about > 1 kb per 
year is observed after birth, due to the fast rate of growth and development at this stage 
of life [Frenck et al. 1998, Rufer et al. 1999]. This rate of decline continues until 
approximately four years of age. After this, the erosion rate plateaus until young 
adulthood when it begins to steadily decrease at a rate of about 100 bp/yr thereafter 
[Frenck et al. 1998], although this has only been shown in cross-sectional data [Aubert 
2014]. Surprisingly, TL has been observed to shorten at equivalent rates in the somatic 
tissues of adults regardless of proliferative potential, suggesting that differences in TL 
are established in early life [Daniali et al. 2013]. This is further supported by results from 
a recent longitudinal study where over a 12-year period TL was found to track throughout 
adulthood and individuals generally retained their ranking, i.e., those with long/short 
LTL at baseline displayed long/short LTL as they aged. Recently, it has been proposed 
that the rate of LTL attrition throughout adulthood is actually heritable with little or no 









Figure 1.4. Telomere length dynamics and ageing in somatic cells 
A model of TL dynamics is shown where the length declines at different rates throughout 
life. A sharp decline is observed at 6-7 weeks of gestational age which then stabilises 
until birth at which time a wide distribution is seen between individuals. The decline in 
telomere length is the most pronounced in the first years of life with an approximate 
decrease of > 1 kb per year until about four years of age due to rapid growth and 
development of the organism. Following this, the erosion rate plateaus until young 
adulthood where there is a steady decline of about 100 bp/yr thereafter. Figure adapted 
from [Aubert 2014].  
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1.3.4 Factors influencing telomere length 
Together, the end-replication problem and exonuclease activity only partially account for 
the loss of telomeric DNA observed experimentally, and therefore it was suggested that 
other mechanisms may be involved in accelerating telomere shortening [Lin et al. 2012, 
Sanders and Newman 2013]. This has given rise to many studies examining links between 
average TL and various genetic, environmental, and biological factors.  
1.3.4.1 Genetics 
Telomere length is strongly influenced by genes, as evidenced by the high heritability 
(Section 1.3.2). Several genome-wide association studies (GWAS) have revealed 
associations between LTL and common genetic variants [Mangino et al. 2009, Codd et 
al. 2010, Levy et al. 2010, Prescott et al. 2011, Mangino et al. 2012, Codd et al. 2013, 
Pooley et al. 2013, Stathopoulou et al. 2015]. Generally, variants were found in genes 
already known to be involved in telomere biology, with the majority of variants only 
having a small effect on TL. TERT variants, for example, have one of the strongest effects 
but only show a decrease in average LTL of about 200 bases per variant allele of TERT 
[Levy et al. 2010, Mangino et al. 2012]. These findings suggest that in humans, LTL is 
altered by a large number of common genetic variants with small individual effect sizes. 
To date, however, the most robust associations have been with TERC and OBCF1 
variants [Mangino et al. 2012]. A limitation in the current GWAS is that results have not 
been highly reproducible. This could be attributed to the studies using various genotyping 
chips, subjects of different ethnicity, and different TL measurement methods, all of which 




Telomere length has now been extensively studied in association with numerous 
phenotypes and health risk factors in cross-sectional epidemiologic studies. The initial 
studies focused on factors such as smoking [Valdes et al. 2005, McGrath et al. 2007], 
alcohol consumption [Pavanello et al. 2011, Harris et al. 2012] and body mass index 
[Nordfjall et al. 2008, Buxton et al. 2011] and have now been extended to include factors 
such as socio-economic status [Needham et al. 2013], childhood abuse [Glass et al. 2010, 
Kananen et al. 2010, Tyrka et al. 2010, Shalev et al. 2013b] and psychosocial factors 
[Epel et al. 2004, Damjanovic et al. 2007, Parks et al. 2009].  
 
To date, however, results have been inconclusive and associations have been weak with 
positive and negative associations being made for similar phenotypes in different studies. 
This is highlighted in a recent study by Weischer et al (2014) that examined associations 
between TL and smoking, body weight, physical activity and alcohol intake in 4,576 
individuals in the general population both cross-sectionally, and with a 10-year follow-
up measurement. They found that with the first measure alone, TL was associated with 
current smoking, increased BMI and physical activity but not alcohol intake. After the 
second examination they found that 56% of participants lost and 44% gained TL and that 
the original associations disappeared [Weischer et al. 2014].  
 
The effects of smoking on telomere attrition have been extensively studied as smoking 
has very significant effects on health, is typically measured in clinical studies, and 
increases levels of oxidative stress which have been shown to accelerate telomere erosion 
(discussed below) [Valdes et al. 2005]. The initial study [Valdes et al. 2005] found a 
dose-dependent relationship between smoking and the decrease in TL, where each pack-
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year smoked was equivalent to 5 bp of TL lost. Since then there have been additional 
studies supporting this association [Morla et al. 2006, Bekaert et al. 2007, McGrath et al. 
2007, O'Donnell et al. 2008, Mirabello et al. 2009, Needham et al. 2013], although not 
all studies have replicated these findings [Harris et al. 2006, Fitzpatrick et al. 2007, 
Farzaneh-Far et al. 2008, Nordfjall et al. 2008, Houben et al. 2009, Cassidy et al. 2010, 
Harris et al. 2012], including two longitudinal studies that assessed TL erosion 
[Ehrlenbach et al. 2009, Weischer et al. 2014].  
 
It has been suggested that concentrating on the environmental factors that influence TL 
at birth and during the growth and development stage may be of more significance as this 
is when TL is influenced the most, and effects appear to be propagated throughout 
adulthood [Entringer et al. 2012, Shalev et al. 2013a].  
 
Research to date has been predominantly based on cross‐sectional studies where it has 
been argued that inconclusive results are due to limitations in study design, sample 
number and methodology used. The lack of longitudinal studies with long term collection 
of data in a prospective fashion has been a limiting factor, as well as the sensitivity of the 
TL measurements. So in order to elucidate the effect of environmental stressors and TL, 
more research is required. Nonetheless, there is a general agreement that environmental 
stressors increase telomere attrition rate [Aviv et al. 2006, Sanders and Newman 2013]. 
 
Telomere attrition has been linked to exposure to high oxidative stress and inflammation, 
both of which are considered to be important drivers of ageing. In vitro and in vivo evidence 
indicates that TL shortens with increasing oxidative stress at a faster rate than that of 
replication [von Zglinicki 2000, Von Zglinicki 2002, Houben et al. 2008]. This was first 
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shown in human diploid fibroblasts cultured under normal conditions where telomere 
shortening occurred as a result of single-stranded breaks caused by oxidative stress [Chen et 
al. 1995, Richter and von Zglinicki 2007]. Telomeres are highly sensitive to damage by 
oxidative stress due to their high content of guanine residues [Oikawa and Kawanishi 1999]. 
These breaks are repaired less efficiently compared to the rest of the genome due to a 
deficiency in base excision repair, most likely causing a temporary stalling of the replication 
machinery and thus the shortening of the telomere [Petersen et al. 1998]. Therefore, oxidative 
stress is believed to arise as a consequence of environmental factors, and modulate TL by 
increasing the attrition rate. In addition, chronic inflammation and stress hormones such as 
cortisol have also been shown to accelerate attrition rate [Epel et al. 2006, O'Donovan et al. 
2011b, Tomiyama et al. 2012]. This is especially evident in several inflammatory diseases 
such as atherosclerosis, Alzheimer’s disease, and chronic obstructive pulmonary disease, 
which are shown to have short telomeres [Samani et al. 2001, Thomas et al. 2008, Aviv 2009, 
Houben et al. 2009, Savale et al. 2009, Salpea and Humphries 2010]. 
1.4 Telomere dysfunction and disease 
As telomeres play an essential role in genomic stability and cellular ageing, it is not 
surprising that telomere dysfunction is associated with disease, and in particular, age-
related diseases [Blasco 2005]. This has become a very prominent area of research since 
Harley et al., (1990) first proposed the idea that telomere shortening is directly related to 
the ageing process, thus instigating the first association with telomeres and disease 
[Harley et al. 1990]. Cawthon et al., 2003 further confirmed this initial theory and 
reported the first association between shorter LTL and increased risk of death. This study 
was conducted in individuals aged 60 years and found an increased mortality rate from 
heart disease and infectious diseases in those with shorter LTL compared to participants 
with longer telomeres, although this was based on a relatively small sample size of n = 
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143 [Cawthon et al. 2003]. Subsequent studies have reported mixed results, with some 
showing an increased mortality rate with shortened telomeres [Bakaysa et al. 2007, 
Kimura et al. 2008b, Ehrlenbach et al. 2009, Epel et al. 2009b], whereas others have not 
[Martin-Ruiz et al. 2005, Bischoff et al. 2006, Harris et al. 2006, Fitzpatrick et al. 2007, 
Njajou et al. 2009], however, it was argued that the age of the participants in different 
studies was a contributing factor to differences in research outcomes. A recent study of 
64,637 participants found that short telomeres were associated with higher rates of 
mortality [Rode et al. 2015]. In contrast, Weischer et al., (2014) looked at mortality and 
morbidity and found that TL did not associate prospectively with these factors in 4,576 
individuals from the general population [Weischer et al. 2014]. Overall, LTL seems to 
be weakly associated with mortality, but it is clear that more research needs to be 
conducted in this area.  
 
Additionally, TL has now been examined in a wide variety of diseases including 
cardiovascular disease, type-II diabetes and various mental disorders including 
depression and schizophrenia. However, these data were primarily derived from case-
control studies, which could be subject to reverse-causation bias, and it is unclear whether 
TL measures add any additional prognostic information for these complex diseases over 
the biomarkers currently used. 
1.4.1 Mutations and disease  
The observation of children with phenotypes resembling premature ageing provided the 
first causal link between telomere dysfunction, accelerating telomere erosion, and 
premature ageing syndromes [Armanios and Blackburn 2012]. The initial discovery 
came from studies of the rare monogenic disorder dyskeratosis congenita [Mitchell et al. 
1999, Dokal 2000, Vulliamy et al. 2001, Vulliamy et al. 2004]. The disease presents early 
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in life and leads to premature death, primarily due to bone marrow failure. Patients were 
found to have very short telomeres and it was later discovered that they carried X-linked 
mutations in DKC1 that encodes dyskerin, an essential component of the telomerase 
haloenzyme [Heiss et al. 1998] [Vulliamy et al. 2001]. Measuring TL in these patients 
has now been adopted in clinical practice, with shortened telomeres being one of several 
diagnostic criteria used to help inform treatment decisions. Interestingly, because of their 
susceptibility to genomic instability, patients with dyskeratosis congenita also have an 
increased incidence of cancer [Alter et al. 2009].  
 
Since the initial discovery of mutations in DKC1 leading to telomere shortening, several 
rare, inherited germ-line genetic mutations have been identified (Table 1.1) that alter 
telomere biology, and the resulting conditions are referred to as ‘telomeropathies’. These 
include a myriad of diseases such as aplastic anemia, idiopathic pulmonary fibrosis, 
Hoyeraal-Hreidersson syndrome, Coats plus syndrome and Revesz syndrome [Savage 
and Bertuch 2010, Savage 2014]. They arise from monogenic, compound or de novo 
mutations, resulting in a wide spectrum of clinical phenotypes with variable penetrance, 
severity and time of onset. Not only do these mutations result in shortened telomeres, 
they also increase the rate of telomere fusions and telomeric DNA breaks [Calado and 
Young 2009, Armanios and Blackburn 2012]. They are defined as accelerated ageing 
disorders leading to proliferative failure in a variety of tissues, especially in the bone 
marrow, lung and liver, and organ failure is the main cause of death [Young 2012, 
Holohan et al. 2014, Townsley et al. 2014]. Additionally, some families with these 
inherited syndromes can display genetic anticipation, whereby the age of onset decreases 
and the severity of symptoms increases in successive generations due to the inadequate 
repair of telomeres in germ cells [Vulliamy et al. 2004]. To date, tissue or organ 
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transplant is the only curative therapy for telomeropathies [Young 2012, Isoda et al. 
2013]. Furthermore, loss-of-function mutations in the telomerase subunits is sufficient to 
reduce telomerase activity, indicating haplo-insufficiency, whereby a single functional 




Table 1.1. Known genes involved in telomere disease 
Gene Protein name(s) Function Chr locus Year 
reported 
 MIM #  Inheritance  Disorder(s) 
DKC1 Dyskerin  Plays an active role in telomerase stabilization 
and maintenance 
Xq28  1998 300126 XLR DC, HH 
TERC Telomerase RNA 
component  
RNA component of telomerase complex that 
serves as a template for the telomere repeat. 
3q26.3  2001 602322 AD  DC, SAA, 
PF, LD 
TERT Telomerase reverse 
transcriptase  
Reverse transcriptase activity of telomerase 
complex 






family A,member 3 
A member of the H/ACA snoRNPs (small 
nucleolar ribonucleoproteins) gene family. 
snoRNPs are involved in various aspects of 
rRNA processing and modification. 






Encodes one of the proteins of the shelterin 
complex which protects telomeres by 
allowing the cell to distinguish between 
telomeres and regions of DNA damage. 





family A, member 2  
A member of the H/ACA snoRNPs (small 
nucleolar ribonucleoproteins) gene family. 
snoRNPs are involved in various aspects of 
rRNA processing and modification. 





antisense to TP53; 
telomerase Cajal 
body protein 1 
Encodes an essential component of the 
telomerase holoenzyme complex. Interacts 
with dyskerin, TERT and TERC, other 
components of active telomerase, and with 
small Cajal body RNAs (scaRNAs), which 
are involved in modifying splicing RNAs. 
17p13.1  2011 612661 AR  DC 
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CTC1  Conserved telomere 
maintenance 
component 1 
Encodes a component of the CST complex, 
which is composed of CTC1, STN1, and 
TEN1. Is involved in restarting stalled 
replication forks during telomeric DNA 
replication, as well as promoting telomere C-
strand fill-in after telomerase activity during 
DNA replication.  
 17p13.1  2012 613129 AR  DC, CP 
RTEL1  Regulator of 
telomere elongation 
helicase 1 
This gene encodes a DNA helicase which 
functions in the stability, protection and 
elongation of telomeres, and interacts with 
proteins in the shelterin complex known to 
protect telomeres during DNA replication 
20q13.33  2013 608833 AD, AR  DC, HH  
Data for the table adapted from [Armanios and Blackburn 2012, Holohan et al. 2014, Savage 2014] 
Abbreviations: XLR, X-linked recessive, AD, autosomal dominant, AR, autosomal recessive, DC, dyskeratosis congenita, RS, Revesz 
syndrome, HH, Hoyeraal–Hreidarsson syndrome, CP, Coats plus syndrome, SAA, severe aplastic anemia, PF, pulmonary fibrosis, FLD, fibrotic 







The discovery that telomerase activity was present in human cancer cell extracts 
suggested a mechanism of how cancer cells become immortal, thus leading to the first 
connection between telomere biology and cancer [Morin 1989]. A study conducted by 
Kim et al., (1994) further confirmed this initial discovery and provided evidence that 
approximately 90% of human cancers up-regulate telomerase to maintain TL [Kim et al. 
1994], with the remaining 10% employing a recombination-mediated mechanism such 
as ALT [Bryan et al. 1997, Reddel et al. 1997]. Initially, the progressive loss of telomeres 
was thought of as a tumour suppressor mechanism to control cellular proliferative 
potential [de Lange et al. 1990]. However, it is now known that telomeres are also 
involved in tumour progression [Hackett and Greider 2002]. Cancer cells typically have 
short telomeres that are genetically unstable [Hastie et al. 1990, Willeit et al. 2010b, Ma 
et al. 2011, Wentzensen et al. 2011, Weischer et al. 2013], although they have the ability 
to bypass the cell cycle checkpoints regardless of the presence of dysfunctional 
telomeres. Cancer cells are strongly selected for and thus have the ability to continue 
acquiring genetic rearrangements, giving rise to uncontrollable, proliferating cells 
encouraging tumorigenicity. It is unclear whether TL is associated with histological type, 
lesion location, or cancer stage. However, several studies have now assessed the use of 
TL in different cancers as a prognostic/diagnostic tool and preliminary data suggests TL 
could provide some value in predicting disease severity, progression and overall 
prognosis [Baichoo and Boardman 2014, Lin et al. 2014, Chen et al. 2015, Qu et al. 
2015].  
 
Targeting telomerase for cancer treatment has generated a lot of interest, an example of 
which is the stabilisation of G4s structures which can inhibit telomerase from binding 
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[Neidle 2010]. This is a very active area of interest, however as mentioned earlier, cancer 
therapeutics cannot just target telomerase as a proportion of cells express the ALT 
pathway, thus tumours containing ALT cells are likely to be drug resistant, and 
telomerase-positive tumours will be placed under strong selection pressure to activate 
ALT.  
1.4.3 Cardiovascular Disease (CVD) 
Cardiovascular disease (CVD) has a high prevalence in the population and is a major 
cause of morbidity and mortality. Age is the strongest predictor of CVD, but there is wide 
variation in the age of onset in individuals. In addition, several risk factors of CVD such 
as smoking, diabetes, obesity, alcohol consumption, and psychological stress have been 
proposed to affect the erosion rate of the telomere [Epel et al. 2004, Valdes et al. 2005, 
McGrath et al. 2007, Nordfjall et al. 2008, Buxton et al. 2011, Pavanello et al. 2011, 
Harris et al. 2012]. Furthermore, multiple alleles associated with shorter telomeres have 
also been associated with an increased risk of coronary artery disease [Mangino et al. 
2012], and as a consequence, telomere shortening has been implicated in this disease, 
although the underlying mechanisms are poorly understood.  
 
Several studies have now reported positive associations between shortened LTL and 
CVD disease and CVD events [Brouilette et al. 2003, Fitzpatrick et al. 2007, van der 
Harst et al. 2007, Farzaneh-Far et al. 2008, van der Harst et al. 2010, Willeit et al. 2010a], 
stroke [Ding et al. 2012, Jiang et al. 2013], as well as atherosclerosis [Samani et al. 2001, 
Benetos et al. 2004, Matthews et al. 2006, Aviv 2009].   
 
However, few longitudinal population studies have been conducted to assess TL erosion. 
A small (n = 332) population based case-control study followed subjects over a 15 year 
29 
 
period to determine if TL was shorter in people that had experienced a myocardial 
infarction (MI) [Nilsson et al. 2011]. They concluded that TL erosion was associated 
with prevalent/incident MI. A much larger longitudinal study monitored 19,838 subjects 
from the general population for up to 19 years. They found that short TL was only 
modestly associated with increased risk of MI, ischemic heart disease, and early death 
[Weischer et al. 2012]. 
 
A recent meta-analysis conducted by Haycock et al., (2014) including 43,725 
participants over 24 studies representative of the general population, found that TL was 
inversely associated with risk of coronary heart disease independently of conventional 
vascular risk factors. The pooled relative risk for coronary heart disease was 1.54 (95% 
confidence interval 1.30 to 1.83; 20 studies). The pooled relative risk for coronary heart 
disease was 1.40 (1.15 to 1.70) in prospective studies and 1.80 (1.32 to 2.44) in 
retrospective studies (p = 0.32 for difference). These associations were consistent across 
all study level characteristics including different mean age, sex distribution, prospective 
and retrospective study design and even when assessing publication bias [Haycock et al. 
2014]. Furthermore, a recent study in 3,275 patients with chronic ischaemic systolic heart 
failure observed a significant association between shorter TL and cardiovascular death, 
non-fatal myocardial infarction (MI), and non-fatal stroke. However the effect size was 
small (hazard ratio 1.10; 95% confidence interval 1.01–1.20; p = 0.03) and the 
association did not add any prognostic information. [Haver et al. 2015] 
 
Telomeres have been extensively studied in CVD and although conclusive evidence is 
lacking and more longitudinal studies are required, telomere attrition is suggested to have 
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an important role in CVD [Serrano and Andrés 2004, Saliques et al. 2010, De Meyer et 
al. 2011] [Nilsson et al. 2013] 
1.4.4 Stress 
Psychological stress, including several different types of stressors that are experienced 
throughout life, is another factor that has been studied in relation to telomere erosion 
[Epel 2009, Shalev 2012, Price et al. 2013]. There are several reasons for this interest 
which are discussed in detail below. 
1.4.4.1 Intra-uterine stress studies  
Fetal development and programming is greatly affected by the conditions experienced 
during the intra-uterine period of life, and can subsequently influence an individuals’ 
susceptibility to complex diseases later in life [Entringer et al. 2011]. Telomeres are 
thought to be plastic during this period and receptive to intra-uterine stress, where levels 
of physiological and severe maternal psychological stress during pregnancy have been 
found to be associated with shortened telomeres in young adulthood [Entringer et al. 
2012, Entringer et al. 2013].  
1.4.4.2 Childhood abuse stress studies 
There is a growing body of evidence showing that early life stress (ELS) during 
childhood, including physical and sexual abuse, violence, maltreatment, time in 
institutional care, and other adverse events, lead to shortened telomeres later in life 
[Tyrka et al. 2010, Drury et al. 2012, Shalev et al. 2013b]. However, some studies have 
failed to replicate these findings [Glass et al. 2010, Savolainen et al. 2014, Shalev et al. 
2014]. Not only are these stressors associated with TL during adulthood, they also appear 
31 
 
to impact TL during the periods of exposure as observed in a study by Shalev et al., 
(2013) which assessed TL erosion from the ages of 5 to 10 [Shalev et al. 2013b].  
1.4.4.3 Adult psychiatric studies 
Childhood adversity can predispose adults to psychiatric disorders later in life, and a 
number of these including major depression [Simon et al. 2006, Wolkowitz et al. 2011, 
Shalev et al. 2014, Schutte and Malouff 2015], bipolar disorder [Elvsåshagen et al. 2011], 
and schizophrenia [Kao et al. 2008] have been associated with shorter telomeres, 
although not all studies agree [Shaffer et al. 2012]. Furthermore, perceived stress has also 
been linked to shorted telomeres. The first study to demonstrate this examined the 
prolonged exposure of a highly stressful situation brought about by caregiving for a 
chronically ill child [Epel et al. 2004]. These findings have been supported by the 
majority of subsequent studies [Damjanovic et al. 2007, Parks et al. 2009], but not all 
[Litzelman et al. 2014]. A recent meta-analysis estimated the effect size to be r = -0.25 
in the direction that higher levels of perceived stress were associated with shorter 
telomeres, although it was noted that taking publication bias into account would reduce 
the effect size to r = -0.15 [Schutte and Malouff 2014]. More research is required to 
elucidate mechanisms that may link stress and TL erosion. One promising step in this 
direction is the demonstration that childhood stress results in elevated inflammation 
levels, suggesting that the effects of stress on telomere erosion could be mediated by 
inflammation and oxidative stress [Danese et al. 2007, Kiecolt-Glaser et al. 2011].  
 
A limitation for the majority of these studies is that TL is measured in adulthood and 
measures of stress and adversity have been assessed retrospectively, are often self-
reported, and may therefore suffer recall bias. Additionally, childhood abuse can lead to 
adverse adult health outcomes [Felitti et al. 1998], and it may be that the reduction in TL 
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is a consequence of these later health problems as opposed to the effect of the 
maltreatment itself. Although many associations have now been observed between 
different types of stress and TL, it is still unknown what types of stress matter the most. 
Does type, timing, severity and chronicity of stress exposure relate to telomere erosion 
or is it cumulative regardless of type and can one really stressful event have the same 
impact?  
1.5 Methods of measuring telomere length 
Overview 
Several methods are available for measuring TL, employing a variety of molecular 
techniques, including Southern blotting, polymerase chain reaction (PCR), fluorescent in 
situ hybridisation (FISH) and flow cytometry. These methods measure different aspects 
of TL in cell populations, single cells or individual chromosomes.  
 
The study design and research question dictates the method of measurement used, as to 
date there is no single measurement technique that is amenable to screening TL in 
populations (high throughput) as well as looking at TL dynamics at the molecular level 
(STELA, Flow-FISH). In addition, several other considerations need to be taken into 
account including the sample type available, quantity and quality of material, the number 
of samples to be processed, how accurate the measurement needs to be, and the detection 
limit required. Furthermore, not all methods are amenable to measure TL in organisms 
other than humans [Lin and Yan 2005, Aubert et al. 2012, Montpetit et al. 2014, Nussey 
et al. 2014]. The most popular methods are detailed below, outlining their advantages 




1.5.1 Terminal restriction fragment analysis (TRF) 
Terminal restriction fragment (TRF), the original method for TL measurement, was 
developed in the 1980s and utilized Southern blotting [Southern 1975]. It is a relatively 
crude, imprecise measurement of average TL, providing information on the distribution 
of telomere lengths for all the chromosomes in a population of cells. This is represented 
as a telomere-specific smear on the blot as a result of the heterogeneity of TL. 
TRF analysis involves digestion of genomic DNA with a combination of frequently 
cutting restriction enzymes such as HinfI and/or RsaI. There are no restriction sites for 
these enzymes within telomeric DNA, leaving these higher molecular weight TRFs intact 
whilst generating low molecular weight fragments for the remaining DNA [Moyzis et al. 
1988, Allshire et al. 1989]. The fragments are resolved by gel electrophoresis and 
transferred onto a positively charged nylon membrane by blotting overnight with 
capillary transfer. This is then hybridised to a telomere-specific probe labelled with either 
radioisotopes (32P) and exposed to X-ray film for detection or by non-radioisotopic 
methods such as digoxigenin (DIG). If a DIG probe is used it is subsequently incubated 
with a DIG-specific antibody covalently coupled to alkaline phosphatase to generate a 
chemiluminescent signal for detection. The length and intensity of the telomere-specific 
smear is detected by densitometry and compared to a size standard to calculate average 
TL. The most intense part of the smear correlates to a higher frequency of telomeres at 
the same length [Kimura et al. 2010].  
This method does not require specialised equipment and is relatively simple to perform, 
but it is labour intensive, requires large amounts (µg) of high quality DNA, and is 
therefore not amenable to high throughput analysis or studies with a restricted amount of 
starting material available [Aviv 2008]. The data analysis methods are also laborious, 
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subjective and somewhat error-prone. There is also a bias towards detection of longer 
telomeres as they have the ability to hybridize more probe, which may misrepresent 
shorter telomeres that cannot bind enough probe to generate sufficient signal for detection 
[Aubert et al. 2012]. In addition, sub-telomeric repetitive DNA regions adjacent to the 
telomere are included in the TRF measurements. This region can vary amongst 
individuals and contain modifications that protect against restriction digestion, so this 
additional material can confound TL measurements, although using a combination of 
restriction enzymes can help mitigate this issue [Steinert et al. 2004]. A reference sample 
is typically included in each assay to correct for ‘gel effects’ between experiments and to 
allow for normalisation between blots. Despite the limitations of sensitivity and accuracy 
of this method, including the technical and analytical differences between research 
groups using TRF, the variation in application of this method is relatively small. 
Consequently TRF is still considered the gold standard method for TL measurement and 
for the validation of newly developed methods. TRF is also used following STELA 
(Section 1.5.6) and additionally, it has been used to calibrate other techniques such as 
Flow-FISH (Section 1.5.3). Despite its recognition as a gold-standard, the imprecision of 
TRF suggests that it is not an ideal measurement method [Aubert et al. 2012]. 
1.5.2 Quantitative fluorescent in situ hybridisation (Q‐FISH) 
Fluorescence in situ hybridisation (FISH) [Lengauer et al. 1990] using a fluorescently 
labelled oligonucleotide probe was the first method applied to examine TL in individual 
chromosomes. However, this approach only generated qualitative data, so the 
methodology was improved and a quantitative approach (Q-FISH) developed which 
allowed analysis of individual chromosome ends at the single-cell level [Lansdorp et al. 
1996]. This method provided an insight into the heterogeneity of TL, including the inter- 
and intra-chromosomal distribution between cells, and paved the way for studies to assess 
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critically short and uncapped telomeres as well as telomere fusions involved in DNA 
damage response [Lansdorp et al. 1996, Slijepcevic 2001].  
Q-FISH uses Cy3 or fluorescein isothiocyanate (FITC) to fluorescently label a telomere-
specific peptide nucleic acid (PNA) probe (CCCTAA)3, that hybridises to denatured 
telomeric DNA repeats in metaphase preparations. Digital fluorescence microscopy is 
used for detection [Lansdorp et al. 1996]. PNA probes are synthetic peptides homologous 
to DNA in which the negatively charged phosphate backbone is replaced with an 
uncharged N-2 amine ethyl-glycine backbone. This modification makes the PNA/DNA 
bonding more stable and stronger than DNA/DNA duplexes so they effectively compete 
with the re-annealing of the strands and generate a more intense and specific 
hybridisation signal, increasing sensitivity for quantification. Conversely, these PNA 
probes do generate higher background fluorescence which can give inaccurate results, 
although this can be mitigated to an extent [Baerlocher et al. 2002]. Known size standards 
are used for quantification and the individual telomere fluorescent signals are analysed 
and typically represented by a histogram showing the distribution of TL frequencies. To 
obtain absolute TL, external calibration using cell lines with stable and known TL is 
required. The analysis of 15 to 20 metaphases per sample is generally required to obtain 
reliable TL measurements, making this method very time consuming and labour 
intensive, and therefore not suitable for high throughput population studies [Vera and 
Blasco 2012]. This limitation was overcome with the development of high throughput 
FISH (HT-FISH) that uses interphase nuclei and automated HT microscopy in 96 well 
plate format to quantify mean TL, with recent improvements that allow for the frequency 




The major advantage of the Q-FISH method is that it is highly sensitive, with a lower 
detection limit of 150 bp, and for this reason is the method of choice for high resolution 
TL measurements at specific chromosome ends for all of the chromosomes [Poon et al. 
1999, Vera and Blasco 2012]. A major drawback of this method is that it is limited to 
cells that are able to proliferate and grow, meaning senescent cells are not analysed. 
Furthermore, it can be problematic to obtain sufficient cells that are in metaphase at the 
time of analysis. This means that Q‐FISH cannot be applied to many study cohorts where 
only purified genomic DNA, rather than intact cells, is available. Q-FISH also requires 
specialised equipment and is labour intensive and time consuming, taking approximately 
a week to process 10 samples. The use of fluorescence for detection also brings about 
some limitations, such as photo-bleaching of the fluorophore, and there is the possibility 
some telomeres will not be detected as they will be below the detection threshold. 
Another drawback is variation in signal intensity between assays, although this can be 
minimised to a degree, with appropriate use of controls [Vera and Blasco 2012]. 
1.5.3 Flow‐FISH 
Flow FISH combines FISH with flow cytometry to enable a medium throughput means 
to measure average TL in a population of cells, whereby the use of different antibody 
marker probes allows for specific cell subpopulations to be identified [Rufer et al. 1998, 
Baerlocher and Lansdorp 2003]. The principle of Flow-FISH is equivalent to that of Q-
FISH, but instead of using fluorescent microscopy Flow-FISH uses flow cytometry for 
detection and analysis. In addition, Flow-FISH was the first method to be validated for 
clinical diagnostic purposes and it is routinely used for the diagnosis of dyskeratosis 




Flow‐FISH requires a large number of cells but also allows for blood samples to be 
analysed, so unlike Q‐FISH it does not require cultured cells and is therefore faster to 
perform and analyse. A limitation of using flow cytometry for analysis is that it only 
provides TL values as fluorescence units per counted cell and therefore only provides 
measures of average TL per cell, making it a less sensitive measure than conventional Q-
FISH. A control cell line is used for normalisation and to compensate for differences in 
the hybridisation steps. As fluorescence is used, the same disadvantages as with Q‐FISH 
also apply to this method, as well as the need for specialised equipment [Baerlocher et 
al. 2002]. 
1.5.4 Quantitative polymerase chain reaction (qPCR) 
Telomere measurement by qPCR was the first high throughput method developed to 
measure average TL, and it is still the preferred method of measurement in large 
epidemiological studies. qPCR is an extension of traditional PCR in which inclusion of 
a fluorescent dye enables the simultaneous amplification and relative quantification of 
target DNA. Initially it was believed intractable to apply this technique to measure TL 
due to the size, terminal chromosomal location, and repetitive nature of telomeric DNA. 
This problem was overcome by designing primers that include specific mismatches to 
avoid complementation and prevent formation of primer dimers. A reference gene that is 
present as a single copy in the genome was used to normalise the reaction and allow 
relative quantification [Cawthon 2002]. This assay is described in more detail in Chapter 
3, but essentially, the telomere-specific primers have the ability to anneal anywhere along 
the telomeric tract. The number of primers bound, and therefore the PCR product 









Figure 1.5. Telomere length measurement by qPCR 
Three pairs of homologous chromosomes are shown. The ovals represent the centromere, the dark grey region the genomic DNA, and the light 
grey the telomeric (TTAGGG)n repeats. The length of the telomeric repeats differs between chromosomes as well as between the p and q arms of 
individual chromosomes. Blue arrows represent telomere primers, which can bind to multiple sites along the repetitive telomeric DNA, and the 
number of primers bound is proportional to the length of the telomere. The red primer pairs represent the single copy reference gene primers, 
which only bind at one position in the genome and are used for normalisation of the reaction. This provides a measure of average telomere length 
using a ratio of the telomere product to the single copy gene (T/S).  
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This method provides a relative measure of average TL from genomic DNA, expressed 
as a T/S ratio by measuring the number of telomere repeats (T) across all chromosomes 
for all cells relative to the amount of a single copy reference gene (S) [Cawthon 2002]. 
Like TRF, qPCR measures average TL in a population of cells and therefore provides no 
information about the shortest telomere or the distribution of telomere lengths within a 
cell. As the sub-telomeric region is not included in qPCR measurements, this method is 
considered to give a more correct measurement of true telomere length than TRF. 
Furthermore, qPCR only requires small amounts of DNA, and good quality DNA is not 
essential [Aviv et al. 2011].  
 
The main limitation of this qPCR method is the amplification efficiency of the target 
DNA, whereby small changes in efficiency in earlier cycles result in large changes in 
subsequent cycles. This can be caused by primers mis-priming, changes in thermal 
cycling temperatures, or reagents creating bias in the results, but this can be reduced by 
using appropriate controls [Heid et al. 1996, Pfaffl 2004]. A potential problem with this 
method involves the use of the fluorescent dye SYBR Green (Molecular probes, Oregon, 
USA) for the detection of products as it can provide artificial results due to its non‐
specific nature. To some degree this limitation can be overcome by using a technique 
called melt curve analysis to validate the amplicon signals [Ririe et al. 1997, Rasmussen 
et al. 1998]. Another issue is that only relative quantification can be achieved, although 
a modified method to allow for absolute quantification of TL using an oligonucleotide 
standard has been developed [O'Callaghan and Fenech 2011].  
40 
 
1.5.5 Monochrome multiplex quantitative polymerase chain reaction 
(MMQPCR) 
In 2009 Cawthon published an improved qPCR methodology, in which the PCR primers 
had been redesigned to allow co‐amplification of the telomere and single copy reference 
gene in one qPCR reaction. Multiplexing exploits the high copy number of the telomere 
product, enabling it to be amplified in earlier PCR cycles compared to the single copy 
reference gene. The major benefit to multiplexing the assay is that it normalises initial 
differences in DNA concentration and therefore greatly improves precision by reducing 
potential inter-assay pipetting error, which can impact on the T/S ratio. It also reduces 
the cost and increases throughput [Cawthon 2009]. This assay is described in detail in 
Chapter 3. 
 
Both the qPCR and MMQPCR methods correlate well with data derived by the historical 
TRF assay, although qPCR methods are reported to have a greater measurement error 
than TRF and can show substantial inter- and intra-assay variability within and between 
different laboratories [Aviv et al. 2011]. Typically, in cohorts of clinical studies, 15% of 
samples need to be assayed a third time as the coefficient of variation is too high, 
necessitating several quality control (QC) and multiple sampling to assure reliability 
[Aviv et al. 2011, Aubert et al. 2012]. 
1.5.6 Single telomere length analysis (STELA) and Universal STELA 
Single telomere length analysis (STELA) utilises the benefits of PCR based assays but 
instead of assessing average TL like the current PCR methods, it amplifies telomere 
lengths from individual chromosomes in a cell population. Unlike the current methods to 
41 
 
assess individual chromosomes, it does not require specialised equipment, however, this 
technique is technically challenging and labour intensive [Baird et al. 2003]. 
 
 
Figure 1.6. Telomere length measurement by STELA 
The XpYp telomere is shown. The centromere is at the proximal end and the telomere at 
the distal end. The white boxes show perfect telomere repeat sequences, whereas the 
black boxes show the telomere repeat variant which are present in the sub-telomeric 
sequence. The ‘telorette’ with seven bases of homology to the telomeric G-rich overhang 
anneals and is subsequently ligated to the C-rich strand. The reverse primer ‘teltail’ 
anneals to the telorette and together with the upstream telomere-specific primer located 
in the sub-telomeric region, the PCR reaction can be performed. From [Baird et al. 2003]. 
Reprinted with permission from Nature Publishing Group.  
 
STELA is carried out by tagging the end of the chromosome with an oligonucleotide that 
serves as a site for the reverse primer of a PCR reaction, which cannot be achieved with 
native telomeric DNA due to its repetitive nature. This oligonucleotide is known as the 
‘telorette’ and comprises seven bases of homology to the telomeric G-rich overhang 
[Makarov et al. 1997, Wright et al. 1997]. The telorette anneals to the G-rich strand and 
is subsequently ligated to the C-rich strand. The seven bases of homology in the telorette 




can anneal, and together with a chromosome-specific upstream forward primer located 
in the sub-telomeric region, the PCR reaction can be performed. The chromosome 
specificity of STELA relies on the design of a forward primer that is unique to a specific 
chromosome arm and relatively close to the beginning of true telomeric repeats. The 
upstream primer can also be made allele-specific, which exploits known polymorphisms 
in the sub-telomeric region [Baird et al. 2003]. To get an accurate measure of the TL, 
several PCRs are performed on each chromosome, which are then resolved by 
electrophoresis and analysed in a manner analogous to the TRF method. 
 
A major limitation of this technique is that it requires a significant degree of initial 
optimisation and the resolution is dependent on the degree of optimisation [Aubert et al. 
2012]. This method is ideal for short telomeres, especially those below normal range. 
Telomeres over 20 kb are not easily amplified with this method and this can potentially 
lead to skewed data for samples with long telomeres. Consequently this method is not 
amenable for studies in mice, which have very long telomeres [Vera and Blasco 2012]. 
A limitation of STELA is that only chromosomes with known sub-telomeric sequence 
data can be analysed. The analysis of single chromosome ends may not be representative 
of the other telomeres present within the cell, so while this method is appropriate for 
studies focusing on individual chromosomes it may not be appropriate for 
epidemiological studies where average TL may be more relevant. However, this 
limitation has recently been overcome by the development of Universal STELA which 
is able to measure all individual chromosome ends and can be used to investigate the 





To date relatively few studies have set out to directly compare the methods of telomere 
measurement, although comparison with TRF is typically performed for validation 
purposes. These studies vary in the number of samples, material tested and disease state 
of participants, and as a result the correlation between the methods is highly variable. For 
example, the correlation between TRF and qPCR ranges from an r2 of 0.2 to 0.83 
[Cawthon 2002, Cawthon 2009, Aviv et al. 2011, Elbers et al. 2014, Gutierrez-Rodrigues 
et al. 2014, Panero et al. 2015], whereas TRF vs Flow-Fish has a more modest correlation 
of r2 of 0.51 - 0.65 [Gutierrez-Rodrigues et al. 2014], but with a slight modification of 
the protocol the r2 improved to 0.96 [Carbonari et al. 2014]. Lastly the correlation 
between qPCR and Flow-Fish is poor, ranging from an r2 of 0.1 to 0.33 [Gutierrez-
Rodrigues et al. 2014]. Overall, the correlation between these three methods for 
measuring average TL is modest, with the initial studies finding a better correlation. The 
intra and inter-assay coefficient of variation (CV) range from 1.25% to 12% for Southern 
blotting and 2.27% to 28% for qPCR. When reported, the inter-assay CV for FISH is > 
5% [Aviv et al. 2011, Elbers et al. 2014, Gutierrez-Rodrigues et al. 2014]. However, 
modifications are continuously being made to the current protocols resulting in a decrease 
in the amount of variation [Martin-Ruiz et al. 2014]. 
 
There appears to be significant methodological variation between laboratories for every 
technique, as there is a lack of standardisation, and it is often difficult to assess from a 
publication what control steps have been undertaken. Introducing standards for telomeric 
qPCR assays, similar to the MIQE guidelines for qPCR experiments [Bustin et al. 2009], 
may help to alleviate this issue. For example, the basic protocol for qPCR alone can be 
modified using different reference genes (36B4, beta-haemoglobin, GAPDH, ALB), 
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reaction components, cycling profiles and qPCR platforms. In addition to this, the way 
in which the samples are processed, including DNA extraction methods and cell culture 
techniques, may contribute to variation between laboratories [Aubert et al. 2012]. This 
makes comparisons across studies difficult and because of the measurement error or 
technical variation between laboratories means that data cannot be easily pooled. 
Furthermore, Martin-Ruiz et al., (2014) reported that the variation seen within samples 
is much larger than that seen between cases and control groups; hence these limitations 
in the methodology may be contributing to the inconsistencies observed between studies 
and problems evaluating the usefulness of TL as a biomarker. At the present time, it is 
clear that there is no single technique that will measure TL easily, rapidly and accurately 
[Martin-Ruiz et al. 2014]. 
1.6 Measurements from blood to assess telomere length 
Although TL is heterogeneous between different cell and tissue types, the majority of 
epidemiological studies utilise blood, and therefore TL is assessed in leukocytes, the 
predominant, nucleated cell type in peripheral blood samples. The major advantage of 
using these cells is they are easily accessible and can be obtained in a minimally invasive 
fashion [Sanders and Newman 2013, Bodelon et al. 2014]. Peripheral blood samples also 
provide high quality DNA which is essential for some of the methods. However, a 
downside in using blood is that it represents a heterogeneous cell population composed 
mainly of lymphocytes and granulocytes, where lymphocytes have shorter telomeres 
[Rufer et al. 1999, Aubert and Lansdorp 2008]. Therefore, any fluctuations in these cell 
subpopulations could affect average TL and contribute to intra-individual variation, and 





Instead of blood, buccal cells from saliva samples have also been used to measure TL in 
epidemiological studies, due to their ease of collection and non-invasive nature. 
Typically in telomere research, their use has been mainly in studies involving babies or 
children due to the ethical issues of obtaining blood. However, as TL is found to be 
significantly greater in saliva than blood, direct comparisons cannot be made between 
studies that have used different sample types, limiting the generalisation of findings to 
other tissues [Theall et al. 2013, Mitchell et al. 2014]. 
 
Despite differences in absolute TL between tissues, there appears to be synchrony in 
relative TL amongst other somatic tissues from the same individual [Friedrich et al. 2000, 
Takubo et al. 2002, Daniali et al. 2013], although not all studies agree [Dlouha et al. 
2014]. Leukocyte telomeres are thought to reflect the major determinants of ageing 
including cellular replication, inflammation and oxidative stress, as well as reflecting 
organ dysfunction elsewhere in the body making them a good proxy of TL dynamics for 
the entire body [von Zglinicki et al. 2005, Oeseburg et al. 2010]. However, more research 
is required in this area to evaluate the relationship between TL in surrogate tissues and 
those affected by disease as well as the susceptibility to environmental factors affecting 
TL regulation in that specific tissue [Thomas et al. 2008, Gadalla et al. 2010, Bodelon et 
al. 2014].  
1.6.1 Commercial interest in TL measurements 
The interest in TL as a biomarker is highlighted by two commercial providers (Telomere 
diagnostics, Inc. (www.telomeredx.com) and Life Length (www.lifelength.com) that 
offer TL measurements for research, clinical and personal use. Two different methods of 
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TL measurement are utilized by these companies, with Telomere diagnostics, Inc. 
employing the qPCR assay and Life Length using Q-FISH. Their stated intention is to 
integrate TL measures into routine health checks and preventative healthcare, using the 
measures to assess health status, disease risk and responses to specific therapies. These 
companies also suggest that they can provide information on your biological age, and 
that it is possible to protect one’s telomeres and slow down biological ageing by changing 
certain lifestyle factors such as nutrition and exercise, as well as reducing stress by 
meditation or yoga [Epel et al. 2009a] (www.telomeredx.com, www.lifelength.com). 
However, the evidence base for these claims does not appear robust.  
1.7 Conclusions and thesis aims 
It is evident there are still many gaps in the literature surrounding the use of TL as a 
biomarker of general health and disease, although there are several factors that make it 
an interesting prospect. The telomere is a biologically plausible candidate because of its 
essential role in genomic stability and normal cellular functioning, with both in vitro and 
in vivo studies suggesting that TL reflects levels of oxidative stress and cellular 
senescence, both of which are hallmarks of ageing. Additionally, shortened telomeres 
have been directly implicated in several rare inherited progeroid diseases which have 
arisen from mutations that alter telomere biology and accelerate telomere erosion. 
Furthermore, telomere length is a highly heritable trait with a substantial amount of 
variation amongst individuals of the same age, and is thought to be influenced by genetic 
factors and the cumulative lifetime effect of environmental factors.  
 
However, association studies have found mixed results with robust associations only 
being made with age, gender and ethnicity. Research in this area has suffered a number 
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of limitations whereby the majority of studies are cross-sectional and unable to measure 
telomere length erosion before and after exposure to environmental stressors. As 
telomere length is a complex trait which is influenced by a plethora of factors, the 
relatively small sample size of studies may mean they lack sufficient power to detect 
small effects. The most important limitation, however, is in regard to telomere length 
measurement. There are several methodological approaches for measuring telomere 
length in epidemiological studies all of which measure average TL in a population or 
subpopulation of cells; however, they do not always provide reproducible and accurate 
results. Furthermore, there is considerable debate as to whether cellular senescence is 
induced by the presence of one critically short telomere or the global decrease of average 
TL.  
 
The principle aim of this thesis was to explore the impact of environmental and genetic 
factors on TL with the additional aim of developing a novel method for accurately 
measuring TL in different contexts.  
 
To achieve these aims, a reliable assay to measure average telomere length using a qPCR 
based technique [Cawthon 2002, Cawthon 2009] on a locally available platform first 
needed to be established. Once completed, it was intended to use the assay in two local 
cohorts with considerable phenotypic and life course information, the Christchurch 
Health and Development Study (CHDS) and The Canterbury Health, Ageing and Life 
Course (CHALICE) Study, to assess the impact of environmental factors on TL. Beyond 
this, the potential impact of rare genetic variation on telomere length was examined, and 
finally, a novel nanopore sequencing device was trialled to assess its possible value in 






Chapter 2: Materials and Methods 
All reagents used were of analytical grade and sourced from reputable companies. The 
supplier is noted next to the reagent, where appropriate, and the procedures for making 
the general stocks are found in (Table 2.10). Any variations to these methods are 
described in the individual experimental chapters. 
2.1 General Laboratory Protocols 
2.1.1 Extraction, quantitation and quality of genomic DNA 
Genomic DNA (gDNA) was extracted prior to the commencement of this project. Whole 
peripheral blood samples were drawn in EDTA tubes and frozen at -20°C until extracted. 
DNA was extracted from the CHDS samples using a modified sodium chloride 
precipitation procedure [Lahiri and Nurnberger 1991] and from CHALICE samples using 
NucleoMag® Blood DNA extraction kits (Macherey-Nagel, Düren, Germany) on a 
KingFisherTM Flex (Thermo Scientific, Finland) automated robotic platform, according 
to the manufacturer’s instructions. DNA samples from these cohorts were normalised to 
50 ng/µL in millipore purified water (MPW), left to diffuse overnight (4°C) and further 
diluted to either 2 ng/µL or 4 ng/µL in MPW before use in the qPCR telomere assays. 
Various gDNA samples from the Gene Structure and Function Laboratory stocks were 
used for the establishment, optimisation, troubleshooting and validation of the assays. 
Samples were stored at 4°C for short term storage and 20°C for long term storage.  
 
DNA was quantified using a NanoDrop 8000 (ND-8000) UV-Vis Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA), by absorbance at 260 nm. MPW or 
Tris-EDTA (TE) was used in blank subtraction. The purity of DNA samples or PCR 
products was assessed by the A260/280 (> 1.7-1.8) and A260/230 (> 1.5-2.0) ratios. The 
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integrity of the sample was determined by running approximately 50ng of gDNA on a 
0.7% agarose gel (Section 2.3), stained with SYBR® Safe (InvitrogenTM, Life 
Technologies, Carlsbad, CA, USA) and visually assessed for the presence of a high 
molecular weight smear.  
2.1.2 Samples 
The telomere length assay (Chapter 3) was applied to subjects from two longitudinal 
studies. The first was the Christchurch Health and Development Study (CHDS) (n = 677), 
which has followed a birth cohort to age 35 years [Fergusson and Horwood 2001]. The 
second was the Christchurch Health, Aging and Lifestyle Cohort (CHALICE) (n = 351), 
based on a population sample of 50 year olds [Schluter et al. 2013]. DNA was obtained 
from subjects who had consented to extensive genetic analyses, and all phases of the 
study were subject to ethical approval from the Canterbury Ethics Committee (now 
known as Upper South A Regional Ethics Committee). For CHDS approval was under 
CTB/04/11/234 in 2004 and for CHALICE, ethical approval was under URA/10/03/021 
in June 2010. The study complied with the ethical standards for human experimentation 
as established by the Helsinki Declaration 1964 (sixth revision 2008), and all forms of 
data collection were subject to the signed consent of study participants. A detailed 
description of the two cohorts can be found in chapters 4 and 5 for the CHDS and 
CHALICE cohorts respectively.  
2.2 Polymerase Chain Reaction (PCR) 
2.2.1 Primer Design and Storage  
All oligonucleotide primers trialled for establishing the telomere assays and those used 
for the verification of the telomeric insert in the plasmids for the MinIONTM experiments 
were obtained from published protocols. The primer sequences and references are listed 
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in (Table 2.1). All primers were ordered from Integrated DNA Technologies (IDT Pte. 
Ltd., Singapore) and reconstituted with 1x TE to a stock concentration of 50 µM. Primer 
stocks were further diluted with MPW to give a working solution of 10 µM for routine 
use in the PCR reactions, with the exception of the primers used in the MMQPCR assay 
which remained at 50 µM. Stocks were stored at -20°C and 4°C for the working solutions.  
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Table 2.1. Oligonucleotide primer sequences  
Primer name Sequence (5'-3') Reference 
tel 1 GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT [Cawthon 2002] 
tel 2 TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA [Cawthon 2002] 
36B4u CAGCAAGTGGGAAGGTGTAATCC [Cawthon 2002] 
36B4d CCCATTCTATCATCAACGGGTACAA [Cawthon 2002] 
ASPG3F GAGCTGTTGACGGAAAGGAG [Cote et al. 2012] 
ASPG4R CAGAAGAGAATCCCGGCTAAG [Cote et al. 2012] 
tel1b CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT [Cote et al. 2012] 
tel2b GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT [Cote et al. 2012] 
telg ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT [Cawthon 2009] 
telc TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA [Cawthon 2009] 
albu CGGCGGCGGGCGGCGCGGGCTGGGCGGAAATGCTGCACAGAATCCTTG [Cawthon 2009] 
albd GCCCGGCCCGCCGCGCCCGTCCCGCCGGAAAAGCATGGTCGCCTGTT [Cawthon 2009] 
SP6 ATTTAGGTGACACTATAG  Addgene (https://www.addgene.org/) 
T3 GCAATTAACCCTCACTAAAGG  Addgene (https://www.addgene.org/) 
T7 TAATACGACTCACTATAGGG Addgene (https://www.addgene.org/) 




2.2.2 Thermal cycling equipment 
All PCR reactions, restriction digests and Sanger cycle sequencing were performed on an 
Eppendorf Mastercycler® Gradient S thermal cycler machine and the Roche LightCycler® 480 
(LC480) real-time PCR platform was used for the quantitative PCR assays.  
2.2.3 Reaction set-up 
To minimise the risk of contamination with post-PCR products or genomic DNA, all pre‐PCR 
reactions were carried out in a separate room using either filter tips or UV-treated pipette tips, 
sterile 200 µL strip tubes and UV/ethanol‐treated pipettes.  
2.2.4 Plasmid PCR 
To verify telomeric inserts were present in the plasmids pBB and f.pRST1, before use in 
downstream applications, touchdown PCR was performed. Touchdown PCR is a two-phase 
cycling protocol designed to improve the specificity of a PCR, and for PCR optimisation and 
hard to amplify templates. In the first phase, the initial annealing temperature is higher than the 
Tm of the primers; this temperature progressively decreases as the reaction progresses until it 
reaches a target annealing temperature identical or slightly lower than the calculated Tm of the 
primers. In the second phase, the PCR continues with the annealing temperature reached during 
the first phase [Korbie and Mattick 2008]. In the first phase of touchdown PCR for the plasmids, 
the annealing temperature started at 65oC and decreased to 55oC over 10 cycles, and for the 
second phase 15 cycles at 55oC was performed. This was done using the reaction master mix in 
Table 2.2, in a total volume of 25 µL. For the plasmid pSXneo, a standard PCR was found to 
be sufficient. The reaction master mix (Table 2.3) was used in a total volume of 25 µL. As a 
hot-start polymerase was used, the initial denaturation step consisted of 15 min at 95°C, 
followed by 30 cycles of 95°C for 30 s, 50°C for 30 s and 72°C for 1 min, with a final extension 
step at 72°C for 10 min.  
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Table 2.2. Reaction master mix for PCR of pBB and f.pRST1inserts 




HOT FIREPol® DNA Polymerase  5 U/ µL 2 U 
HOT FIREPol® Buffer B1 10 X 1 X 
MgCl2 25 mM 2 mM 
dNTP 2 mM 0.2 mM 
T7 Primer 10 µM 500 nM 
T3 Primer 10 µM 500 nM 
Plasmid DNA 10 ng 10 ng 
Made up to 25 µL with MPW 
Table 2.3. Reaction master mix for PCR of pSXneo insert 




HOT FIREPol® DNA Polymerase  5 U/ µL 2 U 
HOT FIREPol® Buffer B1 10 X 1 X 
MgCl2 25 mM 1.5 mM 
dNTP 2 mM 0.2 mM 
T7 Primer 10 µM 500 nM 
Sp6 Primer 10 µM 500 nM 
Betaine 5 M 1 M 
Plasmid DNA 10 ng 10 ng 
Made up to 25 µL with MPW 
2.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to determine the integrity of the gDNA samples, resolve 
PCR products, separate digested genomic DNA for Southern blotting as part of the TRF assay, 
and verify the successful digestion of plasmids. 
2.3.1 Gel preparation 
Typically, a 2% agarose gel was used for the resolution of fragments up to 1 kb, and for the 
separation of fragments larger than 1 kb a 0.7% gel was used. Molecular grade agarose 
(InvitrogenTM) was dissolved by boiling in a 1x Tris-acetic acid- EDTA (TAE) buffer to give 
either a 0.7 or 2% agarose/TAE solution (w/v), with 4 µL SYBR® Safe DNA gel stain 
(InvitrogenTM) added to every 100mL made. Approximately 50mL of solution was poured into 
a casting tray set in an Easy CastTM electrophoresis system (Thermo Scientific, Owl Separation 
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Systems, Portsmouth, NH, USA) and a comb to form the wells inserted near the anode. Once 
set, the gel was submerged in 1x TAE buffer and the comb removed.  
2.3.2 Sample preparation and Electrophoresis 
Typically 5 µL of PCR product was mixed with 1 µL 6x loading dye (Fermentas International, 
Inc., Burlington, Ontario, Canada) and 2 µL 1x TAE buffer prior to loading. Samples were run 
adjacent to 5 µL of a DNA size marker, (100 bp or 1 kb GeneRulerTM, Fermentas International, 
Inc.) and electrophoresed at 10 V/cm for approximately 30‐45 min or until the dye front was 
2/3 down the length of the gel. The gel was placed in an UVItech Alliance Bio-imaging System 
(Cambridge, United Kingdom) for visualisation of the PCR products under UV light and 
photographed using UVItech Alliance Bio-imaging Software (Cambridge, United Kingdom). 
Images were edited as required to allow for adequate visualisation and saved onto a USB drive 
as a JPEG file. 
2.3.3 Microchip Electrophoresis System for DNA/RNA Analysis MCR® - 202 
(MultiNA) 
An automated microchip electrophoresis system (MultiNA, Shimadzu, Kyoto, Japan) was used 
to resolve products in experiments where finer resolution was required, such as the 79 bp 
telomere product in the Taq polymerase test (Section 3.3.1) for example. The DNA-500 kit 
(Shimadzu, Kyoto, Japan), which can detect products up to 500 bp, was used following the 
manufacturers’ instructions. The amount of reagents used depended on the number of samples 
to be analysed and was calculated with the inbuilt MultiNA software. For each run, the 
separation buffer containing 1× SYBR® Gold Nucleic Acid Gel Stain (Life Technologies, 
Carlsbad, CA, USA) was freshly prepared. After each run, the microchips were washed once 
with sterile water. The resulting electropherograms were manually inspected to ensure that the 
analysis was properly completed, which was indicated by correct ladder analysis (marker 
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fragments were well separated) and the presence of both the lower and upper markers (indicated 
on figures as LM and UM respectively) in each sample. 
2.3.4 Restriction digestion of the plasmids 
To prepare plasmid DNA for sequencing on the MinIONTM, it was first linearised with 
restriction enzymes. At least 1 µg of DNA was required for sequencing, so a typical digest 
contained approximately 3 µg of plasmid DNA. A final reaction volume of 50 µL included 10-
30 µL of plasmid DNA, 5 µL of the manufacturers’ supplied buffer, 3 µL restriction enzyme 
(10 U/µL) and MPW to a final volume of 50 µL. DNA was digested for 4 hours at 37°C 
followed by heat deactivation of the enzyme if applicable. To generate sticky ends, the 
restriction enzyme BamHI was used for plasmids pBB and f.pRST1 whereas EcoRI was used 
for pSXneo. When blunt ends were required, SspI was used for all three plasmids. Successful 
digestion was determined by visualisation on a 0.7% agarose gel (Section 2.3). 
2.3.5 Purification of plasmid DNA  
Digested plasmid DNA was purified using phenol:chloroform extraction followed by ethanol 
precipitation before undergoing library preparation (Section 2.10.1) for the MinIONTM 
sequencer. Samples were mixed with an equal volume of phenol:chloroform, vortexed until the 
solution turned cloudy and centrifuged for 5 min at 16,900 g in an Eppendorf 5418-R centrifuge. 
The aqueous (top) phase was carefully removed and transferred to a new tube. Sodium acetate 
to 0.3 M and 2.5x total volume of 100% ethanol were added to the solution, mixed by inversion 
and centrifuged at 16,900 g for 10 min to pellet the DNA. At this stage, the supernatant was 
decanted and the pellet carefully rinsed with 50-100 µL of 100% ethanol. Centrifugation was 
repeated at 16,900 g for 5 min and the ethanol carefully decanted. The tube was spun briefly 
and residual ethanol was removed by pipetting. The DNA pellet was allowed to air dry by 
inversion over a paper towel for approximately 10-15 min or until no moisture was visible in 
the tube. Once dry, the DNA was re-suspended in 1x TE and stored at 4°C until use.  
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2.3.6 Purification of PCR products  
PCR products were purified prior to Sanger sequencing using the AcroPrepTM 384-well Filter 
Plate Omega 30K (Pall Corporation, Washington, NY, USA). Products were centrifuged for 30 
min at 3200 g in an Eppendorf 5810-R centrifuge. PCR products that remained on the 
membrane were recovered in 20 µL MPW and left for 10 min to re-suspend before 
quantification on the NanoDrop 8000 (Section 2.1.1). 
2.3.7 Sanger sequencing 
Purified PCR products were prepared as follows: 1 µL of diluted PCR product (10ng), 1 µL of 
forward or reverse primer (5 µM), 2 µL of 5× BigDye® Terminator v3.1 Sequencing Buffer, 
0.5 µL of Ready Reaction Premix (Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA), and MPW to a final volume of 10 µL. The reaction mixture was subjected to initial 
heating at 96°C for 1 min, then 30 cycles of 96°C for 10 s, 55°C for 15 s, and 60°C for 4 min, 
followed by 4°C for 1 min. Running of Sanger sequencing products was outsourced to 
Canterbury Health Laboratories (CHL; Canterbury District Health Board, Christchurch). Raw 
data files from the AB3130XL sequencer (Carlsbad, CA, USA) were analysed using 
GeneiousTM software (Biomatters Ltd, Auckland, New Zealand). 
2.4 Quantitative Polymerase Chain Reaction (qPCR) 
Average leukocyte telomere length was determined using a qPCR method adapted from the 
original protocols [Cawthon 2002, Cawthon 2009] with several modifications as described in 
Chapter 3 and that have now been published [Jodczyk 2011]. The qPCR methods provide 
relative quantification of average leukocyte telomere length by measuring the number of 
telomere repeats (T) in a genomic DNA sample relative to the amount of single copy reference 
gene (S), and expressed as a T/S ratio. For the below methods, samples were assayed in 
duplicate in a 384 well plate format in a total reaction volume of 15 µL. 
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2.4.1 Multiplexed Monochrome quantitative PCR (MMQPCR) telomere length 
assay 
The MMQPCR assay [Cawthon 2009] was used solely for troubleshooting the source of the 
high sample variability that was evident in preliminary data from the CHDS cohort generated 
prior to this PhD research [Jodczyk 2011]. The MMQPCR assay protocol modified for this 
prior work, and the associated approach to data analysis [Jodczyk 2011], was used here. Table 





Table 2.4. MMQPCR reaction master mix 





LightCycler® 480 probes Master  2 X 1 X Roche, Mannheim, Germany 
SYTO® 9 fluorescent Dye 50 µM 1.5 µM LifeTechnologies, Carlsbad, USA 
Telg Primer 50 µM 900 nM IDT Pte. Ltd., Singapore 
Telc Primer 50 µM 900 nM IDT Pte. Ltd., Singapore 
Albu Primer 50 µM 900 nM IDT Pte. Ltd., Singapore 
Albd Primer 50 µM 900 nM IDT Pte. Ltd., Singapore 
Genomic DNA 2 ng/µL 10 ng  
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Table 2.5. MMQPCR cycling profile on the LightCycler® 480 machine 




Hold (hh:mm:ss) Ramp Rate 
(˚C/s) 
Acqusitions per ˚C Number of cycles 



















































*Telomere product fluorescence is acquired during this step 







2.4.2 Final two-plate method 
The “two-plate” telomere length assay was adapted from the published original qPCR 
method [Cawthon 2002]. The final protocol is recorded here with detailed justification, 
troubleshooting and validation provided in Chapter 3. The qPCR reactions for both the 
telomere and single copy reference gene albumin (ALB) were performed separately on the 
LC480, ensuring that the T and S reactions for each sample were located in the same relative 
well position in each 384 well plate, as previously recommended [Cawthon 2002]. 
2.4.3 Assay Protocol 
2.4.3.1 Assay preparation 
A bulk reaction master mix (MM) was made up for either the MMQPCR (Table 2.4) or the 
two-plate (Table 2.6) assays. For the two-plate assay, two master mixes were prepared, one 
containing the telomere primer pair and the other with ALB primers. The volume used was 
dependent on the number of samples to be assayed and was calculated to allow an extra 10% 
for the ease of pipetting with a multichannel pipette. The MM was vortex mixed, placed into 
a multichannel trough and 10 µL dispensed into all sample wells. 5 µL of genomic DNA (2 
ng/µL or 4 ng/µL for the MMQPCR or two-plate assay respectively) was added for each 
sample and mixed by pipetting up and down. An optical sealer was applied to cover the plate, 
followed by centrifugation for 2 min at 3200 g in an Eppendorf 5810-R centrifuge to make 
sure the samples were at the bottom of the wells and remove bubbles. The plate was then 
inserted into the LC480 and the cycling profile loaded (Table 2.5 for MMQPCR, Table 2.7 
and Table 2.8 for the two-plate assay). 
2.4.3.2 Positive and negative control samples 
Positive and negative controls were included in every assay to determine if the assay was 
performing adequately. This also allowed samples assayed on different plates to be 
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compared and used to calculate the intra- and inter-assay variation. Three positive control 
DNA samples were chosen to provide T/S ratios of different length: a 50-year old for the 
shorter length; a 7-year old child for medium length; and mouse embryonic stem cell lines 
for the longer length [McHugh et al. 2008, Varela et al. 2011]. These were of a known length 
as determined by TRF (Southern blot, Section 2.5) analysis [Jodczyk 2011]. A bulk amount 
of DNA for these controls was prepared and used for all assays in this thesis. These control 
samples were stored at 4°C. A negative control containing MPW was always used to check 
for DNA contamination. 
 






HOT FIREPol® DNA 
Polymerase  
5 U/ µL 1.25 U Solis BioDyne, Tartu, Estonia 
HOT FIREPol® Buffer B1 10 X 1 X Solis BioDyne, Tartu, Estonia 
MgCl2 25 mM 2 mM Solis BioDyne, Tartu, Estonia 
dNTP 2 mM 0.2 mM Fisher Biotech, Western Australia 
Telg Primer 10 µM 900 nM IDT Pte. Ltd., Singapore  
Telc Primer 10 µM 900 nM IDT Pte. Ltd., Singapore 
Albu Primer 10 µM 900 nM IDT Pte. Ltd., Singapore 
Albd Primer 10 µM 900 nM IDT Pte. Ltd., Singapore 
SYTO® 9 fluorescent Dye  50 µM 1.5 µM LifeTechnologies, Carlsbad, USA 
Genomic DNA 4 ng/µL 20 ng  
Note: The MM contained either the telomere or ALB primer pairs 
















































































































2.4.3.3 Sample concentration and data analysis 
Sample concentration was determined using the standard curve method. For each standard 
curve, a reference gDNA sample was prepared by two-fold serial dilutions in MPW to 
produce seven concentrations of DNA ranging from 1.56-100 ng. A bulk amount of these 
concentration standards was made and used for all assays in this thesis. Each dilution was 
allowed to stand at room temperature (RT) for a few minutes to allow adequate diffusion, 
and stored at 4°C. LightCycler® 480 software 1.5.0 (Roche, Mannheim, Germany) was used 
to convert the cycle threshold (Ct) to nanograms of DNA using the second derivative method 
[Pfaffl 2001]. The T/S ratio was calculated by dividing the telomere product by the single 
copy reference gene product and the average taken of the duplicate measures.  
2.4.3.4 Assay quality control (QC) 
During routine usage of the assay several quality control procedures were applied (Figure 
2.1). Plate position effects were assessed by including four replicates of each positive control 
sample, with two replicates positioned on the left side of the 384-well plate (column 1 + 2) 
and two replicates on the right hand side (column 23 + 24) as this was where the severest 
position effects were observed with the MMQPCR assay (Section 3.2.3). These control 
samples were also used to calculate the intra and inter-assay variation and to control for any 
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other issues such as contamination. The amplification efficiency of the assay was assessed 
by ensuring the standard curve for both the telomere and single copy reference gene fell 
within the range of 90-110% [Bustin et al. 2009] and that every point in the curve generated 
the same T/S ratio, to ensure that the assay accounted for the initial differences in sample 
concentration if any were present. Finally, as the telg and telc primers were prone to primer 
dimer formation, the no-template (MPW) control was always checked to ensure no product 
appeared until at least seven cycles beyond the lowest concentration on the standard curve. 
If any of these quality control criteria failed, the assay was repeated. 
If the assay passed these QC measures, then the resulting data were subjected to additional 
checks. For the data from each sample to be acceptable it had to fall within the range of the 
standard curve, the amplicon melt-curve had to display the appropriate temperature profile 
with no evidence for non-specific amplification, and the coefficient of variation (CV) for the 
replicates for either product had to be below 10% which was calculated using the 
concentration of the products and not the Ct. If the sample did not pass, it was re-assayed a 




Figure 2.1. qPCR data analysis flow chart 
Several quality control procedures were applied to the samples before use in the analysis, 
starting with a check of the assay and then the individual sample. 
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2.5 TRF analysis 
TRF was used to validate the results obtained from the modified qPCR assay.  
2.5.1 TeloTTAGGG Telomere Length Assay 
Southern blotting was performed using the TeloTTAGGG assay kit (Roche Applied Sciences, 
Mannheim, Germany), which uses a non‐radioactive chemiluminescent assay to measure mean 
terminal restriction fragment (TRF) length (Figure 2.2). This was performed following the 
manufacturers protocol. 1.5 µg genomic DNA was digested with the restriction enzymes HinfI 
and RsaI for 2 hours at 37˚C to generate low molecular weight fragments, leaving the higher 
molecular weight telomeric and sub-telomeric regions intact. Digested genomic DNA was 
subjected to gel electrophoresis on an 11 cm 0.8% agarose gel at 5 V/cm until the dye front 
migrated 10 cm, which took approximately 4 hours. To ensure accurate length measurement, 
samples were flanked by a digoxigenin (DIG) molecular weight marker ranging from 21.2 kb 
to 81 bp, supplied in the kit. The resolved DNA fragments were transferred onto HybondTM - 
N+ membrane (Amersham Pharmacia Biotech, New Jersey, USA) by blotting overnight using 
capillary transfer. The membrane was hybridized at 42°C with a telomere-specific, DIG 
labelled probe followed by a DIG-specific antibody covalently coupled to alkaline 
phosphatase, to generate a chemiluminescent signal for detection. The blot was visualised with 
auto-exposure using an UVItech Alliance Bio-imaging System (Cambridge, United Kingdom). 
The telomeric DNA was visible as a smear, and images were edited as required and saved as a 
JPEG before analysis with UVIBand imaging software and the TELORUN [Ouellette et al. 





Figure 2.2. Principle of the TRF method 
Southern blotting with chemiluminescent detection is used to measure mean TRF length. 
Genomic DNA is digested leaving the telomeric and parts of the sub‐telomeric region intact. 
The fragments are separated on a 0.8% agarose gel and transferred onto a positively charged 
nylon membrane using overnight capillary transfer. A DIG-labelled telomere-specific probe 
binds to the telomeric DNA, which is then incubated with Anti‐DIG‐AP and converted into a 
detectable signal by CDP‐Star. Reproduced from Roche TeloTTAGGG telomere length assay 
handbook (Cat. No. 12 209 136 001). 
2.5.2 Densitometry analysis 
To convert the telomeric-specific smear on the Southern blot image into mean terminal 
restriction fragment length (TRF), the molecular weight marker (MWM) first had to be 
converted to migration distance to determine the fragment size of the smear. This was 
performed using the UVIBand imaging software (Figure 2.3, A) following the software’s 
workflow and the instructions outlined in TELORUN. A volume analysis was also performed 
(Figure 2.3, B) to validate the marker signals, which could be manually altered if required. 
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Each blot contained two MWM to account for any differences in migration across the gel. The 
blot was rotated as required to align the two markers. To measure the mean density of the 
telomere-specific smear, as advised by the TeloTTAGGG and TELORUN protocol, a vertical 
grid containing 30 boxes of equal size was overlaid on the blot image (as shown in Figure 2.5) 
where each lane was manually adjusted so that only signal from that lane was contained. In 
Excel, the molecular weights from the marker were plotted against the migration distances, and 
a trend line fitted to the data using the power option (Figure 2.4). The equation of the trend line 
was then used to determine the molecular weight (kb) of each of the 30 boxes on the grid. The 
volume density of each box in the grid was calculated with no background subtraction. 
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Figure 2.3. Molecular weight marker analysis 
UVIBand imaging software (Cambridge, United Kingdom) was used to convert the molecular 
weight marker (MWM) to migration distance. The MWM (A) ranges from 21.2 kb to 1.35 kb 
and the software has determined the size (green) and position (red) of the marker. A volume 
analysis was performed (B) to validate the marker signals (C). 
 






Figure 2.4. MWM analysis in Microsoft Excel 
Prior to TELORUN analysis, the molecular weights from the MWM (A) were plotted against the migration distances (B), which was performed 
in Microsoft Excel. A trend line fitted to the data using the power option (C). The equation of the trend line was then used in TELORUN to 
determine the molecular weight (kb) of each of the 30 boxes on the grid.  





Figure 2.5. Densitometry analysis of mean TRF length 
The Southern blot is shown with the telomere-specific smear in black. Lanes B and I contain 
the MWM ranging from 21.2 kb to 1.9 kb. Lanes C-H and J-N all contain different genomic 
DNA samples, with DNA from ES cells in lane A. The grid generated by the UVIBand imaging 
software has been overlaid on the blot and is shown in green with the corresponding box 
number shown in red. 
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2.5.3 TELORUN  
The data obtained from the molecular weight and density analysis were put into the TELORUN 
Microsoft Excel spreadsheet (Figure 2.4). Background subtraction was performed manually by 
examining each DNA sample separately on the blot (Figure 2.5) and determining the extent of 
the smear. The two boxes spanning the smear with no signal present were designated as the 
upper and lower detection limit and were entered into the TELORUN excel worksheet. All the 
values above and below these limits were deleted as they were representative of the 
background. TELORUN then calculates a weighted and un-weighted mean for telomere length. 
The weighted mean does not assume that all telomeres are the same length, whereas the un-
weighted method does.  
2.6 Analysis of exome data 
Here the bioinformatics tools used for processing the exome data (Chapter 6) are described. 
Whole exome capture and sequencing was contracted to Otogenetics Corporation (Norcross, 
GA USA). Next generation sequencing (NGS) produces a large amount of “raw” sequence 
reads which need to be checked for quality, mapped to a reference sequence, realigned and 
recalibrated for them to become analysis ready reads in which variants can be called. The raw 
sequence reads were processed through an analytical pipeline (Figure 2.6 and Appendix A) 
established on the National eScience Infrastructure (NeSI) by Dr Klaus Lehnert (Department 
of Biological Sciences, University of Auckland), to generate a variant call format (VCF) file. 
NeSI provides national high performance computing facilities which are required for the 
processing of exome data. 
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2.6.1 Sample preparation 
Six samples from the Canterbury Health, Ageing and Life Course (CHALICE) study (Section 
2.1.2) were selected for this analysis on the basis that they had the lowest T/S ratios (C100184 
T/S 0.77, C100062 T/S 0.79, C100035 T/S 0.79, C100332 T/S 0.80, C100173 T/S 0.80, 
C100156 T/S 0.82), and therefore the shortest mean telomere lengths of the cohort (as 
determined in Chapter 5). The integrity of the DNA was checked by agarose gel electrophoresis 
and quantified by UV spectrophotometry prior to sending them to Otogenetics (Norcross, GA 
USA) for processing (Section 2.6.2). Samples were sent at ambient temperature using 
DNAstable® (Biomatrica, San Diego, CA), a storage medium that preserves genomic DNA at 
room temperature. Briefly, 5 µg of each sample was added to tubes coated with DNAstable® 
and left to dry in a laminar flow fume hood at room temperature until the sample was 
completely dry. 
2.6.2 Library preparation and WES  
Whole exome capture and sequencing was contracted to Otogenetics Corporation (Norcross, 
GA USA). A detailed description of the full library preparation procedure can be found in 
Appendix B. Briefly, gDNA was fragmented using a Bioruptor, and fragments that met the size 
criteria were made into Illumina libraries using SPRIworks HT Reagent Kit. The resulting 
libraries were subjected to exome enrichment using Agilent SureSelect AV5 (Agilent 
Technologies, Wilmington, DE USA, catalog# 5190-6213) following manufacturer’s 
instructions. The samples were sequenced on the Illumina HiSeq 2000 which produced paired-
end reads of 101 nucleotides (nt), with an average read depth of 30X. Otogenetics performed 
basic bioinformatics analysis on the sequence data; however, this did not contain enough 
information for confident variant calling and was disregarded. The resulting raw FASTQ 
sequence files were therefore downloaded from DNAnexus (bioinformatics provider for 
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Otogenetics; https://www.dnanexus.com) and processed through the New Zealand eScience 
Infrastructure (NeSI) pipeline for variant calling (Sections 2.6.4 and 2.6.5).  
2.6.3 Quality control of raw sequence reads  
The raw reads were first assessed for data quality using FASTQC on the Galaxy server before 
proceeding with the subsequent steps involved with variant calling. FASTQC provides a quick 
quality control overview to determine if there are any problems with the data [Andrews 2010]. 
This is done on the per base and sequence level by assigning quality scores, and checking 
parameters such as the GC and N content, sequence length distribution, duplication levels, 
overrepresented sequences and Kmer content. No problems were found by FASTQC with the 
raw data received from Otogenetics (Appendix C).  
2.6.4 Sequence alignment and variant calling 
Sequence reads from the FASTQ files provided by Otogenetics Corporation (Norcross, GA 
USA) were mapped to GRCh37.p13 using Burrows Wheeler aligner (BWA) v 0.7.10 [Li and 
Durbin 2009]. The following down-stream processing was done with the Genome Analysis 
Toolkit (GATK), SAMTools and Picard. Reads were sorted by chromosome coordinate and 
indexed using SAMtools version 0.1.19 [Li et al. 2009] and PCR duplicates were removed with 
Picard v1.111 (http://broadinstitute.github.io/picard/) before and after local realignment 
around known (1000G) and newly discovered indels (from the call set of interest) with Genome 
Analysis Toolkit (GATK) v 3.3-0 [McKenna et al. 2010]. The final alignments were subjected 
to base quality score recalibration (BQSR) using GATK v3.3-0 [DePristo et al. 2011]. SNPs 
and indels were called simultaneously for each sample individually via local re-assembly of 
haplotypes using GATK, HaplotypeCaller algorithm v3.3-0 [DePristo et al. 2011], in GCVF 
mode. Joint genotyping was done using GATK Genotype GVCF algorithm, v 3.3-0 and 
supported with an additional 119 unrelated New Zealand exome samples, which leveraged 
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information from all samples when calling the genotypes from the individual samples. These 
additional samples were obtained by the same sequencing and alignment procedures, but had 
an unknown telomere phenotype (length) and were used to filter for false positive calls that 
may be population or platform specific. Variants present at a high frequency were deemed 
likely to be irrelevant for our purposes and filtered out. This produced a raw VCF file 
containing unfiltered SNV and indel calls. Before this file could be used in downstream 
analyses it required filtering, which can be done by variant recalibration (Section 2.6.5) or hard-
filtering. 
2.6.5 Variant quality score recalibration (VQSR)  
Variant quality score recalibration (VQSR) was performed by Dr Lenhert (University of 
Auckland) on these six exome sets in combination with 125 exomes from other New Zealand 
subjects, using GATK v 3.3-0 VariantRecalibrator and ApplyRecalibration with 
UnifiedGenotyper [DePristo et al. 2011]. VQSR is a type of statistical or “soft” filtering that is 
applied to the raw variant calls to filter for false positives and improve the accuracy of base 
calling by determining the probability that a SNV is a true genetic variant versus a sequencing 
or data processing artefact. Briefly, an adaptive error model is built using a ‘true’ (training) set 
of variants verified in the 1000G to discover the properties of these variants, including things 
such as strand bias, read position, mapping quality and haplotype score. This model is then 
applied to known and novel variation discovered in the call set of interest to estimate the 
probability that each variant in the call set is a true genetic variant or a machine/alignment 
artefact. The filtering criteria are learned from the data itself and therefore it is recommended 




Figure 2.6. Raw reads to analysis-ready reads through the NeSI pipeline 
The raw sequence reads were processed through the NeSI analytical pipeline to generate 
analysis ready reads. 
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2.7 Telomere purification method for the MinIONTM 
Sequencing on the MinIONTM (Oxford Nanopore Technologies, Oxford, UK) (Chapter 7) 
required enrichment of telomeric DNA from total genomic DNA. This method is referred to as 
the ‘pull-down’ assay and uses a telomere-specific biotinylated oligonucleotide that hybridises 
to the telomeric DNA, and is subsequently captured using streptavidin-coated magnetic beads. 
This method is based on Wright et al., 1997 [Wright et al. 1997] with modifications as 
described in Chapter 7. The final protocol derived from these experiments is recorded below. 
2.7.1 Telomere pull-down assay 
2.5 µg of gDNA was digested in a 50 µL reaction with the restriction enzyme HinfI (10 U/µg) 
for 3 hours at 37°C followed by heat inactivation for 20 min at 80°C. This step should release 
intact telomeric DNA (which will not be digested) from the remaining gDNA. Digested DNA 
was adjusted to 1x saline-sodium citrate buffer (SSC)/ 1% Triton X-100 before addition of 1 
pmol of a biotinylated oligonucleotide (CCCTAA)6 (Integrated DNA Technologies, Coralville, 
IA, USA), complementary to the terminal telomeric single stranded G-rich overhang [Makarov 
et al. 1997, Wright et al. 1997]. Annealing was carried out in a thermal cycling machine at 
65°C, 55°C, 45°C, 35°C, and RT for 15 min each, to allow formation of an 
oligonucleotide/telomere complex. Streptavidin-coated magnetic beads (1mg/mL) 
(MagneSphere® magnetic separation products, Promega, Sydney, Australia) were prepared 
prior to use in the capture process. First, a magnet was used to pull the beads aside so the 
storage buffer (PBS, 1 mg/ml BSA and 0.02% sodium azide) could be removed; this was 
followed by the addition of an equal volume of 0.5x SSC and vortexing to re-suspend the beads 
until the solution was homogeneous. This process was repeated two more times. The washed 
beads were subsequently incubated for one hour in 5x Denhardt’s solution to reduce non-
specific binding, then 20 µL of the beads solution was added to the annealed 
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oligonucleotide/telomere complex and the DNA–bead suspension incubated with gentle 
rocking at 4°C for 30 min to allow the beads to bind to the biotinylated oligonucleotide. The 
magnetic beads were drawn to the side of the tubes and the supernatant containing the unbound 
telomeric DNA removed and saved. The beads were re-suspended and washed twice with 100 
µL of 1× SSC/1% Triton X-100 and the bound telomeres subsequently eluted from the beads 
by melting the oligonucleotide/telomere interaction at 65°C for 10 min in 30 µL of 0.1x 
SSC/1% Triton X-100. 
2.8 Sample preparation and dot-blotting 
Samples were denatured prior to loading onto the membrane using alkali/heat treatment 
[Brown 2001]. Typically, a total sample volume of 100 µL was used including 20-50 µL of 
pull-down product, with the amount dependent on the requirements of downstream 
applications. To ensure complete denaturation, NaOH and EDTA at final concentrations of 0.4 
M and 10 mM respectively were added to the pull-down samples, followed by heating for 10 
min at 100°C, then brief centrifugation. A positively charged nylon membrane HybondTM - N+ 
membrane (Amersham Pharmacia Biotech, New Jersey, USA) was pre-soaked for 10 min in 
MPW before use and the blotting manifold prepared following the manufacturers’ instructions. 
Assembly of the manifold included applying a vacuum, so the membrane was first rehydrated 
with 500 µL MPW before samples were added. Samples were then added and pulled through 
using gentle vacuum or gravity, and once they were completely filtered through, 500 µL of 0.4 
M NaOH was added. After completion, the membrane was removed from the apparatus, rinsed 
in 2x SSC and air dried. The telomeric DNA was detected following the TeloTTAGGG kit 
protocol (Roche Applied Sciences, Mannheim, Germany). 
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2.9 Plasmid positive control samples 
Plasmids were obtained from bacterial stabs supplied by the Addgene 
(https://www.addgene.org/) repository. Purified plasmid DNA was prepared as described 
below. 










used for digest1 
Sequencing 
primers 
pBB [# 53210] 103 bp Ampicillin 37°C BamHI, SspI T3, T7 
f.pRST1 [# 50494] 136 bp Ampicillin 37°C BamHI, SspI T3, T7 
pSXneo [# 12403] 1.6 kb Ampicillin 37°C EcoRI, SspI Sp6, T7 
1BamHI and EcoRI generate sticky ends, SspI to generate blunt ends. 
 
 
2.9.1 Bacterial growth media 
2YT agar plates were made by weighing the following into a 1 L Schott bottle: 2.5 g NaCl, 8 
g tryptone, 5 g yeast extract, 7.5 g agar, then adding MPW to 500 mL, followed by autoclaving. 
If 2YT broth was required, the agar was omitted. After autoclaving, the solution was cooled to 
55°C using a water bath, and ampicillin was added to a final concentration of 100 µg/mL and 
swirled to mix. Approximately 20 mL of this solution was poured per 10 cm polystyrene Petri 
dish, taking care not to introduce any bubbles. Lids were re-placed and the solution allowed to 
cool until solidified which took approximately 30-60 min, following which plates were stored 
at 4°C.  
2.9.2 Isolation of single colonies 
Single colonies from each bacterial stab provided by Addgene were isolated by streaking the 
bacteria onto a 2YT agar plate containing ampicillin (Section 2.9.1) using an inoculation loop. 
This was then incubated overnight at 37°C. After growth, plates were typically stored at 4°C 
for a few weeks. 
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2.9.3 Bacterial growth and storage 
For overnight cultures of these bacteria, a single colony was inoculated into 1-2 mL 2YT broth 
(Section 2.9.2) containing ampicillin to a final concentration of 100 µg/mL, and incubated with 
shaking at 37°C overnight. For the long-term storage of plasmids, bacterial glycerol stocks 
were made where the addition of the glycerol stabilises the frozen bacteria and prevents damage 
to the cell membranes. After bacterial growth from an overnight culture, 500 µL of culture and 
500 µL of 50% glycerol was added to a 2 mL cryovial and stored at 80°C. Bacteria from the 
glycerol stocks were recovered as described in Section 2.9.2.  
2.9.4 Isolating plasmid DNA from bacterial culture 
To purify the plasmid DNA from the cultured bacteria, a ChargeSwitch®-Pro Plasmid Miniprep 
Kit (InvitrogenTM) was used. This kit uses an ion-exchange mechanism to purify plasmid DNA 
from E. coli. Purification was performed following the manufacturers protocol. Typically, 
multiple fresh overnight cultures (Section 2.9.3) were combined (approximately 5 mL) and 
harvested by centrifugation to pellet the bacteria. The bacterial cells were re-suspended and 
lysed to release their contents into solution. The gDNA and proteins were precipitated and 
pelleted by centrifugation, and the plasmid DNA remaining in the supernatant transferred into 
a ChargeSwitch®-Pro Miniprep column inserted into a collection tube. The plasmid DNA 
bound to the column and was subsequently washed, eluted and quantified by UV absorbance 
at 260 nm and stored at 4°C.  
 
2.9.5 Transformation of plasmid DNA into DH5α 
The plasmid pSXneo containing the 1.6 kb telomeric DNA insert was not growing optimally 
in the original bacterial host strain (Stbl3) provided by Addgene, so all three plasmids were 
transformed into DH5α in an attempt to improve yields. Competent cells were made using a 
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calcium chloride treatment to give competent cells in the of the order of 105 colonies per µg of 
DNA [Sambrook et al. 1989]. Reaction components were kept on ice wherever possible. 1 mL 
of an overnight culture of DH5α was added to 100 mL 2YT pre-warmed to 37°C in a 500 mL 
Ehrlenmeyer flask, and incubated with shaking for 2-2.5 hours. This solution was separated 
into two 50 mL Falcon tubes and centrifuged for 15-20 min to pellet the cells, which were then 
re-suspended in 50 mL cold 100 mM CaCl2. Cells were again pelleted and re-suspended in 8 
mL 100 mM CaCl2, then left for 24 hours on ice or at 4oC before use to reach optimal 
competency. Alternatively, they were stored in small aliquots at -80°C with the addition of 
100% glycerol. For the transformation of the plasmids, 100 µL of competent cells and 2 ng 
plasmid DNA were incubated on ice for 20-60 min. Following this, they were heat-shocked at 
42°C in a heating block for 2 min, and returned to ice. 500 µL of 2YT and ampicillin to a final 
concentration of 100 µg/mL was added and 150 µL of this mixture plated to obtain single 
colonies.  
2.10 Use of MinIONTM nanopore sequencing device 
2.10.1 MinIONTM library preparation 
Dr Simone Cree (this laboratory) prepared the sequencing libraries, ran the MinIONTM device, 
and processed the raw data into analysable sequence reads. Three different library preparation 
kits (SQK MAP002-004) were used. The SQK MAP-002 and 003 was used to prepare the 
plasmid libraries and SQK MAP-004 for the preparation of the pull-down products. One 
microgram each of product (purified plasmid or pull-down) was end-repaired using the 
NEBNext® End Repair module (New England Biolabs, Ipswich, MA, USA) and the resultant 
products were cleaned up with 1x by volume Agencourt AMPure XP beads (Beckman Coulter, 
High Wycombe, Buckinghamshire, UK). dA-tailing was then carried out using the NEBNext® 
dA-Tailing Module in either a 30 or 50 µL reaction. When the SQK MAP 002-003 kits were 
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used, the dA-tailed DNA (50 µL) was ligated with 10 µL each of the adaptor mix and HP 
adaptor in 20 µL ONT-supplied ligation buffer using 20,000 U of T4 DNA Ligase (10 µL of 
2000 U/µL). For the SQK MAP-004 kit, dA-tailed DNA (30 µL) was ligated with 10 µL of the 
adaptor mix, 2 µL HP adaptor, 8 µL nuclease-free water and 50 µL Blunt/TA Ligation Master 
Mix (New England Biolabs, Ipswich, MA, USA). These reagents were sequentially added and 
mixed by inversion between each addition. After careful mixing of the reagents, the tube was 
briefly spun at a low speed in a microfuge, sufficient to collect the reagents at the bottom of 
the tube, and incubated for 10 min. For the SQK MAP-002 and 003 kits, adaptor-ligated 
products were then purified using 0.4x Agencourt AMPure XP beads by volume following the 
manufacturer's protocol except that ONT-supplied Wash Buffer and Elution Buffer were used, 
and pelleted beads were washed once rather than twice. The adaptor-ligated products were 
eluted from the beads in 25 µL of Elution Buffer. HP motor (15 µL) was then attached to 
adapted and tethered products by adding 35 µL of reaction mix from the previous step, followed 
by mixing and overnight incubation at RT for the SQK MAP- 002 where only a 10 min 
incubation was required for SQK MAP-003. For the SQK MAP-004 kit, the adapter- ligated 
products were enriched for hair-pin containing adaptors by purifying with 10 µL washed 
Dynabeads® His-beads (Life Technologies) (prepared as per manufacturer’s instructions) and 
eluted in 25 µL of ONT supplied Elution Buffer. This library, referred to as the Pre-Sequencing 
Mix, was loaded on the MinIONTM device after mixing with the EP Buffer and Fuel Mix (12 
µL of Pre-Sequencing Mix plus 135 µL of EP Buffer and 4 µL of Fuel Mix for SQK MAP-002 
and 003, and for SQK MAP-004, 6 µL of Pre-Sequencing Mix plus 141 µL of EP Buffer and 
3 µL of Fuel Mix).  
 
For the second pull-down experiment, following end-repair, clean up and dA tailing, the dA-
tailed DNA (30 µL) was ligated with 20 µL of the adaptor mix using the 50 µL Blunt/TA 
Ligation Master Mix (New England Biolabs, Ipswich, MA, USA) as per the SQK MAP-004 
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kit. The adaptor-ligated products were prepared following the protocol for the SQK MAP-002 
and 003 kits. 
2.10.2 Data analysis 
Raw data generated by the sequencing device was uploaded onto a cloud-based base-caller 
(MetrichorTM Agent v2.19.43228) provided by ONT (Oxford, UK) and converted into 
sequences stored in the Fast5 format. However, being incompatible with current bioinformatics 
tools, these long-read sequences were not analysis-ready and were thus further processed by 
Poretools [Loman and Quinlan 2014] and combined into a single FASTA file. For the plasmid 
runs, the FASTA reads were mapped to a custom reference sequence for the three plasmids, 
using the LASTZ aligner v7.0 [Harris 2007]. This aligner was available as a plugin in Geneious 
8.1.5 (Biomatters Ltd., Auckland, New Zealand). The FASTA file containing all of the 
sequence reads from the pull-down products were put through the Basic Local Alignment 
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov) and aligned to the human reference 
sequence using BLASTN. 
2.10.3 Flow cell quality control and loading 
Prior to loading the library onto the flow cell the MinKNOW (ONT, Oxford, UK) platform QC 
was completed. This was done by connecting the MinIONTM device to the computer and 
monitoring the buffer supply from the port to the sensor area and ensuring that this was a 
continuous process. The number of pores available was also checked to confirm that they met 
the criteria for sequencing. Following this, the flow cell was primed with EP buffer and Fuel 
mix and the Pre-sequencing library added. Each run lasted ~48 hours, with additional library 
added to the flow cell every ~6-8 hours. 
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2.11 Bioinformatics, statistical analysis and software used 
Quantitative PCR (Chapter 3) 
• LC480 Conversion program 
http://www.hartfaalcentrum.nl/index.php?main=files&sub=0 
Used to convert the raw data exported from the LightCycler 480 into a format that could be 
analysed on LinRegPCR. 
• LinRegPCR http://www.hartfaalcentrum.nl/index.php?main=files&sub=0 
For the MMQPCR assay, the cycle threshold (Ct) and PCR efficiency for the telomere and 
single copy reference gene samples was determined by LinRegPCR [Ruijter et al. 2009]. 
LinRegPCR is a program for the analysis of quantitative RT‐PCR (qPCR) data resulting from 
monitoring the PCR reaction with SYBR® green or similar fluorescent dyes. The program 
determines baseline fluorescence and does a baseline subtraction, then calculates PCR 
efficiencies per sample. Starting concentration per sample is then expressed in arbitrary 
fluorescence units [Ramakers et al. 2003] 
• Microsoft Excel (2010, 2013) 
To calculate the average telomere length for the MMQPCR assay, data was exported from 
LinRegPCR to Microsoft Excel (2010, 2013), then manually manipulated and converted into a 
T/S ratio. For the qPCR assay Microsoft Excel was used solely to calculate the T/S ratio. 
Additionally, the molecular weight marker used in the TeloTTAGGG kit was converted to 
migration distance using Excel.  
• UVIBand imaging software (Cambridge, United Kingdom) 
The telomeric specific chemiluminescent signal generated from the Southern blot assay was 
converted to density values and the molecular weight marker analysis.  
• R v2.8.1 (http://www.r-project.org/) 
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Data was analyzed with linear models, correlation coefficient and box plots in R (Vienna, 
Austria) 
 
Statistical analysis (Chapters 4 and 5) 
Association analysis for the Christchurch Health and Development Study was performed by 
Prof. John Horwood and Prof. David Fergusson. They used multiple linear regression and one-
way analysis of variance to examine associations between telomere length and life course 
stressors. Association analysis for the Canterbury Health, Ageing and Life Course (CHALICE) 
study was performed by Dr John Pearson and again, standard linear regression techniques were 
used. A P value of < 0.05 was considered significant for both studies. 
 
Exome analysis (Chapter 6) 
• UCSC Genome Browser http://genome.ucsc.edu/ 
UCSC Genome Browser’s Table Browser was used to extract hg19 genomic coordinates for 
the candidate genes from the track ‘RefSeq Genes’. 
• Human Splicing Finder http://www.umd.be/HSF3/ 
Human Splicing Finder was used to check variants located < 10 bases from a splice site to 
determine if they were predicted to alter splicing. 
• ExAC Browser http://exac.broadinstitute.org/ 
The population MAFs were obtained from the Exome Aggregation Consortium (ExAC) 
browser (http://exac.broadinstitute.org/) as well as the SIFT and PolyPhen-2 predictions. 
 
MinIONTM (Chapter 7) 
• Geneious v8.1.5 http://www.geneious.com/ - used for the analysis of sanger seq too 
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The FASTA reads were mapped to a custom reference sequence using the LASTZ aligner 
v7.0 [Harris 2007] available as a plugin in on Geneious 8.1.5 (Biomatters Ltd., Auckland, 
New Zealand). 
• Basic local alignment search tool (BLAST) (http://blast.ncbi.nlm.nih.gov)  
The FASTA file containing the sequence reads from the pull-down products were put through 





Table 2.10. General solutions and buffers 
 
Proceedure Solutions and/or buffers
Agarose gel electrophoresis 10x TAE buffer 
48.4 g of Tris base
11.4 mL of glacial acetic acid
3.7 g of EDTA, disodium salt
MPW up to 1 L
*1x TAE was prepared by diluting 10x TAE 1 in 10 with MPW
Microchip electrophoresis SYBR® Gold 100× solution
1 µL of SYBR® Gold 10,000× concentrate in 99 µL of 1× Tris-EDTA buffer
Ladder solution
1 µL of ladder stock in 99 µL of 1x Tris-EDTA buffer
Southern blotting 0.25 M HCl
25 mL Analar conc HCl
MPW up to 1 L
Denaturation solution (0.5M NaOH, 1.5M NaCl)
20 g NaOH
87.66 g NaCl 
MPW up to 1 L
Neutralisation solution (0.5 M Tris‐HCl, 3 M NaCl) pH 7.5
121 g Tris
175.32 g NaCl 
MPW up to 1 L
20x SSC (3 M NaCl, 0.3 M Sodium citrate) pH 7.0
88.2 g Sodium citrate 
175.32 g NaCl 
MPW up to 1 L
*2x SSC was prepared by diluting 20x SSC 1 in 10 with MPW
Pull-down assay 50x Denhardt's solution
1 g Ficoll 400
1 g Polyvinylpyrrolidone (PVP)
1 g Bovine serum albumin (Fraction V)
MPW up to 100 mL
Dot-blotting 1 M NaOH
4 g NaOH
MPW up to 100 mL
*0.4 M NaOH was prepared by diluting 1 M NaOH 1 in 2.5 with MPW
200 mM EDTA, pH 8.2
3.72 g EDTA
MPW up to 50 mL
Competent cells CaCl 2
7.35 g Calcium chloride dihydrate
MPW up to 500 mL and autoclaved
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Chapter 3: Telomere length measurement assay 
The work described in this chapter contributed to the publication Jodczyk et al., (2015) 
Telomere Length Measurement on the Roche LightCycler 480 Platform. Genetic testing 
and molecular biomarkers 19, 63-68. 
3.1 Introduction 
Currently, qPCR is the preferred method of telomere length measurement in large 
epidemiological studies. It was the primary method selected for this project as it is 
appropriate for the analysis of many samples and does not require relatively large 
amounts of DNA or live cells, unlike other methods [Aubert et al. 2012]. The qPCR 
method provides a relative measure of average leukocyte telomere length from genomic 
DNA, expressed as a T/S ratio. This is done by measuring the number of telomere repeats 
(T) across all chromosomes for all cells, relative to the amount of a single copy reference 
gene (S). This can be performed in either a single [Cawthon 2002] or multiplex [Cawthon 
2009] reaction format, the latter method being referred to as monochrome multiplex 
quantitative PCR, MMQPCR.   
 
The original qPCR method was implemented on the ABI Prism 7700 real-time thermal 
cycling platform [Cawthon 2002], and MMQPCR was established on the Bio-Rad MyiQ 
Single Color Real-Time PCR platform [Cawthon 2009]. The majority of published 
studies on telomere length report using Applied Biosystems real-time PCR platforms, 
such as the ABI 7000 or 7900. However, the only high throughput qPCR platform 
available for this project was the Roche LightCycler® 480 real-time PCR (LC480, 
Roche, Mannheim, Germany). The LC480 platform has 384-well capability and is in 
widespread use for many applications in research and diagnostic laboratories, although 
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it appears to have only rarely been used for telomere length measurements [Gil and 
Coetzer 2004]. Considerable technical challenges were experienced when establishing a 
reliable qPCR method for telomere length measurement on the LC480 platform, as 
documented below. 
 
As the MMQPCR method appears to offer greater precision and economy, considerable 
efforts were made to establish the method published by Cawthon (2009) [Cawthon 2009], 
prior to beginning this PhD research [Jodczyk 2011]. However, this multiplexed reaction 
format proved problematic, including issues with specific reaction components such as 
the choice of hot-start polymerase and intercalating dye, as well as the data analysis, 
which proved difficult to perform effectively with the LC480 software. Even after 
addressing these issues, difficulty establishing a reliable MMQPCR assay was 
experienced, predominantly due to a considerable amount of assay variation evident in 
the preliminary data generated prior to this PhD research [Jodczyk 2011]. In this pilot 
study of the CHDS cohort, only 255 samples out of 432 assayed (~60%) could be 
included in the final analysis due to extremely large CVs between replicates. Therefore, 
possible sources of this considerable variation were investigated at the outset of my PhD, 





The MMQPCR assay involves the co-amplification of more than one product in the same 
PCR reaction, using specific primer pairs and a single fluorescent dye. This can be achieved 
as the telomeric target amplicons have a high copy number relative to the single copy 
reference gene, enabling the abundant telomere product to be amplified in earlier PCR 
cycles. Therefore, successful multiplexing required a sophisticated design of the primer pairs 
(Figure 3.1) to permit the two targets to be amplified separately and to ensure the fluorescent 
signals did not overlap and interfere with quantification. This was accomplished by 
generating a fixed length telomere product [Cawthon 2009]. The original telomere primers 
(Table 2.1) from the two-plate assay generated products of varying length, which can melt 
at a range of temperatures [Cawthon 2002]. The way in which this is achieved is outlined in 
Figure 3.1. Briefly, a fixed length product is created as the 3’ end of the telc primer was 
designed to contain a mismatch so it could only prime the extension product of the telg 
primer, and would not be able to prime the native telomeric DNA. To enable separate signal 
generation, a G‐C clamp is added to the 5’ end of the single copy reference gene primers, 
thus increasing the melting point of the product and allowing the more abundant telomeric 
DNA target to be amplified in earlier cycles while the single copy gene is still at baseline. 
The annealing temperature is then increased, melting and preventing annealing of the 
telomeric amplicon, sending the signal to baseline and allowing the single copy gene target 
to be amplified in later cycles enabling separate signal generation. After completion of the 
experiment the data were exported from the LC480 (Roche, Mannheim, Germany) as the 
software was unable to process the single fluorescent dye/dual product design. The data was 
rearranged in Microsoft Excel and imported into the LC conversion program which converts 
the data into a grid format, allowing the programme LinRegPCR [Ruijter et al. 2009] to 
process the data and calculate the Ct [Jodczyk 2011]. 
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Figure 3.1. MMQPCR telomere primer design  
A: In Cycle 1, both the telg and telc primers hybridise to the native telomeric DNA but only 
telg can prime synthesis. The telc primer contains a 3’ terminal mismatch and therefore 
cannot prime synthesis. The 5’ ends of both primers (shown in upper case bases) do not 
hybridise to the native telomeric DNA, which prevents the primers’ 3’ ends from priming 
synthesis in the middle of other copies of the telomere product in subsequent cycles. B: As 
shown, primer dimer formation is inhibited due to specific mismatches in both the primer 
sequences. C: In Cycle 2, the telc primer hybridises to the extension product of the telg 
primer that was synthesised in cycle 1 but only in the configuration shown. This generates a 
fixed length 79bp product. Figure from [Cawthon 2009]. Reprinted with permission from 






3.2.1 Troubleshooting of high assay variability 
The external data analysis program LinRegPCR [Ruijter et al. 2009] was required to 
calculate the Ct of the amplicons for the MMQPCR assay, as the LC480 software 1.5.0 
(Roche, Mannheim, Germany) could not process the single fluorescent dye/dual product 
design. These data were therefore exported off the machine and manually separated into two 
independent Excel spreadsheets, before conversion with the LC480 software into a format 
that could then be used for analysis by LinRegPCR [Ramakers et al. 2003]. However, 
LinRegPCR frequently gave the error messages of “noisy data” or “baseline errors” where 
the program was unable to calculate the Ct values for the samples. A noisy sample is defined 
by LinRegPCR as a sample in which the data in the exponential phase do not continuously 
increase, leading to “noisy data” errors (http://www.gene-
quantification.com/LinRegPCR_help_manual_v11.0.pdf). LinRegPCR also called "baseline 
errors" for samples when the fluorescence between the minimum and maximum values of 
the second derivative did not form a straight line. Both errors led to an inability to effectively 
analyse these samples. Therefore, the raw (background) fluorescent data generated in these 
assays was examined as a potential source of assay variability, as described below. 
3.2.2 Background fluorescence 
In the first cycle of a PCR, the template DNA will double from the initial starting 
concentration and again with each subsequent cycle. This means that up to cycle 6 (for the 
LC480) only a very small amount of DNA is available to contribute to the background 
fluorescent level. The fluorescent signal is generated by the fluorophore, which is a 
component of the intercalating fluorescent dye included in the PCR reaction. It binds to the 
double stranded DNA and the signal is proportional to the amount of product generated 
during the reaction. Samples were normalised to have roughly the same initial template DNA 
concentration prior to assaying (Section 2.1.1), thus fluorescent signal should be similar for 
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all samples during these early PCR cycles. However, variable fluorescent values were 
observed for both the telomere and single copy reference gene amplicons even in the first 
PCR cycle (Figure 3.2), with blocks of samples throughout the plate having either higher 
(lanes 19-24) or lower (lanes 6-10, 13-16) fluorescent levels compared to the other samples, 
producing a distinct ‘W’ pattern. These patterns were consistent between two independent 
assays and could not be accounted for by initial DNA concentration alone. This appeared to 
be a possible reason for the noisy data and baseline errors detected by LinRegPCR, so the 








Figure 3.2. Background fluorescent pattern from two separate MMQPCR assays 
To determine the source of the variability, the raw fluorescence units (RFU) were obtained from the first cycle of the reaction. This was done for both 
ALB (A) and the telomere (B) in two independent assays. The average fluorescent values per column of the 384 well plate were calculated (n = 16). A 





3.2.3 Position effects on background fluorescence 
To determine the cause of the background fluorescent variability described above, a series 
of assays were performed that contained the same genomic DNA sample in every well of the 
384-well plate using a single master mix (Table 2.4). This experimental approach allowed 
systematic testing of several potential sources of variability on the LC480 platform. This 
approach was used to test for evaporation due to plate seal leakage, pipetting errors, 
differential effects due to time taken for assay set-up (including potential degradation of 
reaction components such as the fluorophore), potential position effects, differences in 
plastic-ware, and behaviour of the thermal cycler. Each assay was set up the conventional 
way from left to right or from right to left, in two types of plates to test for differences in 
plastic-ware, using two different pipetting methods, either with a liquid handling robot or by 
manual pipetting with calibrated pipettes. Lastly, to test for possible degradation of the 
fluorophore due to the double signal acquisition per cycle (and thus potential for increased 
photobleaching), the cycling profile was modified and one signal acquisition removed. The 
most striking result from this series of experiments was that severe plate position effects 












Figure 3.3. LC480 plate position effects  
To observe the position effects, a single genomic DNA sample was run across an entire 384-
well plate. The T/S ratio was calculated for each sample and then averaged per column. The 
lower and upper quartiles, the mean values (open circles) as well as the outliers (black dots) 
are shown against a horizontal line and band marking the overall mean and 95% confidence 
interval respectively. The T/S ratio is highly variable across the plate and is shown to steadily 
decrease from 1.5 to 0.5 across the plate from column 12 to 24.  
3.2.4 Melt curve verification 
To confirm these effects and attempt to determine the source of variation, the performance 
of the machine’s Peltier block was tested by loading a single PCR product (ALB) across one 
row of a 384 well plate, then examining the melting point (Tm) of the product by high 
resolution melt curve analysis [Von Keyserling et al. 2011]. The PCR product has a distinct 
Tm due to its base composition, and if the apparent Tm measured by melting curve varies, 
then this indicates inconsistent temperatures across the Peltier block which may affect both 
the DNA denaturation and primer annealing. During this experiment a Tm shift of 0.6°C 
degrees was observed across the PCR plate from column 1 to 24 (Figure 3.4), which could 
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reduce the accuracy of T/S ratio determination, particularly if this effect impacted 
differentially on either the telomere or single copy reference gene amplicon.  
 
These plate effects appeared to be a major source of error in the MMQPCR assay and for 
this reason the MMQPCR method was abandoned, and the original Cawthon (2002) “two-





Figure 3.4. Variation in melting temperature between samples 
The LightCycler® 480 software 1.5.0 was used to generate the melt curve which was used 
to test the Peltier block of the LC480. A single PCR product (ALB) generated with primer 
pairs albu and albd was loaded across one row of the 384-well plate. The melt curves from 
the sample in column 1 and 24 of the 384-well plate are shown with melt curves are displayed 
at 93°C and 93.6°C for the samples in column 1 and 24 respectively. 
3.3 Optimisation of the two-plate assay 
During establishment of the Cawthon (2002) method, the original qPCR primers tel 1, tel 2, 
36B4u and 36B4d [Cawthon 2002] gave inconsistent amplification and poor reproducibility, 
as did primer pairs ASPG3F, ASPG4R, tel1b and tel2b that had been previously used by 
others on the LC480 [Cote et al. 2012] (primer sequences found in Table 2.1). This led to 
the testing of the MMQPCR primers telg, telc, albu and albd (Cawthon 2009) in a single 
98 
 
amplicon (“two-plate”) reaction. These primers had previously worked effectively and 
reliably for MMQPCR, but were untested in the two-plate approach.  
 
Non-specific amplification by the primers, and the amplification efficiency were assessed as 
these would interfere with quantification. Melt-curve analysis was used to test for non-
specific amplification. Only one curve is generated per amplicon if non-specific PCR 
products are absent, with the position of the curve determined by the base composition of 
the product and the temperature that is required to dissociate the double stranded DNA. The 
amplification efficiency was evaluated by running a standard curve (Section 0) and ensuring 
it fell within the accepted efficiency range of 1.9-2.1 (90-110%). A score of 2.0 is equivalent 
to 100% efficiency where the amount of PCR product is doubled after each cycle. The 
MMQPCR primer pairs gave no non-specific amplification (Figure 3.5), and the 
amplification efficiency for the telomere reaction (2.0) and ALB (1.984) fell within the 
acceptable range (Figure 3.6).  
 
Further minor modifications were made to the original Cawthon (2002) qPCR assay 
including a change in the thermal cycling profiles for each amplicon (Table 2.7 and Table 
2.8) and omitting DTT and DMSO, as neither improved the amplification efficiency (data 
not shown). The fluorescent dye SYBR Green (Molecular probes, Oregon, USA) was also 
replaced with the intercalating dye SYTO® 9 (LifeTechnologies, Carlsbad, USA) as it gave 
an enhanced and stable fluorescent signal. To increase the precision of the replicates and to 
help ensure the DNA was homogenous, genomic DNA was diluted to 4 ng/µL and 5 µL was 





Figure 3.5. Primer Specificity 
LightCycler® 480 software 1.5.0 was used to determine the specificity of the primer pairs, 
assessed by running a melt curve at the end of each assay. The telomere product (A) 
generated with primer pairs telg and telc, displays a melt curve at 81°C and using the primers 
albu and albd, the ALB (B) product displays a melt curve at 93.6°C.  








Figure 3.6. Standard curve efficiency 
LightCycler® 480 software 1.5.0 was used to assess the efficiency of the assay by ensuring 
the standard curve for both the telomere and single copy reference gene fell within the range 
of 90-110% (ie 1.9-2.1) and that every point in the curve generated the same T/S ratio. The 





3.3.1 Choice of Taq polymerase 
Prior work [Jodczyk 2011] showed that the telg-telc primer pair was prone to primer dimer 
formation through the hybridisation of a complementary 3 bp on the 3’ termini of both 
primers. This primer-dimer product most likely resulted from residual activity of the hot-
start polymerase prior to heat denaturation. Therefore, when optimising the two-plate 
reaction, twelve hot-start polymerases from several suppliers were evaluated (using the 
master mix and cycling profile in Table 2.6, Table 2.7 and Table 2.8), including enzymes 
with different hot-start activation mechanisms such as antibody mediation or chemical 
modification [Kellogg et al. 1994]. The results for five different hot-start polymerases are 
illustrated in Figure 3.7. PCR products were resolved on the MultiNA microchip 
electrophoresis system as detailed in Section 2.3.3. Six of the twelve hot-start enzymes 
generated a strong primer dimer band with telg and telc, in the absence of genomic DNA 
(Figure 3.7, 2-5), and this was not restricted to hot-start enzymes of a particular category. 
Another three polymerases performed poorly in the assay, generating little or no telomere-
specific PCR product. Only three out of the twelve polymerases tested yielded the desired 
result with no primer dimer formation in the no-template control: HOT FIREPol® (Solis 
BioDyne, Tartu, Estonia); Roche GC Rich (Roche, Mannheim, Germany); and 
LightCycler® 480 probes master (Roche, Mannheim, Germany). The HOT FIREPol® (Solis 







Figure 3.7. Primer-dimer formation by hot-start polymerases  
The 79 bp telomere products generated using five different hot-start polymerases were 
resolved on the MultiNA microchip electrophoresis system. The apparent variation in 
telomere product size between samples is an artefact of the MultiNA system when resolving 
products of small size. Lane M contains the 25 bp size standard (DNA-500 Kit, Shimadzu, 
Kyoto, Japan), with the upper and lower internal standard markers indicated as UM and LM. 
Each pair of lanes contains either genomic DNA (+) or water (–). The results for five 
different hot-start polymerases are illustrated: HOT FIREPol® (1), TAQ-Ti (2), TaKaRa Ex 
Taq HS (3), Hotmaster taq (4) and Paq 5000 (5). The only polymerase that did not generate 




Once the two-plate assay was optimised by modifying the parameters described above, the 
position effects experiment using the same gDNA sample across all wells of a plate (Section 
3.2.3) was repeated, and the position effects previously seen in the MMQPCR assay were not 





Figure 3.8. Test for position effects in two-plate assay 
To observe possible position effects, a single genomic DNA sample was used in the two-plate 
qPCR method, across an entire 384-well plate. The T/S ratio was calculated for each sample 
and then averaged per column. The lower and upper quartiles, the mean values (circles) as well 
as the outliers (black dots) are shown against a horizontal line and band marking the overall 
mean and 95% confidence interval respectively. The modified qPCR assay does not show as 




To assess the intra and inter-assay variation of the modified assay, 12 CHDS genomic DNA 
samples were analysed in duplicate on three different days (referred to as Assay 1, 2 and 3), 
giving a total of six data points for each sample. The coefficient of variation (CV), expressed 
as a percentage, was used as a measure of precision. Table 3.1 shows an average intra-assay 
CV of 5.5%. The inter-assay variation was 7.9%, indicating that the assay variation was 
sufficiently low and results were reproducible. This was confirmed by analysing an additional 
25 genomic DNA samples in duplicate on two separate occasions. The mean duplicate values 
for the 37 samples (12 CHDS and 25 genomic DNA) were plotted on an x/y scatter graph 














Sample # 1 2 3 4 5 6 7 8 9 10 11 12
Assay # 1
Rep 1 0.66 0.83 1.16 1.01 1.03 0.66 1.69 0.5 0.94 1.62 0.9 0.96
Rep 2 0.66 0.78 1.27 1.01 0.75 0.68 1.65 0.5 0.9 1.68 0.82 0.93
Mean 0.66 0.81 1.22 1.01 0.89 0.67 1.67 0.50 0.92 1.65 0.86 0.95
StDev 0.00 0.04 0.08 0.00 0.20 0.01 0.03 0.00 0.03 0.04 0.06 0.02
CV% 0.0% 4.4% 6.4% 0.0% 22.2% 2.1% 1.7% 0.0% 3.1% 2.6% 6.6% 2.2%
Intra-assay CV 4.3%
Assay # 2
Rep 1 0.64 0.86 1.24 1.19 0.91 0.95 1.86 0.51 1.07 1.79 1.04 0.88
Rep 2 0.78 0.85 1.19 1.11 0.88 0.95 1.79 0.5 1.04 1.91 1.06 0.92
Mean 0.71 0.86 1.22 1.15 0.90 0.95 1.83 0.51 1.06 1.85 1.05 0.90
StDev 0.10 0.01 0.04 0.06 0.02 0.00 0.05 0.01 0.02 0.08 0.01 0.03
CV% 13.9% 0.8% 2.9% 4.9% 2.4% 0.0% 2.7% 1.4% 2.0% 4.6% 1.3% 3.1%
Intra-assay CV 3.3%
Assay # 3
Rep 1 0.63 0.79 1.18 1.16 0.95 0.89 2.23 0.48 0.87 1.74 1 0.98
Rep 2 0.71 0.78 2.1 1.13 0.93 0.78 1.56 0.48 0.79 2.01 0.98 0.94
Mean 0.67 0.79 1.64 1.15 0.94 0.84 1.90 0.48 0.83 1.88 0.99 0.96
StDev 0.06 0.01 0.65 0.02 0.01 0.08 0.47 0.00 0.06 0.19 0.01 0.03
CV% 8.4% 0.9% 39.7% 1.9% 1.5% 9.3% 25.0% 0.0% 6.8% 10.2% 1.4% 2.9%
Intra-assay CV 9.0% 
Intra-assay mean 5.5% (± 3%)




Figure 3.9. Inter-assay variation using 37 genomic DNA samples    
To assess the reproducibility of the assay, 37 genomic DNA samples were run in duplicate on 
two separate occasions. An average of the duplicate values was used. Assay #1 and #2 are 
plotted against each other and as seen the trend shows a good correlation of 0.755 between the 
two sets of data points [Bland and Altman 1996]. 
3.5 TRF validation of qPCR 
TRF was used to validate the results obtained from the two-plate qPCR assay. Twenty selected 
samples of varying telomere length were assayed using both the T/S and the TRF (Southern 
blot) method. Samples were initially chosen from either the CHDS or CHALICE cohorts 
(Section 2.1.2) to represent a range of telomere lengths as determined by the T/S ratio obtained 
from the two-plate qPCR assay (described in Chapters 4 and 5). The CHDS cohort provided a 
greater spectrum of telomere lengths and included both the highest and lowest T/S ratio 
observed across both cohorts. For Southern blotting, the DNA needs to be of very high quality 
and in sufficient amounts, so the samples were first checked prior to use by running 
approximately 50-100ng of DNA on a 0.7% agarose gel. As shown in Figure 3.10 (lanes 1-6) 
the recently extracted CHALICE samples gave high molecular weight smears with little sign 
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of degradation, whereas for the older CHDS DNA (lanes 7-12) only faint evidence of high 
molecular weight DNA is observed, suggesting significant degradation of this DNA. For this 
reason, the samples from the CHDS cohort were not used for the TRF assay. Mouse embryonic 
stem (ES) cells have ultra-long telomeres [Kipling and Cooke 1990] and as laboratory stocks 
of high quality mouse ES cell DNA were available [Jodczyk 2011], these were included on the 












Figure 3.10. Quality of DNA samples used for Southern blotting 
The DNA quality of samples from the CHDS and CHALICE cohorts were assessed by running 
100-200ng of genomic DNA on a 0.7% agarose-TAE gel, stained with SYBR Safe DNA gel 
stain. Lane M contains the 10 kb Kapa Universal (Kapa Biosystems, Boston, United states) 
size standard. Lanes 1-6: CHALICE samples showing high molecular weight smears, and little 
evidence of degradation. Lanes 7-12: CHDS samples showing evidence of only traces of high 
molecular weight DNA, suggesting degradation. 
 
 M   1    2    3    4    5     6    7   8    9   10   11  12 
10 kb  
 4 kb  
 1 kb  
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3.5.1 TRF blot 
The TRF assay was performed using the TeloTTAGGG assay kit (Roche Applied Sciences, 
Mannheim, Germany) following the manufacturers’ instructions (Section 2.7). Briefly, 1.5 µg 
of each CHALICE gDNA and the mouse ES cell control sample were digested with the 
restriction enzymes HinfI and RsaI, and then subjected to gel electrophoresis on an 11 cm 0.8% 
agarose gel. Resolved DNA fragments were transferred to a HybondTM - N+ membrane 
(Amersham Pharmacia Biotech, New Jersey, USA) by blotting, then hybridised with a 
telomere-specific digoxigenin (DIG)-labelled probe, and detected with chemiluminescence. 
Different samples gave smears of labelled DNA that differed in appearance and suggested a 





Figure 3.11. Example of Southern blot used for TRF assay 
TRF was used to validate the results obtained from the qPCR assay. Lanes 1-7 contain different 
(CHALICE) DNA samples digested with HinfI and RsaI, to give telomere-specific smears of 
different length and intensities. Lane M contains the size standard ranging from 21.2 kb to 1.9 
kb and Lane 5 contains the reference DNA sample used for normalisation (CHALICE ID# 13) 
(Section 3.5.2). 
3.5.2 TRF data analysis 
Poor blotting efficiency was an issue when performing larger blots, so the 20 samples were 
spread over four separate blots (Table 3.2) and therefore a common control DNA sample was 
included on each blot for normalisation (CHALICE ID# 13). This sample was chosen as it had 
a large quantity of high molecular weight DNA available. Samples that did not run, transfer or 
hybridize optimally (as seen in Figure 2.5, lanes D and E) were removed from the analysis. 
Mean TRF was calculated with densitometry using the UVItech imaging software (Cambridge, 
United Kingdom), from the signal generated with the telomere-specific probe. Several methods 
110 
 
of data analyses were trialled. The first was using the formula from the TeloTTAGGG protocol 
where ODi is the chemiluminescent signal and Li is the length of the 
TRF at position i, and the second was using the TELORUN excel spreadsheet (Section 2.5.3). 
Additionally, TELORUN generates both a weighted and an un-weighted average for telomere 
length. The weighted average does not assume that all telomeres are the same length whereas 
the un-weighted average does. A subset of the samples were analysed using all data analysis 
methods, to test if they correlated and determine which one to use for the analysis. The results 
obtained using the formula from the TeloTTAGGG protocol correlated well with the weighted 
TRF value using TELORUN (r2 = 0.9889), whereas the un-weighted average did not correlate 
as well (r2 = 0.7449) and neither did the weighted vs. un-weighted methods using TELORUN 
(r2 = 0.7525). For these reasons the weighted value using TELORUN was chosen for the TRF 
length measurements, as it was more automated and less time consuming than manual 
calculations with the TeloTTAGGG protocol formula.  
 
The TRF data were then compared with T/S ratios generated for the same samples with the 
two-plate qPCR method. This gave a good overall correlation (r2 = 0.71 or r = 0.853; Figure 
3.12) [R Core Team 2013] equivalent to the correlation of r = 0.847 reported by Aviv et al 
(2011) [Aviv et al. 2011]. Although the ES DNA was included in the TRF assay, it could not 



















C100187 1.00 6.16 0.86 7.90 5.98 1 
C100184 0.77 5.67 0.80 7.31 5.60 1 
C100099 1.20 7.96 1.12 10.27 7.63 1 
C100001 1.49 9.39 1.32 12.11 10.06 1 
C100109 1.22 9.84 1.29 11.39 9.45 2 
C100126 1.06 9.52 1.25 11.83 9.08 2 
C100305 0.97 7.98 1.05 10.35 7.50 2 
C100035 0.79 6.61 0.87 7.59 6.37 2 
C100202 1.09 7.76 1.11 8.50 7.52 3 
C100028 1.14 9.63 1.37 14.03 9.63 3 
C100121 1.29 8.96 1.28 12.78 8.78 3 
C100100 1.18 9.12 1.30 11.88 8.76 3 
C100169 1.09 8.16 1.16 11.15 7.93 3 
C100088 1.01 8.34 1.19 11.33 7.93 3 
C100165 0.83 7.19 1.03 9.31 6.83 3 
C100175 0.92 8.71 0.95 10.38 7.45 4 
C100268 1.00 8.80 0.96 10.00 7.10 4 
C100241 1.09 9.75 1.06 12.23 7.70 4 
C100005 1.14 9.92 1.08 12.33 9.74 4 
1Samples were normalised by dividing the weighted TRF of the sample by that of the positive 







Figure 3.12. Correlation of qPCR Vs TRF 
Normalised mean TRF length was determined by Southern blot for 20 genomic DNA samples, 
and compared with relative T/S ratio data generated by the two-plate qPCR assay. All samples 
were normalised to a reference sample (CHALICE ID# 13) that had a mean TRF of 7.7 kb. 
Each T/S value is the average of duplicate measurements and each TRF length is a single 





3.6 Descriptive statistics 
The modified assay was used to examine telomere length in 1028 subjects (Chapters 4 and 5). 
The average telomere length measurement for the CHDS cohort (n = 677) was 1.184 (± 0.371), 
and for the CHALICE cohort (n = 351) 1.104 (± 0.153). Assay performance was evaluated by 
calculating variation of all samples within a plate (intra-plate variation), as well as the variation 
of the three QCs between plates (inter-plate variation). This was done separately for the T and 
S plates. For CHDS the intra-plate variation was 12% for T and 10% for S, and the inter-plate 
variation was 9% for T and 11% for S. For CHALICE the intra-plate variation was 3% for T 
and 7% for S, and the inter-plate variation was 6% for T, and 5% for S. The CVs for CHALICE 
were significantly lower than for CHDS. This is most likely attributable to higher DNA quality 
of the CHALICE samples as these were much more recently extracted than CHDS. 
3.7 Discussion  
This chapter describes a number of issues relating to the qPCR measurement of leukocyte 
telomere length, and the adaptation of the single amplicon method for use on the Roche 
LightCycler® 480 platform. Some general principles of broader relevance to telomere 
measurement were established, the most important of which is that many commercial hot-start 
polymerases appear to have residual activity prior to the activation step, and that the telg-telc 
primers, with their propensity for forming primer dimers due to their 3’ three base pair overlap, 
are very sensitive to this residual activity. In all cases, the appearance of primer-dimer in the 
no-template control reaction occurred with the same kinetics as product formation in reactions 
containing genomic DNA, indicating that the primer-dimer was most likely forming in the 
presence of genomic DNA, and limiting the production of genuine telomeric PCR product. 
Therefore, the choice of hot-start polymerase is critical to success of this assay. In addition, the 
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telg-telc primer pair is a useful tool for easily testing for residual polymerase activity of 
enzymes prior to use in this or other methods. 
 
The second issue was the significant plate position effects which had a marked impact on assay 
variability (Figure 3.3). The observed variation in temperatures across the Peltier block of the 
LC480 presumably impacted on the accuracy of the T/S ratio determination by affecting DNA 
denaturation and primer annealing. Temperature heterogeneity has been observed in several 
qPCR platforms, particularly at the edges and corners of plate based instruments [Wilhelm et 
al. 2000, Herrmann et al. 2007]. Personal communication with Dr Daniel Eisenberg 
(Department of Anthropology, University of Washington, Seattle, Washington) confirmed 
these plate effects were not unique to our device, as he reported seeing a similar effect on his 
LC480 machine after learning of our observations. MMQPCR employs a very complex 
temperature cycling profile, the reaction mix contains multiple primers, and the single dye/dual 
product design is very demanding, so it is reasonable to expect that MMQPCR will be more 
sensitive to such effects than traditional single amplicon PCR formats.  
 
These findings established that the MMQPCR approach was incompatible with the LC480 
platform, and further work demonstrated that reliable data could only be obtained by 
implementing a modified two-plate form of the original qPCR method for telomere length 
measurement [Cawthon 2002]. The final assay protocol reported here incorporates multiple 
quality controls for machine variation and other potential sources of artefact, and generates 
reliable measurements as judged by correlation with data derived by the TRF Southern-blot 
based method. Parameters have now been established to effectively use this platform for 
reliable telomere length measurements and determined the critical factors in the success of this 
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method on the LC480. This assay protocol provides a well-controlled, reproducible method for 






Chapter 4: Telomere length and life course stress and 
adversity 
The work described in this chapter contributed to the publication Jodczyk et al., (2014) 
No Association between Mean Telomere Length and Life Stress Observed in a 30 Year 
Birth Cohort. PLoS ONE.2014;9(5):e97102.  
4.1 Introduction 
In 2004, Epel et al first reported an association between self-perceived psychological 
stress and reduction in telomere length, which has been further supported by subsequent 
studies [Damjanovic et al. 2007, Parks et al. 2009, Schutte and Malouff 2014]. In addition 
to perceived stress in adulthood, there is now a growing body of evidence that stress 
during fetal development [Entringer et al. 2011, Entringer et al. 2013] or as a child, 
including sexual or emotional abuse, violence or other adverse events, also leads to 
shortened telomeres in adulthood [Kananen et al. 2010, Tyrka et al. 2010, Kiecolt-Glaser 
et al. 2011, O'Donovan et al. 2011a, Surtees et al. 2011, Drury et al. 2012, Shalev et al. 
2013b]. However, not all studies concur [Glass et al. 2010, Savolainen et al. 2014, Shalev 
et al. 2014]. Early life stress can also predispose to mood disorders or mental illness, and 
some of these, including schizophrenia [Kao et al. 2008] and depression [Simon et al. 
2006, Wolkowitz et al. 2011, Schutte and Malouff 2015] have been associated with 
shorter telomeres, although again, findings are not consistent [Shaffer et al. 2012]. 
 
Research in this area has suffered a number of limitations. The most important of these 
has been that most studies have used retrospective report measures of stress and adversity 
where it is possible that these measures are affected by a reporting bias. A closely related 
problem is that few studies have used a life course perspective that examines the effects 
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of stressful exposures at various stages of human development [Price et al. 2013, Shalev 
et al. 2013b]. However, one recent example of a longitudinal study found that exposure 
to abuse during childhood was associated with a significant erosion of telomere length 
[Shalev 2012]. 
 
Genetic association studies have become very popular over the past decade, and are 
widely used in psychiatric genetics with an estimated publication rate of one per day 
[Munafò 2006, Burmeister et al. 2008]. The general problem with association studies is 
that they provide indirect evidence that genetic variation is involved in the phenotype, 
and an association is not proof of causality. Furthermore, there is a high rate of non-
replication in association studies, and often the initial promising finding that generates a 
considerable amount of interest cannot be replicated by the majority of subsequent 
studies, an effect often described as the ‘Winners Curse’ [Sullivan 2007, Munafo 2009]. 
Individual genetic effect sizes are generally small for multi-genic traits thus requiring 
studies with large sample sizes for detection [Ioannidis 2005], and initial reports using 
small sample sizes are often prone to false positives. Meta-analyses, a statistical tool for 
combining results across studies are becoming increasingly popular to resolve these 
discrepancies in genetic association studies [Munafo and Flint 2004]. 
 
The Christchurch Health and Development Study (CHDS) is a longitudinal study of a 
birth cohort established by recruiting children born in the Christchurch urban region 
during mid-1977. The parents of 1265 (97%) children born during the recruitment period 
agreed to participate in the study, making this a representative sample of New Zealanders. 
Sample retention rates were high throughout the study and at age 30 the study was still 
able to assess over 80% of the surviving cohort. Data collection was carried out at birth, 
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four months, one year and annually to age 16 years, and again by interview at ages 18, 
21, 25 and 30 years [Fergusson and Horwood 2001, Fergusson et al. 2005]. 
 
The measures of life course stress included: (1) antenatal/perinatal events including 
maternal smoking during pregnancy, low birth weight, being small for gestational age, 
admission to neonatal intensive care; (2) exposure to adverse childhood events including 
childhood physical and sexual abuse, neglect, inter-parental conflict and violence, and 
related sources of childhood adversity; (3) exposure to adverse events in adolescence and 
young adulthood, including drug and alcohol behaviours, mental health, lifetime trauma 
and major events, and pregnancy/parenthood events. It was hypothesised that LTL would 
be related to the individual’s exposure to adverse antenatal/perinatal, childhood, 
adolescent and adult experiences and that the reduction in LTL would be proportional to 
the individual’s cumulative exposure to life course adversities. 
4.2 Samples for telomere length measurement 
916 CHDS participants at age 28-30 consented to provide a peripheral blood or saliva 
sample for DNA analysis. Participants with only saliva samples available were excluded 
from the analysis as direct comparisons cannot be made between LTL in blood and saliva 
[Theall et al. 2013, Mitchell et al. 2014]. DNA from this cohort was prepared in 2005, 
and a proportion of the samples showed severe degradation. Therefore, fresh DNA for 
these samples was extracted from spare tubes of whole blood stored at -20°C, using a 
KingFisher™ Flex (Thermo Scientific, Finland) automated robotic platform (Section 
2.1.1). This is further discussed in Section 4.6. For 17 participants there were no spare 




Once poor quality DNA, missing samples and those derived from saliva were excluded, 
739 good quality DNA samples were available. The present analysis is based on the 
subset of 677 participants (86% New Zealand European, 14% NZ Māori/Pacific Island 
ethnicity, male n = 338, female n = 339) who gave acceptable telomere length measures 
using the qPCR assay (Section 2.4) and which met the quality control criteria (Figure 
2.1).  
4.3 Measures of life course stress or adversity (0-25 years) 
The following measures were selected from the CHDS database to characterise exposure 
to various forms of stress and adversity over the life course. A summary of these data is 
shown in Table 4.1. With the exception of questions administered at age 30 involving the 
participants’ lifetime exposure to a series of potentially traumatic life events, all measures 
were assessed prior to the collection of DNA and assessment of LTL. 
120 
 
Table 4.1. Summary data for measures of life course stress and adversity 
Measure Mean (SD)/% Range Cut-point Used to Define Adversity 
Indicator, % 
Antenatal/Perinatal Factors    
Birthweight (g) 3358 (526) 1270-4880 < 2500g, 5.0% 
Gestation (wk) 39.7 (1.6) 29-44 < 36wk, 2.3% 
Maternal smoking during pregnancy (cigs/day) 4.1 (7.8) 0-50 ≥20 per day, 8.9% 
Admission to neonatal intensive care 17.4%   
Antenatal/perinatal risk score 0.34 (0.69) 0-4  
Child Abuse/Family Violence (0-16 years)    
Childhood sexual abuse 0.35 (0.88) 0-3 Contact CSA, 12.3% 
Childhood physical abuse 1.17 (0.58) 0-3 Regular or severe punishment, 16.6% 
Parental care score 28.9 (6.2) 2-36 Lowest decile, 9.4% 
Inter-parental violence and conflict 9.2 (2.2) 8-24 Highest decile, 11.1% 
Child abuse/family violence risk score 0.49 (0.82) 0-4  
Adolescent/Young Adult Substance Misuse (16-25 years)    
Nicotine dependence 31.4%   
Alcohol dependence 13.3%   
Cannabis dependence 13.8%   
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Other drug dependence 4.1%   
Number of substance use disorders 0.63 (0.92) 0-4  
Adolescent/Young Adult Mental Health (16-25 years)    
Major depression 42.9%   
Anxiety disorder 33.7%   
Suicidal ideation/attempt 28.7%   
Traumatic life event score (lifetime) 4.4 (3.0) 0-18 Highest quartile, 29.0% 
Mental health problems score 1.34 (1.28) 0-4  
Adolescent/Young Adult Life Events (16-25 years)    
Employment related events 2.11 (0.98) 0-3  
Serious illness/accident events 1.88 (0.94) 0-4  
Serious relationship problems 2.01 (1.08) 0-4  
Victimisation events 1.06 (0.82) 0-4  
Pregnancy/parenthood events 0.57 (0.86) 0-4  
Average total life events per annum 2.13 (1.29) 0-8  
Abbreviation: CSA, childhood sexual abuse
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4.3.1 Antenatal/perinatal factors 
Selected factors included child birth weight, gestation (weeks since last menstrual period), 
admission to neonatal intensive care (no/yes) following birth, and maternal smoking 
(cigs/day) during pregnancy. To provide an overall measure of antenatal/perinatal adversity 
a risk score was constructed from a sum of four dichotomous indicators reflecting potential 
risk/adversity on each of the above measures. These indicators were: child of low birth 
weight (< 2500g), child born premature (< 36 weeks gestation), admission to neonatal 
intensive care, and mother smoked a pack a day or more during pregnancy. 
4.3.2 Child abuse/family violence (0-16 years) 
Exposure to abuse, violence and neglect during childhood (< 16 years) was assessed in the 
following ways. Child sexual abuse (CSA) exposure was assessed using retrospective reports 
obtained at ages 18 and 21 years for a range of unwanted sexual experiences in childhood. 
Using these data, participants were classified on a 4-level scale reflecting the most severe 
form of abuse reported at either age: no CSA; non-contact abuse only; contact abuse 
involving inappropriate touching, fondling of genitals; attempted or completed sexual 
penetration [Fergusson et al. 2000, Fergusson et al. 2008]. Child physical abuse (CPA) was 
assessed on the basis of retrospective reports obtained at ages 18 and 21 of the extent to 
which the individual’s parents used physical punishment during their childhood. Using these 
data, participants were classified on a 4-level scale reflecting the most severe form of 
punishment reported at either age: parents never used physical punishment; parents rarely 
used physical punishment; at least one parent regularly used physical punishment; at least 
one parent used severe or harsh physical punishment [Fergusson et al. 2000, Fergusson et al. 
2008]. At age 16 participants completed the parental care scale of the Parental Bonding 
Instrument [Parker et al. 1979]. This scale assesses the extent to which the parents are 
reported to have provided a loving, caring and supportive home environment during 
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childhood. Separate ratings were obtained for mothers and fathers and these ratings were 
averaged to provide an overall assessment of the level of care [Raudino et al. 2013]. 
Exposure to inter-parental violence and conflict was assessed on the basis of retrospective 
reports obtained at age 18. Participants were questioned using a selected series of items from 
the Conflict Tactics Scale [Straus 1979] to assess the extent to which they reported 
witnessing incidents of inter-parental violence and conflict during childhood. These items 
were combined to produce an overall scale measure of inter-parental violence/conflict 
[Fergusson and Horwood 1998]. Finally, to provide an overall measure of exposure for child 
abuse/family violence a risk score was constructed from a sum of four dichotomous 
indicators reflecting exposure to different forms of abuse, violence or neglect. These 
indicators were: child exposed to CSA involving inappropriate contact or 
attempted/completed intercourse; child exposed to regular or severe physical punishment; 
child fell into the lowest decile on the measure of parental care; child fell into the highest 
decile on the measure of inter-parental violence/conflict.  
4.3.3 Adolescent/young adult substance misuse (16-25 years) 
At ages 18, 21 and 25 years participants were interviewed about their use/misuse of tobacco, 
alcohol, cannabis and other illicit drugs over the period since the previous assessment 
[Fergusson et al. 2008]. As part of this interview, items from the Composite International 
Diagnostic Interview (CIDI) [World Health Organization 1993] were used to assess DSM-
IV [American Psychiatric Association 1994] symptom criteria for alcohol, cannabis and 
other drug dependence; symptoms of nicotine dependence were assessed on the basis of 
custom written survey items. These symptom data were combined over the three interview 
periods to construct dichotomous measures reflecting whether the participant had ever met 
DSM-IV diagnostic criteria for nicotine dependence, alcohol dependence, cannabis 
dependence and other drug dependence over the period from age 16-25 years. An overall 
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measure of extent of exposure to problem substance use behaviours was also constructed 
based on a count of the number of substance use disorders for which the individual met 
diagnostic criteria.  
4.3.4 Adolescent/young adult mental health (16-25 years) 
As part of the interviews conducted at ages 18, 21 and 25 participants were questioned using 
components of the CIDI to assess DSM-IV symptom criteria for major depression and a 
range of anxiety disorders (generalised anxiety disorder, panic disorder, agoraphobia, social 
phobia, specific phobia). Participants were also questioned about suicidal behaviours 
including suicidal ideation and suicide attempt since the previous assessment [Fergusson et 
al. 2008]. These data were used to classify participants on three dichotomous measures of 
mental health problems reflecting whether the participant met DSM-IV diagnostic criteria 
for major depression, or an anxiety disorder, or reported suicidal ideation/attempt over the 
period from age 16-25 years. In addition at age 30, as part of questioning about symptoms 
of PTSD, participants were questioned about their lifetime exposure to a series of potentially 
traumatic life events [Mulder et al. 2013]. A measure of total lifetime exposure to trauma 
was constructed from a count of the number of traumatic events reported. Finally, an overall 
measure of mental health problems was constructed by summing the three dichotomous 
measures of depression, anxiety disorder and suicidal ideation/attempt together with a fourth 
dichotomous measure reflecting whether the participant fell into the highest quartile of 
exposure to lifetime trauma.  
4.3.5 Adolescent/young adult life events (16-25 years) 
Participants were questioned about life events occurring for each 12 month period since the 
previous assessment using a life events checklist that combined custom written items with 
selected items from existing life event scales [Fergusson et al. 2011]. This was done as part 
of the interviews conducted at ages 18, 21 and 25. These data were used to classify 
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participants on five broad measures reflecting common classes of life event. These classes 
were: employment related events (redundancy, unemployment, changes of job); serious 
illness or accident to self, close friends or family members; serious relationship problems 
with friends, partners or other family members; victimisation events (physical/ sexual 
assault, robbery, etc); and pregnancy/parenthood events (pregnancy/getting a partner 
pregnant, pregnancy loss, termination, childbirth). For each class of event a score was 
constructed based on a count of the total number of events reported over the period 16-25 
years. Finally, a measure of total life event exposure was constructed by first summing all 
life events reported for each year from age 16-25 and then averaging over all years to provide 
a measure of the average number of life events reported over the whole interval. 
4.4 Results 
Associate Professor John Horwood and Professor David Fergusson (Christchurch Health and 
development study, Department of Psychological Medicine, University of Otago, 
Christchurch) performed the following statistical analyses. Figure 4.1 shows the distribution 
of LTL in the cohort, with T/S ratios ranging from 0.50 to 4.35. The data are not normally 
distributed (Shapiro-Wilks test of normality p < 0.001) and show a thinner distribution 
(kurtosis 12.3) which is skewed to the right (skewness = 2.3). The different methods of DNA 




Figure 4.1. Distribution of LTL 
The distribution of observed telomere lengths (T/S ratio) for the CHDS cohort (n = 677) is shown as a histogram. A density curve for a normal distribution 
with the same mean ( x = 1.18) and standard deviation (s = 0.37) has been superimposed. 
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4.4.1 Association between gender, ethnicity and socio-economic status 
A one-way analysis of variance was used to test for differences in mean LTL by sex, 
ethnicity (European, Māori/Pacific Island) and family socio-economic status at the 
participant’s birth (classified into three levels on the basis of paternal occupation: 
professional/managerial; clerical/technical/skilled; semi-skilled/unskilled). LTL was found 
to be unrelated to sex or SES. However, Māori/Pacific Island participants had significantly 
higher mean LTL than Europeans (p = 0.04) (Figure 4.2). 
 
Figure 4.2. Difference in mean LTL by ethnicity 
A box and whisker plot showing LTL (T/S ratio) versus ethnicity (European/ Māori/Pacific 
Island). The vertical lines indicate the upper and lower quartiles and the outliers are plotted 
as individual points. The Māori/Pacific Island participants had significantly higher mean 
LTL than Europeans (p = 0.04). 
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4.4.2 Associations between developmental factors (age 0-25) and LTL (age 
28-30) 
Table 4.2 reports the partial correlations and tests of significance between a series of 26 
measures of life course stress or adversity assessed prior to the age of 25 years and LTL at 
age 28-30 adjusted for sex, ethnicity and family SES at birth. The predictors of telomere 
length are organised into a series of groups reflecting various developmental stages spanning 
the antenatal/perinatal period, childhood, adolescence and young adulthood. The pervasive 
feature of Table 4.2 is a consistent lack of association between life course stress or adversity 
and LTL. In general the correlations were very small ranging from -0.06 to 0.06 with a 
median of 0.01, and none was statistically significant at p < 0.05. This absence of association 
held for both specific measures and for the summary risk scores for each developmental 
domain. Application of standard power calculations [Cohen 1988] showed that with 677 
cases, the sample had in excess of 80% power at α2 = 0.05 to detect a partial correlation in 




Table 4.2. Standardised regression coefficients for CHDS cohort 
Standardised regression coefficients for CHDS cohort (β) linking measures of 
developmental stressors (birth – 25 years) and average leukocyte telomere length (28-30 







 Adolescent/Young Adult 
Mental Health (16-25 
years) 
  
Birth weight (g) -0.01 DSM-IV Major depression 0.03 
Gestation (wk) -0.05 DSM-IV Anxiety disorder 0.02 
Admission to neonatal 
intensive care 
0.01 Suicidal ideation/attempt -0.01 
Maternal smoking in 
pregnancy (cigs/day) 
-0.02 Lifetime trauma -0.01 




Violence (0-16 years) 
 Adolescent/Young Adult 
Life Events (16-25 years) 
 
Childhood sexual abuse 0.06 Employment problems -0.02 
Childhood physical abuse 0.03 Serious illness/accident to 
self or others 
-0.01 





-0.01 Victimization problems -0.01 
Abuse/violence risk score 0.05 Pregnancy/parenthood 0.04 
Adolescent/Young Adult 
Substance Use (16-25 
years) 
 Total life events exposure -0.02 
DSM-IV Nicotine 
dependence 
0.01   
DSM-IV Alcohol 
dependence 
0.01   
DSM-IV Cannabis 
dependence 
0.02   
DSM-IV Other drug 
dependence 
0.02   
Total substance use disorders 0.02   
No correlation is statistically significant (p < 0.05) 
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4.4.3 Sample stratification 
To examine issues of sample stratification, the associations between LTL and the measures 
of life course stress/adversity (Table 4.2) were examined by fitting a series of multiple linear 
regression models in which LTL was regressed on each measure of stress/adversity, 
controlling for sex, ethnicity and family SES at birth. For each stress measure the strength 
of the adjusted association with LTL was estimated by the partial correlation (standardised 
regression coefficient) and corresponding test of significance from the fitted model. Wald 
chi square tests were used to test the equivalence of effects across levels of the factor. In six 
of the 78 tests conducted there was evidence of significant (p < 0.05) differences in the 
strength of association across strata. However, only one of these (SES and number of mental 
health problems, p = 0.004) approached significance after applying Bonferroni correction 
for multiple tests (p = 0.0024): amongst high SES (professional/managerial) families the 
association with LTL was negative (β = -0.14, p < .01) compared to the associations in those 
from moderate or lower SES families (β = 0.08, 0.01 respectively, p > 0.10).   
4.4.4 Variations in telomere length data analysis  
The data were re-analysed using several different approaches to handling the LTL 
measurement data. These methods included analysing LTL: a) as a log transformed measure 
to reduce heteroscedasticity, b) after eliminating outliers over 2 standard deviations above 
the mean, c) after including an additional 62 participants excluded from the initial data 
analysis because their LTL measures exceeded the 10% coefficient of variation quality 
threshold, d) as a dichotomous (short/long) variable where ‘short’ was defined on the basis 
of a series of arbitrary cut-points ranging from those who fell into the lowest decile, the 
lowest quartile or below the median on the distribution of LTL. A Bonferroni corrected p-
value of 0.0024 was applied for all analyses to control for the possibility of Type I errors 




All of these analyses led to conclusions that were consistent with the findings in Table 4.2. 
When the data was re-analysed using the different approaches to handling the LTL 
measurement data (a-c), all of the observed correlations remained small and statistically non-
significant. When the data were analysed using a decile split to define a short/long telomere 
criterion statistically significant linear associations were observed with three measures: 
history of major depression (r = -0.08, p = 0.04), lifetime traumatic life events (r = -0.09, p 
= 0.02) and serious relationship problems (r = -0.08, p = 0.04). Using a median split there 
was a significant correlation with total life event exposure (r = 0.08, p = 0.04). Three of the 
four significant correlations were in a direction suggesting that exposure to stress or 
adversity was associated with shorter telomeres. However, none of the above associations 
remained significant upon correction for multiple significance testing and there was no 
evidence that the findings of the analysis varied with the way in which telomere length was 
scaled or classified.  
4.5 Genome-wide association study (GWAS) 
Genome-wide association studies (GWAS) have identified several common genetic variants 
associated with telomere length (reviewed in Section 1.3.4.1). The opportunity arose to carry 
out a GWAS of LTL as gene-chip data for consented CHDS participants had been generated 
as part of the Genes, Environment and Development Initiative, funded by the National 
Institute on Drug Abuse (USA) [Costello et al. 2013]. Due to the relatively small sample size 
of this study, the aims were exploratory, and sought to answer the question of whether loci 
identified in other, larger GWAS on telomere length could also be detected in the CHDS 




Dr John Pearson (Biostatistics and Computational Unit, University of Otago, Christchurch) 
performed this analysis. Genotyping was completed on an Illumina Human660w-quad v1 
chip (Illumina, San Diego, CA) which interrogates ~600,000 single nucleotide 
polymorphisms (SNPs). The relationship between telomere length and the SNPs were 
examined by fitting a linear regression model with response to T/S ratio and predictors of 
gender, 1st and 2nd predictor for ethnicity, and an additive model for genotype from the 
probe (0, 1, 2 minor alleles). The model did not need to be adjusted for age as the CHDS 
participants were all the same age.  
 
The Manhattan plot of the analysis is shown in Figure 4.3 and the SNPs that reached 
statistical significance are presented in Table 4.3. Five SNPs reached genome-wide 
significance, with three clustered on chromosome 2 and two on chromosome 10. The SNPs 
from chromosome 10 were in the genes C10orf53 and ADARB2 and those from chromosome 
2 were located in an intergenic region. These SNPs have not been identified in previous 





Figure 4.3. Manhattan plot of CHDS  
Data are displayed as –log10(P values) against chromosomal location for the SNPs that were 
tested. The red dotted line represents a genome-wide level of significance and loci that 
showed an association, located in chromosomes 2 and 10, are above this plotted line. 
 
 
Table 4.3. GWAS hits that reached genome-wide significance 
SNP Genomic position1  P P adjusted Gene  Function class 
rs1258267 10:50,895,770 4.09E-10 0.002984 C10orf53 Intron-variant 
rs12611863 2:224,184,330 5.50E-09 0.02009 - Intergenic region 
rs7597538 2:224,225,681 1.28E-08 0.03108 - Intergenic region 
rs12621610 2:224,227,805 1.73E-08 0.03157 - Intergenic region 
rs11250741 10:1,739,576 3.01E-08 0.04396 ADARB2 Intron-variant 
1Genomic co-ordinates from hg19 






Table 4.4. Genes identified in GWAS studies 
 
*The n quoted is that in the discovery set 
Data obtained from: 1. [Codd et al. 2010], 2. [Levy et al. 2010], 3. [Prescott et al. 2011], 4. [Mangino et al. 2012], 5. [Codd et al. 2013], 6. [Pooley et al. 
2013], 7. [Saxena et al. 2014], 8. [Liu et al. 2014], 9. [Mangino et al. 2015] 
 
 
1 2 3 4 5 6 7 8 9 CHDS
Gene name Chromosomal region (n = 2,917) (n = 3,417) (n = 3,554) (n = 9,910) (n = 37,684) (n = 2,240) (n = 1, 616) (n = 2,632) (n = 20,022) (n = 677)
TERC 3q26.2 P = 3.72 × 10
−14
P = 1.1 × 10
−5 P = 0.003 P = 1.1 x 10
-8
P = 2.54 x 10
-31
P = 1.0 x 10
-19
OBFC1 10q24.33 P = 3.9 × 10
−9
P = 9.1 x 10
-11
P = 6.90 x 10
-11
P = 4.0 x 10
-14
CXCR4 2q22.1 P = 2.9 × 10
−8
ZNF676 19p12 P = 3.3 x 10
-8
CTC1 17p13.1 P = 3.6 x 10
-8
TERT 5p15.33 P = 4.38 x 10
-19
P = 5.0 x 10
-17
P = 1.93 x 10
-5
NAF1 4q32.2 P = 4.35 x 10
-16
RTEL1 20q13.3 P = 6.71 x 10
-9
ACYP2 2p16.2 P = 4.48 x 10
-8
ZNF208 19p12 P = 11.1 x 10
-9
PXK 3p14.4 P = 4.0 x 10
-10
ZNF311 6p22.1 P = 1.0 x 10
-7
BCL2L1 20q11.2 P = 6.0 x 10
-7
CSNK2A2 16q21 P = 4.5 x 10
-8
KRT80 12q13.3 P = 6.96 x 10
-6
DCAF4 14q24.2 P = 6.4 x 10
-10
C10orf53 10q11.22 P = 0.002984




This study used data gathered over the course of a 30 year longitudinal study to examine the 
relationships between exposure to a wide range of life course stressors and telomere length 
at age 28-30 in a sample of 677 study participants who provided DNA and for whom 
satisfactory LTL measurements were obtained.  
 
The life course stressors spanned pregnancy and perinatal events (birth weight, gestational 
age, pregnancy smoking), childhood circumstance (childhood maltreatment, family 
conflict), adolescent and young adult measures (substance use and misuse, mental health, 
life events). In total a series of 26 associations between LTL at age 28-30 were examined. 
The partial correlations adjusting for sex, ethnicity and family SES at birth ranged from -
0.06 to 0.06 with a median value of 0.01, and in no case was there a significant association 
between life course stress and LTL. These findings were supported in further analyses 
examining the implications of stratification by sex, ethnicity or SES, and using different 
approaches to handling the LTL data. All analyses led to the common conclusion that when 
due allowance was made for multiple tests of significance there was no evidence from this 
cohort that a wide range of life course stressors assessed up to the age of 25 were related to 
LTL at 28–30 years. 
 
These findings do not support several previous research reports [Kananen et al. 2010, Tyrka 
et al. 2010, Kiecolt-Glaser et al. 2011, O'Donovan et al. 2011a, Surtees et al. 2011, Drury et 
al. 2012, Shalev et al. 2013b] [Epel et al. 2004, Lin et al. 2012] about the effects of 
environmental stressors on telomere length. There are a number of possible explanations for 
these findings. The first explanation is that the measurement of LTL does not provide a 
sensitive enough measure of the effects of environmental stress and that a better measure is 
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that of telomere erosion obtained by comparing telomere length before and after exposure to 
stress [Aviv 2008, Shalev 2012, Shalev et al. 2013a]. While this explanation is possible it 
implies that LTL and telomere erosion are poorly correlated measures. The only 
circumstance under which this can occur is if initial telomere length is negatively correlated 
with subsequent telomere length. Further, LTL has been used in many previous studies as a 
proxy measure of telomere erosion [Damjanovic et al. 2007, Kao et al. 2008, Nordfjall et al. 
2008, Parks et al. 2009, Tyrka et al. 2010, Entringer et al. 2011, Kiecolt-Glaser et al. 2011, 
O'Donovan et al. 2011a, Surtees et al. 2011, Drury et al. 2012, Entringer et al. 2013]. Only 
one recent study used telomere erosion measures, in 236 children exposed to at least one 
violent incident, and concluded that violence exposure before age five can result in 
accelerated telomere erosion by age ten [Shalev et al. 2013b].  
 
No other blood samples were taken from the CHDS cohort so there was no opportunity to 
measure telomere length erosion. Birth blood spots are a possible source of DNA which 
could be used for telomere length measurement [Zanet et al. 2013]. Blood spots were 
collected in New Zealand for this age group; however poor storage systems and conditions 
meant that most of the blood spots for this age group are no longer available. 
Notwithstanding these points, there is a clear need to replicate the findings of this study using 
measures of telomere erosion, perhaps with blood drawn on the CHDS cohort at a later 
interview period. 
 
The second possible explanation is that LTL was inadequately assessed in this study. This 
explanation does not seem likely given the validation measures for the LTL assay described 
in Chapter 3. Our T/S ratios were carefully controlled by inclusion of standard samples in 
each run, and the assay was validated by comparison of 20 control samples also subjected to 
the TRF method of telomere length measurement. This comparison yielded an r2 correlation 
of 0.71 / r = 0.853 which is comparable to that reported by Aviv and Blackburn (r = 0.847) 
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[Aviv et al. 2011]. In addition, our T/S ratio distribution and range is similar to that in other 
reports [Epel et al. 2004, Tyrka et al. 2010, Entringer et al. 2011, Shalev et al. 2013b]. 
 
The third possible explanation is that we have not assessed the types of stressor that have 
adverse effects on telomere length. This seems unlikely since we have assessed a 
comprehensive set of well recognised life course stressors. To our knowledge no previous 
study has examined the relationship between telomere length and life course stress using 
such a comprehensive set of measures. However, it is worth noting that there is considerable 
heterogeneity in the measures and study designs used for telomere length association 
analyses [Aviv et al. 2006, Chen et al. 2011, Vera and Blasco 2012, Steenstrup et al. 2013], 
and this may also impact on replicability of findings.  
 
The fourth possible explanation is that during the period from birth to age 28-30, life course 
stressors do not have detectable effects on LTL. Several studies have reported an association 
between stress during childhood and shorter telomere length in adulthood [Kananen et al. 
2010, Tyrka et al. 2010, Kiecolt-Glaser et al. 2011, O'Donovan et al. 2011a, Surtees et al. 
2011, Drury et al. 2012, Shalev et al. 2013b]. Six of these studies were of a cross sectional 
nature, with retrospective collection of adversity data in all but one [Drury et al. 2012]. Four 
had small samples sizes and were relatively preliminary studies [Tyrka et al. 2010, Kiecolt-
Glaser et al. 2011, O'Donovan et al. 2011a, Drury et al. 2012]. The study of Kananen et al., 
(2010) was larger, involving subjects aged 30-87 with anxiety disorders and matched 
controls (total n = 939), and it found that the number of reported childhood adverse life 
events was associated with shorter telomere length in adults [Kananen et al. 2010]. An even 
larger retrospective study on a population-based sample of women aged 41-80 years (n = 
4441), reported suggestive evidence for association of adverse childhood experiences with 
shorter telomere length in adult [Surtees et al. 2011]. Finally, a large retrospective study of 
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UK twins (n = 1090) found no correlation between childhood maltreatment and telomere 
length. The diversity in approaches, sample sizes, age of participants, measures of stress, 
method of telomere length measurement [Steenstrup et al. 2013], and the predominantly 
retrospective nature of these reports, means it is difficult to form confident conclusions from 
these studies.  
 
The final possible explanation is that a specific technical limitation experienced within our 
study could account for why no associations were found between life course stress and 
telomere length in this cohort. As explained in Section 4.2, the CHDS DNA samples were 
extracted using two different methods. Recently, Denham et al., (2014) showed that the 
method of DNA extraction impacts on the T/S ratio [Cunningham et al. 2013, Denham et al. 
2014]. This was attributed to the quality of the DNA generated by either method. They did 
not use the same extraction methods that were used in our study; nonetheless this effect could 
still apply to our data as approximately half of the samples were extracted with either 
method.  To clarify this issue, the T/S ratio could be compared for these samples using the 
two different extractions methods in our study. However, this was not possible as the quality 
of the original DNA was of poor quality and not suitable for the qPCR method.  
 
The GWAS was an opportunistic and exploratory study, as this data was available for 
analysis in this cohort. Previous GWAS findings could not be replicated including any sub-
significant support, however, this is not surprising with the small sample size and the number 
of samples required for the detection of variants in GWAS studies of complex traits. This 
non-replication is evident in other telomere GWAS studies (Table 4.4), with only SNPs 
found in TERC and OBFC1 appearing in several studies. This exploratory study identified 
five SNPs that reached statistical significance, with two residing in ADARB2 and C10orf53, 
and the other three in an intergenic region. The rs1258267 variant is in the gene C10orf53 
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which is of unknown function, whereas the rs11250741 SNP resides in ADARB2 which is 
involved in RNA editing. This gene has been associated with longevity in humans in four 
independently conducted centenarian studies (n= 1147, 791, 568, 1008). Additionally, the 
functional association of ADARB2 with lifespan has been evaluated in c.elegans, where the 
inactivation of the ADARB2 orthologue (adr-2) reduced median survival by 50% [Sebastiani 
et al. 2009]. Therefore, there is potential that this variant could impact on TL but it needs to 
be explored further in a larger cohort. 
4.7 Summary and future directions 
In summary, our hypothesis was not supported and LTL was not associated with measures 
of the individual’s exposure to adverse antenatal/perinatal, childhood, adolescent and adult 
experiences, and LTL was not proportional to the individual’s cumulative exposure to life 
course adversities. The two most likely explanations of our findings are that either LTL is 
not a good measure of telomere erosion or that up to the age of 25 life course stressors have 
negligible effects on LTL and telomere erosion. Clarification of these alternatives will 
require data from further longitudinal research which has the capacity to measure telomere 
length prior to and following stress exposure. The CHDS study is continuing with the 
potential of obtaining blood samples in the future in which this study could be revisited with 
telomere erosion rates being assessed; this may provide a different outcome to our findings. 
The GWAS SNPs that reached genome-wide significance in our study could be further 
explored and replication in a much larger sample would be required to provide confidence 
in this result. Additionally, the data generated from this study could be integrated into any 






Chapter 5: Telomere length as a biomarker of current health 
status 
5.1 Introduction 
It is well established that mean telomere length decreases with age, and this association 
is clear in large samples [Harley 1991] [Lapham et al. 2015]. However, the individual 
predictive power of mean telomere length is debateable, with early studies likely over-
estimating the prognostic power of telomere length due to small study sizes [Zglinicki 
2012]. The predictive power of telomere length is now believed to be modest at best, and 
associations are generally stronger with other candidate markers of ageing [Martin-Ruiz 
et al. 2011] such as systolic blood pressure, hand grip strength, forced respiratory volume, 
cholesterol and inflammatory cytokines [Franklin et al. 1997, Rantanen et al. 1999, Singh 
and Newman 2011]. 
 
Nonetheless, there is interest in the use of telomere length as a biomarker of general 
health, and the possibility of using mean telomere length to gauge individual disease risk, 
and to promote lifestyle changes to improve health. Two commercial providers Telomere 
diagnostics, Inc. (www.telomeredx.com) and Life Length (www.lifelength.com) offer 
telomere length measurements for clinical and personal use, with the intention of 
integrating them into routine health checks and using them in preventative healthcare. 
Although the tests are promoted on the basis that they provide information on current 
health status, it is not clear that telomere length provides any extra information over other 
widely used biomarkers of health or disease status [Aviv 2008, Zglinicki 2012, Sanders 




Telomere length has been studied in association with numerous phenotypes in cross-
sectional epidemiologic studies but consistent associations have been made only with 
age, gender and race [Sanders and Newman 2013]. Associations with other health risk 
factors such as smoking [Valdes et al. 2005, McGrath et al. 2007], alcohol consumption 
[Pavanello et al. 2011, Harris et al. 2012], BMI [Nordfjall et al. 2008, Buxton et al. 2011] 
and stress [Epel et al. 2004, Glass et al. 2010, Jodczyk et al. 2014] are weak with both 
positive and negative associations in each case being made. Weischer et al (2014) 
[Weischer et al. 2014] looked at the associations between telomere length and smoking, 
body weight, physical activity and alcohol intake in 4,576 individuals in the general 
population both cross-sectionally and with a 10 year follow-up measurement. They found 
that with the first measure alone, telomere length was associated with current smoking, 
increased BMI and physical activity but not alcohol intake. After the second examination 
they found that 56% of participants lost and 44% gained telomere length and that the 
original associations disappeared. They also looked at mortality and morbidity and found 
that telomere length did not associate prospectively with these factors in the general 
population.  
 
The Canterbury Health, Ageing and Life Course (CHALICE) cohort is a population 
based multidisciplinary study of aging with telomere length measured at age 49-51. 
Although it was established as a prospective longitudinal study, funding has not yet been 
obtained for ongoing studies, and therefore CHALICE is essentially a cross-sectional 
study of ~50 year olds. Participants were randomly selected from the Canterbury region 
with a participation rate of 63.7% for the first 300 participants. Māori were oversampled 
so that they represented approximately 20% of the sample [Schluter et al. 2013]. The 
present analysis is based on a sample of 351 cohort members (85% Non-Māori, 15% NZ 
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Māori ethnicity). A large amount of data were collected on participants’ health, well-
being and lifestyles including sociodemographics, physical state, cognition, mental 
health, clinical history, family and social, cardiovascular health, and lifestyle domains. 
Data collection was carried out at baseline, with a brief annual postal follow-up since 
inception of the study in 2010. Average telomere length was examined in this population 
sample with the aim of assessing its effectiveness as a biomarker for an individual’s 
current overall health status at age 49-51.  
5.2 Assessment of current health status 
CHALICE participants took part in a comprehensive baseline assessment that lasted 
approximately 4-5 hours to evaluate their general health and well-being. This assessment 
spanned several modules including physical health, health history, family and social 
health, heart health, mental health, cognitive aspects and lifestyle. The assessments used 
internationally recognised standardised instruments with good psychometric properties 
where possible [Schluter et al. 2013]. The following measures were selected from the 
database to provide a measure of current health status, and because they were able to 
provide sufficient statistical power for analyses. All measures were assessed at the time 
of DNA collection and prior to assessment of LTL.  
5.3 Socio-demographic characteristics 
Several laboratory analyses and physical measures were undertaken (summarised in 
Table 5.1.). These included cholesterol and triglyceride levels as well as the participants’ 
height and weight from which their body mass index (BMI) was calculated. In addition 
to this the participants’ health history including current smoking status was recorded and 
their alcohol audit score (AlcoholAS) calculated. A score of 8 and above is classed as 
hazardous drinking and a score of 13 or 15 indicates dependence for women and men 
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respectively. Socioeconomic status was evaluated using the Economic Living Standards 
Index Short Form (ELSISF) [Jensen et al. 2005] which uses a scale from 0-31 to assess 
standard of living. A score of 0 is considered severe hardship decreasing in severity up 
to 31 which is described as socioeconomically very good. Total household income was 
also recorded with a 13 point scale scored using different brackets of total income. 
 
Table 5.1. List of socio-demographic measures 
Socio-demographic measure Male (n = 165) Female (n = 186) 
Telomere length (T/S) 1.08 (± 0.16) 1.12 (± 0.14) 
Māori ethnicity 16%, (27/165) 13%, (25/186)  
ELSISF 25.39 (± 4.34) 24.09 (± 5.54) 
Household income 13.45 (± 11.86) 15.45 (± 20.03) 
Current Smoker 15%, (24/165) 13%, (24/186) 
Alcohol audit score 7.21 (± 4.97) 4.76 (± 3.86) 
Height (cm) 177.47 (± 6.31) 164.32 (± 6.04) 
Waist (cm) 97.67 (± 11.26) 62.30 (± 17.22) 
Weight (kg) 87.52 (± 15.21) 79.16 (± 20.48) 
Body mass index (BMI) (kg/m2) 27.76 (± 4.49) 29.40 (± 7.83) 
Cholesterol (mmol/L) 5.41 (± 0.95) 5.37 (± 0.99) 
Triglycerides (mmol/L) 1.61 (± 1.13) 1.28 (± 0.98) 
HDL cholesterol (mmol/L) 1.22 (± 0.24) 1.44 (± 0.35) 
Total cholesterol/HDL cholesterol ratio 4.49 (± 1.09) 3.89 (± 1.03) 
LDL cholesterol (mmol/L) 3.50 (± 0.87) 3.40 (± 0.0.84) 
Abbreviation: ELSISF, Economic Living Standards Index Short Form  
 
5.3.1 SF36 v2 
Participants completed the 36 question SF-36v2 survey [Ware and Sherbourne 1992] 
[Ware et al. 2000] (Table 5.2), a self-perceived measure of health status. It is a generic 
measure and does not target a specific age, disease or treatment group. The questionnaire 
consists of 8 subscales of functional health and well-being including physical 
functioning, role limitations due to physical problems (role-physical), bodily pain, 
general health perception, vitality, social functioning, role limitations due to emotional 
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problems (role-emotional) and mental health. Each subscale is scored, summed and 
transformed into a 0-100 scale, with 0 being the worst possible health state and 100 the 
best possible health state.  
 
Table 5.2. SF-36 measures 
SF-36 subscales Male Female 
Physical Functioning (SF-36PF) 90.76 (± 13.07) 85.57 (± 18.90) 
Role-Physical (SF-36RP) 88.61 (± 17.79) 85.51 (± 21.46) 
Bodily Pain (SF-36BP) 73.71 (± 20.89) 72.99 (± 22.78) 
General Health (SF-36GH) 70.62 (± 18.09) 71.58 (± 21.83) 
Vitality (SF-36VT) 61.01 (± 18.13) 59.17 (± 18.38) 
Social Functioning (SF-36SF) 85.06 (± 19.53) 83.78 (± 22.58) 
Role-Emotional (SF-36RE) 89.33 (± 16.53) 87.91 (± 19.02) 
Mental Health (SF-36MH) 77.10 (± 14.70) 75.32 (± 17.54) 
Physical Component Summary norm-based 
T score (SF-36PCS) 51.93 (± 6.47) 51.15 (± 9.30) 
Mental Component Summary norm-based 




Dr John Pearson (Biostatistics and Computational Unit, University of Otago, 
Christchurch) performed the following statistical analyses. Figure 5.1 shows the 
distribution of LTL in the cohort, with T/S ratios ranging from 0.65 to 1.66. The data are 





Figure 5.1. Distribution of LTL in the sample 
The distribution of observed telomere lengths (T/S ratio) for the CHALICE cohort (n = 351) is shown (A) as density functions for males (M), 
females (F) and combined (solid, Total), and (B) a histogram for all samples with the density curve for a normal distribution with the same mean 
( x = 1.104) and standard deviation (s = 0.153) superimposed. 
 
 




















Women showed significantly longer LTL than men, with LTL at 1.123 compared with 1.08 in 
men, a difference of 0.044 (95% CI 0.012, 0.076, P < 0.007) or approximately 4% longer on 
average. This difference was not significantly altered by adjusting for Māori ethnicity, current 
smoking and standard of living (P < 0.008). There was no evidence for differences in LTL with 
Māori ethnicity, current smoking or standard of living. Participants’ height was the only 
measurement significantly associated with LTL (Beta = -0.0025, P < 0.006), however this 
association was due to sex differences with no significant correlation (r2 < 0.007, P > 0.2) 
detected in females and males separately. The obesity related measures, waist circumference, 
weight, BMI, cholesterol, total triglycerides, HDL, LDL all showed no association with LTL 
both with and without adjustment for gender, ethnicity and socio economic status (all P > 0.2). 
Similarly, the SF36 8 subdomains and 2 composite measures of physical and mental health 





Figure 5.2. Analysis of health measures versus telomere length in CHALICE 
First three graphs are box plots of TL (T/S ratio) versus gender, ethnicity and smoking. 
Remaining graphs are scatter plots for CHALICE participants, colour coded by gender (female 






This study used data gathered from 361 participants of a New Zealand study on a 50-year old 
population sample to assess the effectiveness of using telomere length as a biomarker for an 
individuals’ overall health status. We examined several measures in order to gauge current 
health status including SF-36 score, current smoking status and a comprehensive obesity 
phenotype. We found a significant association between LTL and gender but not for any of the 
other measures, suggesting that telomere length measurements are unlikely to provide 
information of much significance to the individual.  
 
There are a number of possible explanations for our findings. The first is that a cross-sectional 
measure of telomere length is not sufficient to measure current health status and that measures 
of telomere length erosion, obtained by comparing telomere length at birth, as well as repeated 
measures throughout the lifetime would provide a more comprehensive picture of telomere 
length dynamics in health and disease [Aviv 2008]. 
 
A second possible reason for lack of association may be that the age of participants’ in this 
study was inadequate, as telomere length is thought to be influenced the most during the earlier 
stages of life, leading to adverse health outcomes later in adulthood [Entringer et al. 2011]. 
However, a recent longitudinal study by Hjelmborg et al., (2015) [Hjelmborg et al. 2015b] over 
a wide age range (19-64) found that over a 12-year period telomere length tracked throughout 
adulthood and individuals generally retained their ranking, i.e., those with long/short leukocyte 
telomere length (LTL) at baseline displayed long/short LTL as they aged. Given these findings, 
it would seem surprising if the lack of association between health measures and telomere length 




Another possible explanation is that leukocyte telomere length is not a good proxy for current 
health status as telomere length is very heterogeneous in different cells/tissues. However, 
despite differences in absolute telomere length between tissues, there appears to be synchrony 
in relative telomere length amongst other somatic tissues from the same individual [Daniali et 
al. 2013]. Additionally, leukocyte telomeres are thought to reflect the major determinants of 
ageing [Oeseburg et al. 2010] and the effect of different environmental stressors as well as 
reflecting organ dysfunction elsewhere in the body [von Zglinicki et al. 2005].  
 
The final explanation is that we did not adequately assess current health status or LTL. 
However, the SF-36 questionnaire is routinely used to evaluate an individual patients’ health 
status, and although it has not been used in direct association with telomere length, it has been 
used in relation to telomerase levels; the enzyme that elongates telomeres and counteracts 
shortening. This was evaluated in a pilot study of 24 men with low-risk prostate cancer where 
changes in telomerase activity were not associated with changes in mental and physical health 
related quality of life [Ornish et al. 2008]. Furthermore, smoking and obesity are important risk 
factors for many age related diseases and are known to increase the levels of oxidative stress 
and inflammation, which have been shown to erode telomere length. It is also unlikely that 
LTL was inadequately assessed as well recognised standardised measures were used and our 
T/S ratios were carefully controlled by the inclusion of several quality controls. Two limitations 
of this study were the relatively small sample size, and the use of a single, cross-sectional 
measure of telomere length rather than a longitudinal telomere length erosion measurement. 
Telomere length has now been extensively studied in association with these health risk factors 
[Valdes et al. 2005, Harris et al. 2006, Morla et al. 2006, McGrath et al. 2007, Nordfjall et al. 
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2008, Ehrlenbach et al. 2009, Kim et al. 2009, Buxton et al. 2011, Pavanello et al. 2011, Harris 
et al. 2012, Needham et al. 2013, Weischer et al. 2014] in different settings, but the associations 
have been weak with mixed outcomes. All studies thus far have assessed measures of mean 
telomere length with the majority using qPCR as the method for measurement, but it is yet to 
be determined if mean telomere length provides a sensitive enough measure to assess the 
impact of various stressors on telomere length. One study [Morla et al. 2006] used Flow-FISH 
and found that smoking had a dose dependent effect on telomere length; although this study 
had a small sample size and telomere length was measured in the lymphocytes of smokers and 
non-smokers with and without chronic obstructive pulmonary disease. Another study [Valdes 
et al. 2005] using TRF measurements found that in 1122 healthy white woman, shortened 
telomeres were associated with both smoking and obesity. Lastly, only two studies have 
measured telomere length erosion [Ehrlenbach et al. 2009, Weischer et al. 2014]. The first 
found no correlation with smoking and short telomeres whereas the second did find an 
association with smoking and obesity at baseline but these disappeared after the second 
measurement was taken 12 years later. Other factors that have been found to impact on health 
and that we have evaluated in our study include alcohol consumption and socioeconomic status. 
Few studies have assessed these factors [Harris et al. 2006, Pavanello et al. 2011, Harris et al. 
2012, Needham et al. 2013] but the general consensus is that there is no association with 
shortened telomere length.  
5.5.1 Summary and future directions 
In summary, we have assessed several measures that gauge current health status in a population 
sample of ages 49-51, and in no case did we find a statistically significant association between 
any of these measures and leukocyte telomere length. We conclude that individual telomere 
measurements are unlikely to provide any information on health status at an individual level, 
at least in this age range. Further longitudinal studies with repeated measures from the same 
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individual throughout the life time are required to determine the merit of telomere length 
measurements to assess current health status.  
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Chapter 6: Analysis of rare genetic variants that may impact 
on telomere length 
6.1 Introduction 
Telomere length shows a considerable amount of heterogeneity within the population 
arising from a combination of factors, with contributions from environmental influences 
as well as genetic components (reviewed in Section 1.3.4) [de Lange et al. 1990]. In 
humans, telomere GWAS studies have shown that a large number of common genetic 
variants with small individual effect sizes influence telomere length (Section 1.3.4.1). 
The most robust associations have been for variants found in the TERT, TERC and 
OBCF1 genes. TERT variants have the strongest effect with a telomere length decrease 
of about 200 bases per variant allele.  
 
As well as associations between telomere length and common genetic variants of small 
effect size, a number of rare mutations with large effect sizes cause inherited genetic 
diseases that lead to severe telomere shortening. These include diseases such as 
dyskeratosis congenita, aplastic anemia, idiopathic pulmonary fibrosis and Hoyeraal-
Hreidersson syndrome which typically present early in life and result in premature death 
(Section 1.4.1 and 6.1.2).  
 
Large scale analyses of human genomes and exomes such as the 1000 Genomes Project 
and the Human Knockout Project have catalogued most common and many rare variants 
contributing to human genetic variation [Abecasis et al. 2010, MacArthur et al. 2012]. 
Through these studies, it has been revealed that each ‘personal genome’ harbours an 
abundance of variants including approximately 200,000-500,000 SNVs, and a significant 
number of these are rare and unique to the individual [Abecasis et al. 2010, Lupski et al. 
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2011, Abecasis et al. 2012]. These rare mutations are of recent origin and provide a 
significant source of phenotypic variation, including disease susceptibility, than variation 
that arose from distant ancestors [Lupski et al. 2011].  
 
This chapter describes a pilot study applying exome sequencing as an initial test of the 
hypothesis that rare genetic variants may be enriched in subjects with short telomeres 
drawn from the normal population. 
6.1.1 NGS and exome analysis 
Over the past decade, methods for sequencing DNA have undergone radical 
improvements in regard to throughput, leading to a range of methods known as “next 
generation sequencing” (NGS) [Mardis 2008b, a, Shendure and Ji 2008, Wheeler et al. 
2008, Abecasis et al. 2010, Metzker 2010, DePristo et al. 2011]. Generally, NGS 
produces millions of short sequence reads of 100-400 bases in comparison to the longer 
read length of up to 1 kb with Sanger sequencing. The massive throughput at reasonable 
cost possible with NGS methods means re-sequencing of human genomes and exomes 
has become widely available.  This technology has hugely advanced genetic studies of 
Mendelian disorders since it was first applied [Yang et al. 2013, Rabbani et al. 2014]. 
 
NGS technology can be used to sequence the whole genome (WGS) or only the protein 
coding regions (exons), where the choice of method is generally dictated by the research 
question and cost. The exons represent less than 2% of the human genome, making whole 
exome sequencing (WES) very cost effective and a more manageable technique in terms 
of data volume by creating a significantly smaller data file in comparison to WGS 
[Biesecker and Green 2014]. This is of great benefit as a significant limitation of NGS 
technology is the amount of computing power required for data analysis. Furthermore, 
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the protein coding regions contain many known disease-causing variants and additionally 
harbour variants that have a greater penetrance and are therefore more probable 
candidates for being causative [Bamshad et al. 2011, Rabbani et al. 2014].  
 
For WES, the exomes are first ‘captured’ from genomic DNA using exome-enrichment 
kits. Several target enrichment strategies are available including PCR, molecular 
inversion probes, hybrid capture and in-solution capture, with the latter being the most 
common and efficient strategy [Shendure and Ji 2008, Metzker 2010, Meienberg et al. 
2015]. In-solution capture uses custom pools of oligonucleotides or probes labelled with 
magnetic beads that have been designed to hybridise only to the exonic regions. The 
genomic DNA is fragmented, and after hybridisation to the probe, the beads are pulled-
down, washed, and lastly removed to allow sequencing to occur. Currently, there are 
three commercial exome enrichment kits based on the in-solution capture mechanism: 
TruSeqTM Exome Enrichment Kit (Illumina Inc), SeqCap EZTM Human Exome Library 
(Roche NimbleGen), and SureSelectTM Human All Exon (Agilent Technologies). For this 
thesis, exome sequencing was outsourced to Otogenetics (Section 2.6.2), who used the 
Agilent SureSelect Human All Exon AV5 (Agilent Technologies, Wilmington, DE USA, 
catalog# 5190-6213) (Figure 6.1) for exome capture. This method uses ultra-long 
(120mer) biotinylated RNA baits and magnetic streptavidin beads for selection. The 
current capture methods fragment the DNA to an average size that exceeds the mean 
length of an exon (164 bp), thus producing a significant amount of off-target sequences 
[Gnirke et al. 2009]. Therefore, this extra non-exonic information can also be included 





Figure 6.1. Exome enrichment using in-solution capture mechanism 
Target enrichment of the exons using in-solution capture starts with fragmentation of the 
genomic DNA. Ultra-long (120mer) biotinylated RNA baits are added that hybridise to 
the exonic regions and streptavidin coated magnetic beads are used for selection. The 
beads are pulled-down, washed and lastly removed to allow sequencing to occur. Figure 






Several NGS platforms are available, all with their own strengths and limitations, as well as 
utilizing different template preparation, sequencing and imaging strategies [Shendure and Ji 
2008, Metzker 2010, Schadt et al. 2010, Mardis 2013]. Although there are several competing 
NGS platforms, Illumina are the predominant one and the Illumina HiSeq 2000 was used to 
generate exome data for this thesis. 
 
Generally, the core NGS workflow is based on the in vitro creation of sequencing libraries. 
Index adapters are ligated to the end of each genomic DNA fragment. The template is then 
prepared for the NGS reactions using either clonally amplified templates originating from 
single DNA molecules or with single DNA molecule templates. Most imaging systems cannot 
detect single fluorescent events and therefore the clonal amplification of templates by PCR is 
required to increase signal intensity for these platforms. The Illumina platform employs solid-
phase amplification for this purpose, in which the template is attached to a solid surface or 
support (flow cell) (Figure 6.2), followed by bridge amplification with immediately adjacent 
primers covalently attached to the slide, forming clusters. These template sites are spatially 
separated to allow thousands to billions of sequencing reactions to be performed 
simultaneously. 
 
The sequencing reaction is initiated using a universal sequencing primer that hybridises to the 
free end of the template. To sequence clonally amplified templates, Illumina employs a ‘cyclic 
reversible termination’ method with four different coloured fluorophores to identify each type 
of nucleotide [Metzker 2010]. This approach uses modified nucleotides that permit only single-
base incorporation in each cycle, followed by imaging of the fluorescent dye which is then 
translated into DNA sequences. This is performed in a cyclic fashion of nucleotide 
incorporation, fluorescent imaging and cleavage [Nyren et al. 1993, Metzker et al. 1994, 
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Ronaghi et al. 1996, Ronaghi et al. 1998, Mitra et al. 2003, Shendure et al. 2005]. The length 
of DNA sequences that can be determined through such “sequencing by synthesis” techniques 
is typically short, in the range of 200-400 bases. However, paired-end sequencing can be 
performed whereby both ends of the fragment are sequenced. This generates high-quality, 
alignable sequence data that is more likely to align to a reference. Paired-end sequencing 
facilitates the detection of genomic rearrangements and repetitive sequence elements, as well 





Figure 6.2. Illumina sequencing workflow 
Illumina NGS workflow from genomic DNA through library construction and generation of 






6.1.2 Rare variant and telomere length analysis 
The application of exome analysis in relation to telomere length appears to have been restricted 
to the study of severe telomeropathies. Four studies identified RTEL1 (regulator of telomere 
elongation helicase 1) mutations in the severe form of dyskeratosis congenita, Hoyerall-
Hreidarsson syndrome [Ballew et al. 2013, Deng et al. 2013, Le Guen et al. 2013, Walne et al. 
2013]. RTEL1 encodes a DNA helicase essential in the stability, protection and elongation of 
telomeres, and which interacts with proteins in the shelterin complex. RTEL1 was also found 
to be implicated in idiopathic pulmonary fibrosis [Cogan et al. 2015] along with TINF2 (TERF1 
(TRF1)-interacting nuclear factor 2) [Alder et al. 2015] which encodes one of the shelterin 
proteins, hTERT [Alder et al. 2011], and PARN (poly(A)-specific ribonuclease) which had no 
prior connection to telomere biology or disease [Stuart et al. 2015]. An additional study 
identified a rare variant in the gene for another member of the shelterin proteins POT1 
(protection of telomeres 1) that resulted in the susceptibility to familial melanoma [Robles-
Espinoza et al. 2014, Shi et al. 2014]. Carriers of this variant had increased telomere length as 
well as an increased number of fragile telomeres. Lastly, mutations found in CTC1 (conserved 
telomere maintenance component 1), which protects telomeres from degradation, was found to 
cause Coats plus syndrome; a rare disorder where the most characteristic features are retinal 
telangiectasia [Anderson et al. 2012]. With the exception of POT1, variants in these genes 
impact on telomere maintenance resulting in shortened telomeres.  
 
Rare genetic variants of potentially significant impact on gene function may be enriched in 
subjects with short telomeres; therefore I carried out a pilot study to explore the use of WES 





6.2.1 Annotation and filtration of variants 
The raw sequence reads (as FASTQ files provided by Otogenetics Inc.) were processed into a 
reduced variant call format (VCF) file through the analytical pipeline established on NeSI by 
Dr Klaus Lehnert (Department of Biological Sciences, University of Auckland) (as detailed in 
Section 2.6 and Appendix A). The VCF file was annotated using SeattleSeq Variant Annotation 
141 (http://snp.gs.washington.edu/SeattleSeqAnnotation138/) [Ng et al. 2009], build 9.03 (last 
updated on 3 May 2015). SeattleSeq provided additional information on the variants such as 
dbSNP rsID, allele frequency, amino acid changes, conservation scores and pathogenicity 
predictions, allowing further filtering of variants. As we sought only relatively rare variants, 
only those with a minor allele frequency (MAF) of <5% as defined in the Phase I 1000 
Genomes Project [Abecasis et al. 2010, Abecasis et al. 2012], were retained . The population 
MAFs were obtained from the HapMap and Exome Variant Server (EVS) databases 
(http://evs.gs.washington.edu/EVS/), as well as the Exome Aggregation Consortium (ExAC) 
browser (http://exac.broadinstitute.org/). Variants were then filtered by Combined Annotation-
Dependent Depletion (CADD) C scores [Kircher et al. 2014], which is a tool for scoring the 
deleteriousness of SNVs by integrating several annotations including functional information 
and conservation metrics into a single measure. However, CADD C scores cannot be generated 
for indels, so these variants were treated separately from the SNVs and instead filtered by their 
Genomic Evolutionary Rate Profiling (GERP) scores [Cooper et al. 2005] in accordance with 
the recommended cut-off value [Cooper et al. 2010]. The functional effect of the remaining 
variants was assessed with funtionGVS and functionDBSNP. Synonymous mutations were 
removed because they were considered relatively unlikely to have high impact. Intronic 
variants were discarded unless they fell within 10 bp of a splice site, in which case they were 
evaluated using human splicing finder to determine if they may affect function of a splice site.  
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6.2.2 Variant quality metrics 
After filtering, the quality metrics of the variants that looked promising were further inspected. 
Higher quality scores increase the probability of being a true genetic variant versus a 
sequencing or data processing artefact. This information is found in the INFO field of the VCF 
file. A description of these and their cut off points as determined by the GATK guidelines for 
filtering is listed in page 16 of the GATK guidebook 2.7-4 
(https://www.broadinstitute.org/gatk/guide/pdfdocs/GATK_GuideBook_2.7-4.pdf). Variants 
matching any of these conditions were considered poor and filtered out. Variant sites that did 
not pass VQSR were removed, i.e. those that fell within truth-sensitivity tranches of 99 to 99.9 
and 99.9 to 10, although this ran the risk of excluding true positive variants. Variants that 
showed reference bias were removed by assessing the allele counts provided by EVS and 
dbSNP databases, as well as those with a read depth lower than 10. For the remaining variants, 
the quality metrics of the reads were checked, although the majority of these metrics are taken 
into account with VQSR. Most importantly the genotype call was inspected, with a good 






Figure 6.3. Example of a good quality genotype call in a VCF file. 
(a) The most probable genotype, 0 represents the reference allele, and 1 the alternate allele. 
(b) Allelic depth, with the number of reference reads, and the number of alternate reads.  
(c) Approximate read depth, the number of reference reads plus the number of alternate reads 
(d) Genotype quality (Phred-scaled) 
(e) Normalised, Phred-scaled liklihoods for the genotypes, 0/0, 0/1, 1/1. The larger the value 
the less likely the genotype, in this case the heterozygote 0/1 is the most probably and is 
assigned a value of zero 
6.2.3 Selection of candidate telomere genes for exome analysis 
As this was an exploratory study with a small sample size (n = 6), a candidate gene approach 
was adopted. A list of 88 genes (Table 6.1) was compiled from the literature, incorporating 
genes that were implicated in telomere diseases (telomeropathies), identified in GWAS studies, 
or otherwise implicated in telomere biology, genomic stability, DNA damage and repair as well 
as maintenance and regulation. The variants from these genes were extracted from the filtered 
VCF file using the Galaxy bioinformatics server. Briefly, UCSC Genome Browser’s Table 
Browser was used to extract hg19 genomic coordinates for these candidate genes from the track 
‘RefSeq Genes’, creating a BED file. The prefixes ‘chr’ were manually removed in Notepad++ 
from the resultant intervals as they were not compatible with Galaxy. This edited intervals file 
was then used to extract variant calls originating only from the candidate genes, splitting SNVs 
and indels into separate files to help with downstream processing.  
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Table 6.1. Candidate genes involved in telomere maintenance, regulation and biology 
Candidate genes1 Reference 
Telomerase complex  
TERC, TERT, DKC1  [Greider and Blackburn 1985] 
Shelterin complex  
TERF1 (TRF1), TERF2 (TRF2), POT1, ACD 
(TPP1, formally known as PTOP), TERF2IP 
(RAP1), TINF2 (TIN2)  [de Lange 2005] 
Telomerase associated  
TEP1 [Chang et al. 2002] 
PINX1 [Zhou and Lu 2001] 
ADA [Concetti et al. 2015] 
DAXX [Tang et al. 2015] 
PIF1 [Li et al. 2014] 
ZSCAN4 [Lee and Gollahon 2014] 
MEN1 [Mirabello et al. 2010] 
Telomere diseases   
BLM (RECQL3), WRN (RECQL2), SBDS, ATM, 
FANCD2, TP53, RECQL4, NBN (NBS1), 
DCLRE1B (Apollo) [Aubert and Lansdorp 2008] 
NOP10, NPH2, GAR1 [Vulliamy et al. 2008] 
WRAP53 [Batista et al. 2011] 
SLX4 [Kim 2014] 
GWAS hits  
OBFC1 (STN1), CXCR4 [Levy et al. 2010] 
CTC1, ZNF676, MYNN [Mangino et al. 2012] 
ACYP2, NAF1, ZNF208, RTEL1 [Codd et al. 2013] 
C10orf53, ADARB2 CHDS GWAS (Chapter 4) 
CST complex (CTC1-STN1-TEN1)  
TEN1 [Miyake et al. 2009] 
*Note the genes OBFC1 (STN1) and CTC1 are included with the GWAS hits 
MRN Complex (Mre11-Rad50-Nbs)  
MRE11A, RAD50 [Jackson and Bartek 2009] 
*Note the NBS gene is included as a disease gene  
Genomic stability / DNA damage and repair / homologous recombination / telomere 
biology 
RIF1, ERCC1, ERCC4 (XFP), PRKDC (DNA-PK), 
RAD51D, PARP2 [Aubert and Lansdorp 2008] 
BRCA1, BRCA2 [Martinez-Delgado et al. 2013] 
DDX11 [Vasa-Nicotera et al. 2005] 
RAD52, ATR, RAD51, RAD9A, RAD1, HUS1, 
EXO1, RPA1 [Jackson and Bartek 2009] 
XRCC6 (Ku70 ), XRCC5 (Ku80) [Boulton and Jackson 1998] 
163 
 
CHEK1 (CHK1) [Fagagna et al. 2003] 
CHEK2 (CHK2) [Garcia-Beccaria et al. 2014] 
FEN1 [Wang et al. 2014] 
UBE2D2  [Cipressa and Cenci 2013] 
NEK2 [Lee and Gollahon 2013] 
CDKN2A [Wang et al. 2013] 
TOP1 [Serra et al. 2003] 
TNKS (TIN1), TNKS2 [Smith et al. 1998] 
MUS81 [Pepe and West 2014] 
MSH2 [Bertorelle et al. 2014] 
PAXIP1 (PTIP), TP53BP1 [Orthwein et al. 2014] 
PARP1 [Houben et al. 2008] 
HNRNPA1 [Jean-Philippe et al. 2013] 
DHX 9 [Lee et al. 2014] 
LMNA [Das et al. 2013] 
DEK [Ivanauskiene et al. 2014] 
ATRX [Clynes et al. 2014] 
RECQL5 [Mirabello et al. 2010] 
Tumour suppressor  
APC [Bertorelle et al. 2014] 
Apoptosis  
BCL2, BIRC5 (Survivin) [Martinez-Delgado et al. 2013] 
Miscellaneous telomere biology  
SIRT1 [Chen et al. 2014] 
THOC1, THOC2 [Pfeiffer et al. 2013] 
RBL2 [Benetti et al. 2008] 
 
1Gene lists are separated by commas and alternative gene names are in brackets 
 
6.2.4 Variant discovery from exome data 
Variant discovery was restricted to regions specifically targeted by the Agilent SureSelect AV5 
exome enrichment kit (Agilent Technologies, Wilmington, DE USA) with the addition of 100 
bp padding at the 5’ and 3’ ends of each exon. A total of 168,619 variant sites were identified 
in the six participants with short telomere length (Figure 6.4). Selecting only those variants 
located within the candidate genes reduced the number of variants to 894 SNVs and 137 indels. 
Figure 6.4 outlines the multiple variant reduction strategies applied to this list, with only 35 
SNVs and no indels passing these criteria. Most of these 35 variants occurred only once in the 
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six samples, and some had a MAF of less than 1%. Included in the thirty five SNVs were three 
intronic variants (rs34437789, rs146304558, rs2227922). These were located within 10 bp of 
a splice site and were further analysed using the Human Splicing Finder 
(http://www.umd.be/HSF3/). These variants were predicted to potentially alter splicing by the 
creation of either an exonic splicing silencer (ESS) or exonic splicing enhancer (ESE) site and 





Figure 6.4. Filtering strategies employed to identify variants that impact telomere length 
Multiple variant reduction strategies applied to the variants identified through NeSI, with 35 
SNVs and no indels passing these criteria. 
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6.2.5 Prioritisation of variants for follow-up genotyping analysis 
The 35 SNVs identified in Table 6.2 and Table 6.3 were candidate rare variants which could 
potentially impact on telomere length. In order to test this possibility these variants needed to 
be examined in a large cohort for whom telomere length measurements were available. A 
subset of these variants was selected for this analysis, choosing only those that were regarded 
as the most promising in order to limit multiple testing issues. As the majority of SNVs were 
missense mutations, functional effect predictions for the variants were assessed. Both 
PolyPhen-v2 and SIFT predictions were taken into account as they use different algorithms 
with varying degrees of accuracy [Ng and Henikoff 2006, Cooper and Shendure 2011, Hicks 
et al. 2011, Thusberg et al. 2011], but those predicted to be benign or tolerated with both 
PolyPhen-v2 [Adzhubei et al. 2010] and SIFT [Ng and Henikoff 2003, Kumar et al. 2009] were 
removed. Variants that had a high intra-sample allele frequency (i.e. the number of samples 
that contained the variant), those that had a MAF < 1%, and variants predicted to affect splicing 
were deemed most likely to be of significance and were prioritised for further analysis. Table 
6.2 shows the top fifteen variants chosen for this analysis and their quality metrics (Table 6.4), 
as well as the remaining 20 variants that were not genotyped (Table 6.3). It is interesting to 
note that these prioritised variants are distributed amongst the six CHALICE subjects such that 
























ExAC/        




1:242,023,898 A/G N,S EXO1 
Involved in mismatch repair and 
recombination. 5' to 3' 
Exonuclease activity.  





19:22,364,031 T/C Y,C ZNF676 
A zinc finger protein that binds to 
DNA. A potential stabiliser of G-
quadruplexes 
Missense 2.024 PoD D 115951008 1.1, NA, 1 
C100062, 
C100156 
12:1,023,218 G/T S,stop RAD52 
Important for DNA double-strand 








13:32,953,550 G/A A,T BRCA2 
Involved in maintenance of 
genome stability, specifically the 
homologous recombination 
pathway for double-strand DNA 
repair. 




11:65,631,361 C/T R,W MUS81 
Structure-selective endonuclease 
responsible for fork cleavage and 
restart in human cells. Also 
responsible for telomere 
maintenance in telomerase-
negative ALT (Alternative 









15:43,733,730 A/G V,A TP53BP1 Tumour suppressor binding protein Missense 21.3 






16:3,632,372 G/A R,W SLX4 
Forms a multi-protein complex 
required for repair of DNA lesions 
and is critical for cellular responses 
to replication fork failure. 
Missense 17.26 








4:106,156,163 G/A G,D TET2 
Defects in this gene have been 













17:73987590 G/T A,S TEN1 
Appears to function in a telomere-
associated complex with STN1. 




11:108,123,551 C/T P,S ATM 
ATM plays a dual role at 
telomeres, activating the DNA 
damage response program at 
dysfunctional telomeres and yet 
preventing this activation at 
functional telomeres 




17:76,219,685 G/C G,R BIRC5 
Inhibitor of apoptosis, which 
encode negative regulatory 
proteins that prevent apoptotic cell 
death. 
Missense 12.87 






9:21,970,916 C/T A,T CDKN2A 
Protective function in proliferative 













8:145,741,142 T/A None RECQL4 
Is a DNA helicase and may 
modulate chromosome 
segregation. Mutations in this gene 
are associated with Rothmund-








1Single letter amino acid code 
Abbreviations: PrD, probably damaging, PoD, possibly damaging, B, Benign, U, Unknown, D, deleterious, T, Tolerated, NA, not available 
All reported genotypes had a quality score of ≥30 and DP ≥10  
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ExAC/  HapMap/    
MAF(EVS) % 
15:43,769,851 A/G S,P TP53BP1 Missense 16.9 PrD T 61751060 0.006, NA, 0.009 
4:106,155,185 C/G P,R TET2 Missense 16 PrD D 12498609 0.06, 0, 0.015 
2:47,656,871 T/C None MSH2 Intron-variant 27.7 U NA 17224360 0.01, NA, 0.018 
18:60,985,773 C/T A,T BCL2 Missense 5.526 PrD T 1800477 0.02, 0, 0.0002 
13:32,906,480 C/C N,H BRCA2 Missense 12.07 PrD T 766173 0.05, 2.9, 0.037 
3:10,070,336 G/C None FANCD2 5-prime-UTR 10.15 U NA 3732974 0.007, NA, 0.001 
15:91,295,110 C/T T,M BLM Missense 11.27 B T 28384991 0.009,0.9,0.0005 
3:10,103,845 C/T P,S FANCD2 Missense 0.008 B T 147523071 0.001, NA, 0.001 
10:70,450,582 G/A V,M TET1 Missense 1.087 B T 150708897 0.001, NA, 0.002 
2:152,321,516 C/T P,S RIF1 Missense 12.35 B T 61748234 0.004, NA, 0.008 
20:62,321,128 G/A R,Q RTEL1 Missense 13.53 B T 35640778 0.01, NA, 0.01 
5:1,254,594 C/T A,T TERT Missense 10.86 B T 35719940 0.01, NA, 0.02 
3:10,115,033 G/T G,VL FANCD2 Missense 11.13 B T 35495399 0.02, NA, 0.035 
13:32,911,463 G/G N,D BRCA2 Missense 0 B T 1799944 0.05, 2.8, 0.037 
8:48,852,225 C/T M,I PRKDC Missense 9.454 B T 8178017 0.03, 5.2, 0.045 
16:75,690,279 A/G K,E TERF2IP Missense 5.039 B T 4888444 0.04, 4.1, 0.05 
8:48,710,955 A/G I,T PRKDC Missense 5.265 B T 7830743 0.14, 4.1, 0.05 
16:3,639,827 G/A S,F SLX4 Missense 19.87 PrD D 3810813 0.06, 4.9, 0.05 
1:242,045,275 C/T R,C EXO1 Missense 7.986 PoD T 1635498 0.95, 2.7, 0.98 
16:14,026,007 G/A None ERCC4 Intron-near-splice 5.576 U NA 254942 0.96, 3.6, 0.98 
1Single letter amino acid code 
Abbreviations: PrD, probably damaging, PoD, possibly damaging, B, Benign, U, Unknown, D, deleterious, T, Tolerated, NA, not available 
All variants had a quality score of ≥30  
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1:242,023,898 A/G EXO1 4149909 C100035 28 25 53 99 3.4 
    C100332 21 26 47 99  
19:22,364,031 T/C ZNF676 115951008 C100062 30 17 47 99 2.35 
    C100156 17 21 38 99  
12:1,023,218 G/T RAD52 4987207 C100173 12 16 28 99 2.87 
13:32,953,550 G/A BRCA2 11571769 C100062 54 33 87 99 4.8 
11:65,631,361 C/T MUS81 34891773 C100062 36 36 72 99 2.93 
15:43,733,730 A/G TP53BP1 45482998 C100156 33 36 39 99 3.32 
16:3,632,372 G/A SLX4 199736788 C100173 5 6 11 99 3.93 
4:106,156,163 G/A TET2 61744960 C100184 32 36 68 99 5.19 
8:10,623,254 C/A PINX1 17855458 C100332 27 35 62 99 2.74 
17:73,987,590 G/T TEN1 11544990 C100156 17 15 32 99 2.79 
11:108,123,551 C/T ATM 2227922 C100332 7 5 12 99 1.69 
17:76,219,685 G/C BIRC5 17885521 C100184 12 13 25 99 2.52 
9:21,970,916 C/T CDKN2A 3731249 C100062 10 9 19 99 3.47 
6:33,287,796 G/C DAXX 146304558 C100332 23 21 44 99 4.55 




6.2.6 Sequenom MassARRAY genotyping  
Typically, variants identified from WES studies are first validated with Sanger sequencing to 
confirm that they are not false positives resulting from sequencing artefacts, but in our case it 
was more efficient to move straight onto genotyping, which would independently confirm if 
the variant calls from each sample were correct. To test for association between telomere length 
and the 15 selected variants, high-throughput genotyping was undertaken on the entire 
CHALICE cohort (n = 351). Genotyping was carried out on a Sequenom MassARRAY 
platform, which allows multiplexed analysis of up to ~40 SNPs (performed by Phillip 
Shepherd, UniServices, University of Auckland). MassArray genotyping identifies multiple 
SNPs in a single sample by locus specific PCR (Figure 6.5). Primers are located immediately 
upstream of the polymorphic site of interest and single base extension incorporates mass-
modified dideoxynucleotide terminators. The distinct mass of each extended primer is 
determined by Matrix-Assisted Laser Desorption/Ionization – Time Of Flight (MALDI-TOF) 







Figure 6.5. Sequenom MassARRAY genotyping workflow 
Genotyping workflow for Sequenom MassARRAY platform. Described in more detail in 
text. MALDI-TOF: Matrix-assisted laser desorption/ionization – time of flight; SAP: shrimp 
alkaline phosphatase. Reproduced from [Gabriel et al. 2009].  
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6.2.7 Association analysis of candidate SNVs in CHALICE cohort 
After the removal of failed samples, n = 347 remained for genotyping analysis. All genotype 
calls of variants identified from WES were validated on the subjects for whom exome data was 
obtained. As seen in Table 6.5, five of the fifteen variants were common in this cohort (MAF 
of > 5%), and at the other end of the scale, one variant in SLX4 (rs199736788) was found to be 
a singleton in this population sample.  
 
To assess if these selected variants were enriched in subjects with short telomeres, the 
relationship between telomere length and the variant genotype was examined by fitting a 
regression model to telomere length and adjusting for ethnicity and gender (Figure 6.6). The 
p-values obtained from this analysis can be found in Table 6.5, where two variants, 
rs199736788 and rs2227922, reached statistical significance (p < 0.05) with p-values of 0.034 
and 0.040 for the two variants respectively. However, rs199736788 was the singleton variant 
in SLX4, and rs2227922 (in ATM) was also very rare in this cohort with only two subjects 





Table 6.5. Genotyping results from the 15 variants identified with WES 
 
A p-value of < 0.05 is considered statistically significant 







rs11544990 GT 19 5%
G 328 0.24178
rs11571769 AG 6 2%
G 341 0.53793
rs115951008 CT 10 3%
T 337 0.27326
rs146304558 CG 6 2%
G 341 0.91095
rs17855458 CA 13 4%
C 334 0.68575
rs17885521 CG 3 1%
G 344 0.09863
rs199736788 AG 1 0%
G 346 0.03394
rs2227922 TC 2 1%
C 345 0.04032
rs34437789 TA 27 8%
T 320 0.81633
rs34891773 TC 24 7%
C 323 0.44825
rs3731249 CT 18 5%
C 328
NA 1 0.98080
rs4149909 AG 19 5%
A 325
NA 3 0.10887
rs45482998 GA 7 2%
A 340 0.50964
rs4987207 GT 9 3%
G 338 0.85949






Figure 6.6. CHALICE telomere length by number of variant alleles for each SNP 
 
Box plots on CHALICE cohort for the 15 top SNPs, TL versus number of variant alleles (0 or 
1 only). Box and whisker plots are shown beside the raw data points. The only SNPs 
significantly associated with T/S ratio with or without adjusting for gender and Māori ethnicity 
were rs199736788 and rs2227922 (middle row, 2nd and 3rd plot respectively), however both 
SNPs have very low numbers of variant alleles (1 and 2 respectively). For rs61744960, the 












































































































































Telomere length is likely to be a complex trait that is influenced by a plethora of factors 
including genetic factors, with several genes of relatively small effect already identified 
through GWAS (Section 1.3.4.1). GWAS studies are generally constrained to evaluate 
relatively common genetic variants, due to the design of the genotyping chips. This means that 
rare variants of potentially large effect size, present in some individuals, will be overlooked by 
GWAS. In the present pilot study, WES was used to investigate the occurrence of rare variants 
in six individuals from the CHALICE cohort with short telomere length. A candidate gene 
approach was undertaken, using a set of 88 genes compiled from the literature that arose from 
GWAS findings, known disease genes, and those implicated in telomere biology. Gene variants 
from exome analysis were filtered based on their MAF and deleteriousness as determined by 
CADD C scores, PolyPhen-v2 and SIFT. 
 
Fifteen variants were chosen for genotyping in the entire CHALICE cohort to test for 
association with telomere length. Of the fifteen variants, two appeared to be significantly 
associated, although both were very rare and replication in a much larger sample would be 
required to provide confidence in this result. The two variants are in genes known to cause 
diseases relevant to telomeres. The singleton variant (rs199736788) occurred in SLX4 which 
encodes part of a multi-protein complex required for the repair of DNA lesions, which is critical 
for cellular responses to replication fork failure. Causative mutations have been identified in 
patients diagnosed with Fanconi anemia, a rare recessive genetic disorder characterized by 
genomic instability and predisposition to cancers [Kim 2014]. This variant is extremely rare 
with a MAF of 8.323e-05 on the ExAC browser, and no information in the ClinVar curated 
database of human gene variants (http://www.ncbi.nlm.nih.gov/clinvar). It has a CADD score 
177 
 
of 17.46, results in an amino acid change from Arg to Trp and is predicted to be probably 
damaging with PolyPhen-v2, and deleterious with SIFT.  
 
The second potentially associated variant (rs2227922) was in ATM, a gene which is involved 
in the DNA damage and repair response. Mutations in this gene have been found to result in 
the disease Ataxia telangiectasia, a rare inherited neurodegenerative disease causing severe 
symptoms which typically present in early childhood and lead to accelerated telomere 
shortening and premature ageing [Metcalfe et al. 1996]. This variant has a CADD score of 
15.46, results in an amino acid change from Pro to Ser, is predicted to be possibly damaging 
with PolyPhen-v2, and tolerated with SIFT. It is rare, with a MAF of 0.00309 on ExAC and 
was found in only two subjects from the CHALICE cohort. The ClinVar database indicates 
conflicting interpretations of pathogenicity for this ATM gene variant, so that it is of uncertain 
significance. However, given the low population allele frequency of rs2227922, it seems 
surprising that two CHALICE subjects with short telomeres both carried this allele. 
 
The design of this pilot study meant that it was not well powered for the de novo detection of 
rare variants that impact on telomere length, so a candidate gene approach was employed. 
However, such an approach is naturally limited by the extent of published evidence for genes 
chosen as candidates, and has a significant risk of overlooking potentially causative variants 
that did not reside in these loci. One approach that could have been adopted to increase the 
power of this study would have been to include a control group for comparison such as samples 
at the other end of the spectrum with long telomere length. Careful consideration was taken 
when determining samples to include in the current analysis, as budgetary constraints meant 
only six samples could be sequenced; as we were interested in variants relevant to short 




A limitation of this pilot study was the use of WES over WGS as it does not capture information 
from intronic or regulatory regions. Noncoding regions can have important biological functions 
and play an important role in complex diseases and traits [Manolio et al. 2009, Cooper and 
Shendure 2011, Abecasis et al. 2012], therefore in this study we may have missed important 
variants not covered by exome analysis. WES was chosen as the more cost-effective approach 
for this pilot study, with much reduced computational requirements for processing and 
analysing the data, although the cost and accessibility of WGS is decreasing [Belkadi et al. 
2015]. 
 
WES has other inherent problems including variability in coverage across the exome, with 
some regions either over-represented or under-represented. Typically only 80-90% of the 
targeted regions are covered above 10× which can leave between 1000-2000 genes without 
sufficient coverage for variant detection [Kiezun et al. 2012]. This can arise from biological 
variation such as duplications or technical variation from the capture probes, for example. WES 
bioinformatics is also an imperfect process and is susceptible to errors such as incorrect 
alignment. To minimise the impact of this, the most up-to-date tools and software were used 
for processing exome data, following the GATK guidelines and the use of VQSR.  
 
The filtering approach employed here may have caused the loss of true positive variants, or led 
to retention of false positive variants. To reduce the probability of this occurring, several 
criteria were used to reduce the variant list to include only the highest confidence variants, 
judged more likely to have an impact on candidate gene function. This process can be 
somewhat subjective, where the cut-off points for certain criteria were relatively arbitrary and 
mainly driven by the number of variants that could be genotyped in the subsequent analysis. 
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Furthermore, no indels were found to pass the filtering criteria. The calling of insertion–
deletion polymorphisms remains especially challenging and improved detection of these 
important variants will likely require a new generation of sequence analysis tools (Dr Klaus 
Lehnert, University of Auckland, personal communication). Additionally, the variant calling 
strategy used to generate a VCF file through the analytical pipeline established on NeSI may 
have been imperfect. Joint incremental variant calling was used and was performed on 125 
unrelated exomes, however, this is an experimental technique in which there is limited 
experience with the variants produced this way, although the underlying approach is sound (Dr 
Klaus Lehnert, University of Auckland, personal communication).  
 
A potential confounder of the results comes with the use of VQSR. This was performed to filter 
for false positives due to platform or alignment errors, but it could have also filtered out true 
genetic variants as the telomere lengths of the additional 119 samples were unknown. These 
‘convenience controls’ are used to increase sample size but this multiple sample variant calling 
approach may also interfere with variant discovery by negatively impacting on the allele 
frequency estimates.  
6.3.1 Summary and future directions 
This exploratory pilot study did not definitively identify any rare genetic variants likely to be 
impacting on gene function resulting in shortened telomeres in the CHALICE cohort. Two 
interesting but very rare variants gave nominally significance in the association analysis, but at 
best this must be considered a tentative finding. There is the possibility that this pilot study 
could be scaled up by measuring telomere length in the 119 subjects that were used for the joint 
variant calling in collaboration with Dr Klaus Lehnert. This would greatly increase the power 
of finding rare variants that may be impacting on short telomeres in healthy subjects. 
Furthermore, with the additional 119 exomes, there could be merit in exploring a new method 
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for estimating telomere length from NGS data known as TelSeq [Ding et al. 2014]. Software 
available from github (git://github.com/zd1/telseq.git) estimates telomere length from the 
BAM files of WGS data, but it has also been suggested to work effectively with WES. NGS 
data generally provides little information about telomeres as it is difficult to map this repetitive 
region to the reference sequence. Furthermore, the ends of the chromosomes are represented 
as stretches of Ns in the human reference sequence (build GRCh37). As we only had a small 
sample number of exomes (n = 6) we did not pursue this method, but with the additional 119 
exomes it would be interesting to see how well this method compares to the current 





Chapter 7: Trialling the MinIONTM nanopore DNA sequencer 
for direct measurement of human telomere length 
7.1 Introduction 
A major issue limiting assessment of telomere length as a putative biomarker for general 
health and disease is the nature of current measurement methods [Aubert et al. 2012]. 
There are several methods available that employ a variety of molecular techniques, 
including Southern blotting, PCR, FISH and flow cytometry. These methods (reviewed 
in Section 1.5) measure telomere length either of specific chromosomes in single cells, 
or of all chromosomes in a population of cells. Each method also differs in the level of 
technical complexity, requirement for specialised equipment, and how labour intensive 
they are. Large epidemiological studies that require a high throughput technique 
generally employ the TRF and qPCR methods, but as they measure average telomere 
length from a population of cells they provide less sensitive measures. In contrast, the Q-
FISH and STELA methods measure individual telomere length, offering an increased 
level of sensitivity, but they are more labour intensive allowing only low throughput. 
Overall, there is only a modest correlation between the different methods of 
measurement, as described in Section 1.5.7 [Martin-Ruiz et al. 2014] and of the methods 
used for measuring telomere length, the qPCR methods show the greatest amount of 
inter- and intra-assay variation (2.27-28%). This variation within the samples is often 
larger than that seen between cases and control groups, making it hard to draw robust 
conclusions from the studies [Aviv et al. 2011].  
 
Considering that the biological relevance of telomere length variation is not clearly 
elucidated, it would be of a great benefit to have a high throughput method that provides 
a quick, easy, and more accurate way of measuring telomere length in various contexts. 
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Current evidence suggests that telomere-associated senescence is triggered by one or 
more short telomeres within the cell, and not necessarily by a global decrease in the mean 
telomere length that the majority of studies are currently measuring [Vera and Blasco 
2012]. 
 
Oxford Nanopore Technologies (ONT) has developed a tiny, real-time system for the 
detection of single molecules such as protein, DNA and RNA. This device, called the 
MinIONTM, is based on nanopore sensing technology that has been miniaturised into a 
portable sequencing platform approximately the size of a small chocolate bar. The device 
is plugged directly into a laptop or desktop computer via a USB port (Figure 7.1). In 
2014, to drive the adoption of this new technology, ONT established an early access 
program (MinIONTM Access Programme, or MAP) allowing selected laboratories to trial 
the device and share their experiences within an online user community. Our laboratory 





Figure 7.1. MinIONTM sequencing device 
Components of the system are the MinIONTM device (right), disposable flow cell 
containing nanopore membrane (left), and USB cable for connection to a suitable 
computer. 
 
At the core of this technology is an array of nanopore proteins each containing a nano-
scale hole, embedded into a membrane bilayer made of a synthetic polymer with a high 
electronic resistance (Figure 7.2). An ionic current is applied across the membrane which 
flows through the aperture of each nanopore, and when a single molecule enters the 
nanopore, it causes a characteristic disruption in the current which is subsequently used 
to identify the molecule (Figure 7.2, C). For double stranded DNA, the strands are 
separated and a single strand is drawn through the nanopore using a specialised motor 
protein (the identity of which is not disclosed), and each of the four bases (as well as 
modified bases) generate a distinct electronic signature as they pass through the pore. 
The signals are sensed in real-time using the MinKNOWTM software and later translated 
into DNA sequence using the cloud based Metrichor software to call the sequence, 
interpreting changes in the ionic current caused by groups of five contiguous bases (5-
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mers). Both the forward and reverse strands of the DNA fragment can be sequenced 
consecutively by ligating a hairpin adapter during library preparation, to tether the two 
strands together and allowing the second strand to be drawn through the pore once the 
first strand has been read. When both strands of the molecule are read successfully, the 
base calling software attempts to call a consensus sequence, referred to as a two-
dimensional (2D) read. 2D reads are more accurate compared to one-dimensional (1D) 





Figure 7.2. Overview of nanopore sensing technology 
A nanopore protein reading a single DNA molecule is shown (A) and multiple nanopores 
in B. When the DNA passes through the nanopores, they create a characteristic disruption 
to the current, which is depicted in C.  
 
One of the key features of the MinIONTM is its ability to carry out long-read sequencing 
at the single molecule level, with several hundred molecules able to be read 
simultaneously. This feature provided the opportunity to explore the use of the 
MinIONTM as a novel means of accurately measuring telomere length, and we 
A B C 
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hypothesised that the device would be able to directly count telomere repeats in human 
chromosomal DNA. To test this hypothesis a PCR-free, telomere pull-down approach 
was adopted to enrich for telomeres from genomic DNA, prior to loading on the 
MinIONTM.  
7.1.1 Pull-down of telomeric DNA 
Genomic DNA (gDNA) was first digested with the restriction enzyme HinfI to cleave 
the telomeric DNA from the remaining gDNA [Kimura et al. 2010]. A biotin labelled 
(CCCTAA)6 oligonucleotide probe complementary to the single-stranded G-rich 
overhang found in human telomeres [Makarov et al. 1997, Wright et al. 1997], was then 
annealed to the cleaved DNA and captured using streptavidin coated magnetic beads. 
The bound telomeres were eluted from the beads, dot-blotted onto nylon membrane and 









Figure 7.3. Schematic of the pull-down assay 
Genomic DNA is digested with the restriction enzyme HinfI to release intact telomeric DNA from 
the remaining gDNA. A biotin labelled (CCCTAA)6 oligonucleotide probe complementary to the 
characteristic terminal telomeric single stranded G-rich overhang is added which anneals to the G-
tail, and is subsequently captured with streptavidin coated magnetic beads. The DNA is then 




7.2.1 Detection of pull-down products 
Preparation of libraries and sequencing on the MinIONTM is relatively costly; therefore the 
telomeric DNA pull-down procedures were extensively optimised before using the device. This 
was achieved with DNA dot-blot procedures and detection reagents from the TeloTTAGGG TRF 
kit (Roche, Mannheim, Germany; Sections 2.5.1and 2.8). Samples were prepared prior to loading 
on the membrane following the protocol outlined in Brown et al., (2001) [Brown 2001] for dot 
and slot blotting of DNA. 
7.2.2 Positive and negative control samples 
Plasmid DNA was used for both positive and negative controls on the blot. Laboratory plasmid 
stocks of pBluescript SK (+/-) were used as negative controls. For the positive controls, three 
plasmids containing telomeric inserts of known length were obtained from the plasmid repository 
Addgene (https://www.addgene.org/). These plasmids were pBB, f.pRST1 and pSXneo (Section 
2.9 and Appendix D and E), which contained telomeric repeat inserts of 103 bp, 136 bp and 1.6 
kb respectively. Sanger sequencing (Section 2.3.7) was used to verify the presence of telomeric 







Figure 7.4. Sanger sequence of the telomere repeat from plasmid pBB 
To confirm the presence of the telomeric repeat insert in plasmid pBB, Sanger sequencing was performed following touchdown PCR using the 
T7 and T3 primer pairs. The enlarged region illustrates 9 of the 17 T2AG3 repeats in this plasmid insert. Sequence image was generated using 





7.2.3 Dot-blot optimisation 
A preliminary dot-blot was carried out using control plasmids and a genomic DNA sample to 
determine if the sample preparation, dot-blotting and detection using the TeloTTAGGG kit was 
adequate for the verification of telomeric DNA (Figure 7.5). It was apparent that positive control 
plasmids containing the telomeric inserts (Figure 7.5 B1, B2, and B5) generate a telomere-specific 
signal, and plasmids without an insert (Figure 7.5, A2, B3, B4) did not. To further establish if the 
protocol was working sufficiently, two human gDNA samples and a water control were included. 
A signal was only obtained for the gDNA sample (Figure 7.5 A1 and A3) and not the water control, 
(Figure 7.5 A4). This experiment confirmed that the sample preparation and detection process was 
adequate to verify if telomeric DNA was present in a sample. All future experiments included 
human gDNA and pSXneo as positive controls, and pBluescript SK- as a negative control, 
although these are not shown in every figure. 
 
 
Figure 7.5. Dot-blot of positive and negative controls  
100ng of plasmid DNA and 1 µg gDNA was added to a nylon membrane by dot-blotting and 
detected with the TeloTTAGGG TRF kit. The positive control plasmids containing telomeric 
inserts are in positions B1, B2, B5, and a strong telomeric specific signal is apparent. For the 
plasmids without an insert (A2, B3, B4) no signal is observed. Position A1 and A3 contain the 
human gDNA controls and position A4 the water (no DNA) control. No sample was added to 
position A5. 






7.2.4 Sensitivity of the dot-blot 
The average recovery of telomeric DNA using this method was estimated to be 33% ± 15% 
[Wright et al. 1997]. Therefore, to determine the amount of starting gDNA required for a 
detectable signal, a dilution series of gDNA was directly spotted on the membrane. Figure 7.6 
shows that the signal intensity increases in proportion to the amount of gDNA used (Figure7.6 
A1-5) and that even 0.5 µg is sufficient for visualisation (Figure 7.6 A1). For the pull-down 
experiments, a starting concentration of 2.5 µg was chosen, because even with lower than expected 




Figure 7.6. Concentration range of genomic DNA  
One gDNA sample at differing concentrations was added to a nylon membrane by dot-blotting 
and detected with the TeloTTAGGG TRF kit. Positions A1-A4 show samples of 0.5, 1, 2.5 and 5 
µg of gDNA respectively, with the amount of telomeric signal visualised proportional to the 
amount of gDNA added.  
7.2.5 Initial telomere pull-down attempt 
The initial pull-down experiment involved replicating the Wright et al., protocol (1997) for the 
purification of telomeres [Wright et al. 1997], with the exception of decreasing the starting amount 
of DNA from 30 µg to 2.5 µg as described above, and to limit the use of costly streptavidin coated 
magnetic beads. The amounts of the remaining reagents were therefore adjusted proportionally. 
No telomere product was apparent after pull-down using this method (data not shown).  




To determine if the biotinylated oligonucleotide and magnetic beads were a factor in failure of this 
initial experiment, the experiment was repeated except that these two reagents were added at a 12-
fold greater concentration. These two components were also separately omitted from two reactions 
as controls. Telomeric signals were apparent (Figure 7.7) suggesting that the amount of beads or 
oligonucleotide was the limiting factor in the initial experiment. In order to estimate the amount 
of telomeric DNA that could be recovered using this method, telomeric signals were compared for 
pulled-down fractions versus supernatants (Figure 7.7). The amount pulled-down (Figure 7.7, A1) 
compared to that left in the supernatant (Figure 7.7, B1) suggested recovery of roughly a third of 
the telomeric DNA, similar to that reported for the original protocol [Wright et al. 1997]. When 
no oligonucleotide or beads were added to the reaction, no telomeric DNA was pulled-down 
(Figure 7.7, A2, A5) and it all remained in the supernatant (Figure 7.7, B2, B5).  
 
Figure 7.7. Dot-blot with excess oligonucleotide and beads 
Pull-down products containing a starting gDNA amount of 2.5 µg were added to a nylon 
membrane by dot-blotting and detected with the TeloTTAGGG TRF kit. The sample containing 
all reaction components is found in column 1, with the pulled-down fraction in position A1 and 
the supernatant in B1. Column 2 is the same except that oligonucleotide was omitted, and 
telomere-specific signal is apparent only in the supernatant (B2) and not in the pulled-down 
fraction.  Column 5 is the same except that magnetic beads were omitted, with the same outcome 
as column 2. The plasmid negative and positive controls were in B3 and B4 respectively. No 






sample was added to positions A3 and A4 as these wells were not draining correctly when 
preparing the blot prior to loading the samples. 
 
7.2.6 Optimisation of the pull-down assay 
7.2.6.1 Establishing the optimal concentration of biotinylated oligonucleotide  
Biotinylated oligonucleotide and streptavidin coated magnetic beads were added in excess in the 
previous experiment, so the next step was to determine the optimal amounts of these components 
for recovery of telomeric DNA from 2.5 µg gDNA. Oligonucleotide concentrations of 1, 2, 5, 10 
and 15 pmol (Figure 7.8 A1-5) were trialled in the pull-down experiment. Unexpectedly, the 
higher concentrations resulted in less telomeric DNA being pulled-down. Although concentrations 
of less than 1 pmol were tested, they appeared to recover less telomeric DNA (data not shown), 




Figure 7.8. Establishing the optimal concentration of oligonucleotide  
Pull-down products containing a starting gDNA amount of 2.5 µg were added to a nylon 
membrane by dot-blotting and detected with the TeloTTAGGG TRF kit. The same gDNA sample 
was used with differing amounts of biotinylated oligonucleotide added, ranging from 1, 2, 5, 10 
and 15 pmol (positions A1-5). The telomeric signal decreased with an increasing amount of 
biotinylated oligonucleotide.  
7.2.6.2 Establishing the optimal amount of streptavidin coated magnetic beads  
Using 1 pmol biotinylated oligonucleotide, and varying amounts of beads (30 µL, 20 µL, 15 µL, 
10 µL, 5 µL of 1 mg/mL) were trialled. In this experiment both the pulled-down telomeric DNA 




and supernatant were added to the blot, although nothing could be visualised in the supernatant 
from any of the samples (Figure 7.9 A2, A4, B2 and B4). The greatest amount of telomeric DNA 







Figure 7.9. Establishing the optimal amount of streptavidin coated magnetic beads 
Pull-down products containing a starting gDNA amount of 2.5 µg were added to a nylon 
membrane by dot-blotting and detected with the TeloTTAGGG TRF kit. The amount of telomeric 
DNA bound in the pull-down assay using 1 pmol biotinylated oligonucleotide and varying 
amounts of magnetic beads from 30 µL, 20 µL, 15 µL, 10 µL, 5 µL of 1 mg/mL can be seen in 
positions A1, A3, A5, B1 and B5 respectively. The telomeric signal is greatest using 20 µL 
(1mg/mL) beads (A3). No telomeric-specific signal can be seen in the supernatant from any of the 
samples (columns 2 and 4). B5 contains a gDNA control.  
7.2.6.3 Optimal time for hybridisation of bead/oligonucleotide  
The initial pull-down procedure was time consuming, taking 3 days to complete. Therefore I 
sought to streamline the protocol and tested whether a shorter incubation time for the hybridisation 
between the bead/oligonucleotide interaction would be as effective. As well as the original 
overnight incubation, incubations of 4, 2, 1 hour and 30 min were tested. All times appeared to 
give similar yields; therefore a 30 min (Figure 7.10, A1) incubation was used for further 
experiments. 







Figure 7.10. Hybridisation of bead/oligonucleotide interaction 
Pull-down products containing a starting gDNA amount of 2.5 µg was added to a nylon membrane 
by dot-blotting and detected with the TeloTTAGGG TRF kit. The same gDNA sample was used 
with different bead/oligonucleotide incubation times, ranging from 30 min, 1, 2, 4 hours and 
overnight (A1-5 respectively). All times gave similar yields.  
7.2.7 Modification of the reaction components 
To establish if the restriction digest and addition of Denhardt’s solution were essential to the 
success of the pull-down, these components were successively omitted. The restriction digest is 
used to free the telomeric DNA from the bulk of the gDNA because it is assumed that unless 
telomeric DNA is freed in this way it will not be effectively captured and recovered. Omitting the 
restriction enzyme step certainly had an adverse effect on telomere pull-down (Figure 7.11, A2), 
with most telomeric DNA remaining in the supernatant (Figure 7.11, B2), suggesting the above 
assumption may be correct. Denhardt’s solution is used in the reaction to reduce the amount of 
non-specific binding, and when it was excluded from the reaction the amount of telomere bound 
(A1) and that in the supernatant (B1) was very similar. This suggested very little effect of 
Denhardt’s solution, but compared to a conventional reaction that was included on the blot, there 
appeared to be less signal for the pulled-down telomeric DNA and an increased signal in the 
supernatant (data not shown). Therefore, Denhardt’s solution was retained as part of the protocol. 
 





Figure 7.11. Modification of the reaction components 
Pull-down products containing a starting gDNA amount of 2.5 µg were added to a nylon 
membrane by dot-blotting and detected with the TeloTTAGGG TRF kit. Column 1 contains a 
sample with no Denhard’s solution added. The telomere-specific signal of pulled-down material 
(A1) versus supernatant (B1) is similar. Omission of the restriction digestion reaction is tested in 
Column 2. The telomere-specific signal of pulled-down material (A2) versus that of the 
supernatant (B2) is very low, suggesting very poor capture and pull-down of telomeric DNA.  
7.2.8 Attempted approach to increase the yield of telomeric DNA 
Initial experiments suggested the recovery of telomeric DNA from the gDNA was incomplete, so 
multiple rounds of pull-down from the same sample were attempted to increase the yield. In these 
experiments the telomeric DNA remaining in the supernatant was subjected to successive recovery 
attempts using two different methods. The first involved adding the unbound telomeric DNA (i.e. 
that remaining in the supernatant) back into the original, previously hybridised 
bead/oligonucleotide complexes once the bound (first round) telomeric DNA had been eluted 
(Figure 7.12, row A). In the second approach, the remaining unbound telomeric DNA was treated 
as the starting material and underwent treatment with fresh beads and oligonucleotide (Figure 7.12 
row B). Both methods show that a negligible amount of telomeric DNA is recovered with 





Figure 7.12. Multiple pull-down recovery cycles 
Pull-down products containing a starting gDNA amount of 2.5 µg were added to a nylon 
membrane by dot-blotting and detected with the TeloTTAGGG TRF kit. Two gDNA samples in 
row A and B respectively underwent multiple rounds of recovery with Column 1 showing the 
pulled-down products after one round. The sample in row A underwent two additional rounds of 
recovery (A2 and A3) whereas the sample in B underwent three successive recoveries (B2, B3 
and B4). The residual supernatant material from sample A and B are A4 and B5 respectively. A5 
contains a gDNA control. 
7.3 MinIONTM runs on telomere pull-down product  
After optimisation of the telomere pull-down procedures, 1 µg of the enriched telomeric DNA 
product was loaded onto the MinIONTM. Two sequencing runs were carried out using the R7.3 
sequencing chemistry and the SQK MAP-004 library preparation kit (Section 2.10.1). As seen in 
Table 7.1, the first run produced a total of 1,595 sequence reads and of these, 46 were two-
directional (2D) (2.9%). The low percentage of 2D reads suggested a problem had occurred with 
the library preparation or the addition of the adapters. One possible cause for this may have been 
interference by the single stranded 3’ G-rich telomere overhang with the ligation or other aspects 
of library preparation. The adapters were therefore omitted in the second sequencing run, which 
generated a total of 2,234 sequence reads (Table 7.1), and of these 13 were 2D (0.58%). This small 
percentage of 2D reads obtained when no adapters are present most likely results from false calling 
with the Metrichor base-calling software. The software identifies 2D reads based on the signal 






from abasic markers present within the hairpin adaptor linking template and complement strands. 
This false calling indicates the presence of abasic sites within a small population of DNA 
fragments in this library (Dr Simone Cree, University of Otago, Christchurch, personal 
communication). 
 
A number of long sequence reads were obtained (Figure 7.13) with the longest achieved for the 
first and second run being 79,901 and 282,705 bases, with a mean length of 482 and 2,280 bases 
for the first and second runs respectively. As shown in Figure 7.13, reads of this length were the 
exception and not representative of the distribution. Within all sequence reads, only a small 
number of perfect T2AG3 telomere repeats were present with a total of 118 single repeats in reads 
from the first run and 434 in the second. The longest perfect repeat sequence consisted of two 
tandem repeats, which occurred five times and only in reads from the second run. As the majority 
of the sequence reads were not telomere repeats, the FASTA file containing all of the sequence 
reads was analysed with the Basic Local Alignment Search Tool (BLASTN) 
(http://blast.ncbi.nlm.nih.gov), to test for matches with any human genome sequence. Four reads 
in the first run and one in the second showed clear similarity to human sequences, and although 
the identity was very high, ranging from 87-96%, there were only short segments of similarity (< 
50 bases). These data did not provide strong evidence for recognisable human DNA sequences in 




Table 7.1. Metrics for telomeric DNA pull-down reads on the MinIONTM run 
 Run 1 Run 2  
Total number of reads 1,595 2,234  
Total 2D reads 46 13  
% 2D reads 2.9 0.581  
Total base pairs 769,127 5,095,078  
Longest read length (base) 79,901 282,705  
Mean read length (base) 482 2,280  
Total number of TTAGGG or complement repeats 118 434  
Number of > 1 TTAGGG 0 5(TTAGGG2)  






Figure 7.13. Sequence length distribution for MinIONTM pull-down assays 
Two sequencing libraries using 1 µg of pull-down product, the R7.3 sequencing chemistry and the 
SQK MAP-004 library preparation kit were analysed on the MinIONTM sequencer. The sequence 





1,595 sequence reads were produced with a mean length of 482 bases and the longest read 
consisted of 79,901 bases. The second run generated 2,234 sequence reads with an average length 
of 2,280 bases and the longest read was 282,705 bases. Sequence image was generated using 
Geneious 8.1.5 (Biomatters Ltd., Auckland, New Zealand). 
7.4 Telomere repeat plasmid preparation for MinIONTM sequencing 
The prior MinIONTM analysis generated very little evidence of true telomeric DNA in the enriched, 
pull-down fraction. It was not clear whether this resulted from low overall telomeric DNA content 
in the enriched fraction, such that remaining background genomic DNA was swamping out a 
relatively small proportion of telomeric DNA, or whether there were abundant telomeric DNA 
sequences present but the MinIONTM system was not accurately reading or calling these repetitive 
regions. To further explore this question, the three plasmids previously used as positive controls 
for the dot-blot (Section 7.2.2) were subjected to MinIONTM analysis.  
 
The plasmids were sequenced on two MinIONTM runs using the R7 and R7.3 chemistries and the 
SQK MAP-002 and SQK MAP-003 library preparation kits respectively (Section 2.10.1). The first 
run included two of the three plasmids (pBB and f.pRST1) as pSXneo proved technically 
challenging to grow and prepare, presumably due to the large telomere insert (1.6 kb) it contained. 
Therefore, prior to the second run, all plasmids were transformed into DH5α, a strain of E.coli that 
produces one of the highest yields of good quality plasmid DNA for sequencing [Taylor et al. 
1993]. After transformation into DH5α, better quality and a higher yield of plasmid DNA was 
obtained, and all three plasmids were included in the second sequencing run. For the first run, the 
plasmids were linearised with BamHI which produces sticky ends, but as it was unknown what 
effect this may have on library preparation, plasmids for the second run were linearised with the 
restriction enzyme SspI, which generates blunt ends. All plasmid DNA preparations were checked 
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on a 0.7% agarose gel to verify successful digestion, before they were loaded onto the MinIONTM. 
The DNA was cleaned up with phenol/CHCl3 before library preparation (Section 2.3.6). 
 
For the first MinIONTM run, two sequencing libraries were prepared for the two plasmids (pBB 
and f.pRST1), which meant they could be loaded individually, and reads from the individual 
plasmids could be obtained and analysed separately. The library preparation for the second run, 
however, contained a mix of all three plasmids (pBB, f.pRST1 and pSXneo) which were not 
indexed with different adapters, as this was judged to be unnecessary and a more efficient 
approach.  
7.5 MinIONTM runs on telomere repeat-containing plasmids 
MinIONTM runs on these plasmid libraries generated many more reads than the runs for genomic 
telomeric DNA pull-down samples. A total of 19,160 reads were produced from the first run and 
6,823 in the second. A marked increase in the proportion of 2D reads was also noted, with 11-15% 
2D reads for the plasmid libraries compared to only 2.9% in the pull-down runs (Table 7.2). The 
read lengths were much greater than that expected to be produced from the plasmid. The largest 
plasmid was approximately 4 kb, meaning that the 2D reads would give a maximum length of 8 
kb. However, the longest read in the first and second runs far surpassed this, with lengths of 
167,546 and 20,157 bases respectively. These long reads were most likely to be very long 
concatamers of ligated plasmids, a problem that ONT had noted with this library preparation kit, 
and which they are addressing with future kit modifications [Oxford Nanopore Technologies 










Figure 7.14. Sequence length distribution for the telomere repeat plasmids on the MinIONTM  
1 µg of purified plasmid DNA containing all three plasmids was analysed on the MinIONTM using 
the R7.3 sequencing chemistry and the SQK MAP-003 library preparation kit. The sequence 
length distribution for all three plasmids pBB (A), f.pRST1 (B) and pSXneo (C) is shown. The 
longest read obtained from this sequencing run was 20,157 bases with a mean sequence length of 






Table 7.2. Metrics for telomeric plasmid reads on the MinIONTM sequencer 
 Run 1 Run 2 
Total number of reads 19,160 6,823 
Total 2D 2,926 767 
% 2D reads 15.3 11.2 
Total base pairs 29,705,638 2,088,760 
Longest read length (base) 167,546 20,157 
Mean read length (base) 1,550 306 
 
7.5.1 Comparison of MinIONTM data with known plasmid sequences 
To determine whether the three telomere repeat plasmids were present in the sequence reads 
obtained from the MinIONTM, they were compared to the plasmid reference sequences provided 
by Addgene (Appendix D) using LASTZ [Harris 2007]. The two plasmids that were included in 
the first run (pBB and f.pRST1) were confirmed to be present and in the second run all three 
plasmids were observed. To further explore these data, a pairwise alignment was performed using 
LASTZ (with alignment settings given in Table 7.3) to determine the % identity to the reference 
sequence. As shown in Table 7.4, the degree of identity to the reference was low at approximately 
50% for both sequencing runs. When all of the reads were used in the analysis of the first run, 
there was a total % identity to the reference of 42.1% for pBB and 41.8% for f.pRST1. The 2D 
reads gave a slightly better pairwise identity with a total of 51.3% for pBB and 48.8% for f.pRST1. 
For the second run, when all of the sequence reads were used a pairwise identity of 50.2% for 
pBB, 50% for f.pRST1 and 53.2% for pSXneo was obtained and when 2D reads only were used 
there was a slight improvement in the % identity with 51.2% for pBB, 51.2% for f.pRST1 and 
58.2% for 58.2% 
 
Furthermore, as separate libraries were prepared for the two plasmids in the first run, the sequence 
specific to the vector backbone and the telomeric insert could be analysed separately. The 
telomeric insert from plasmid pBB was found to have a slightly higher % identity relative to the 
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vector, but the opposite was observed for f.pRST1 where the plasmid had a slightly better % 
identity than the insert. Additional inspection of the individual sequence reads of these runs 
showed that they were highly error prone with numerous substitution errors and indels compared 
to the reference (Figure 7.15).  
 
Table 7.3. Alignment settings using LASTZ 
Parameter Value 
Step length 4 
Seed pattern 12 of 19 
Search strand Both 
HSP threshold score 5 
Gapped threshold score 5 
Abbreviation: HSP, high scoring segment pairs 
 
 
Table 7.4. LASTZ pairwise identity analysis of MinIONTM telomeric plasmid reads 
Plasmid name Run 11   Run 2 




















N/A N/A N/A 
53.2% 
(58.2%) 
The % pairwise identity for the 2D reads are in brackets 
1Libraries for run 1 were loaded separately for the two plasmids pBB and f.pRST1, and pSXneo 
was not included 







Figure 7.15. Example of sequencing reads from the telomere repeat plasmid pBB on the MinIONTM 
Several reads generated from the MinIONTM sequencer are aligned to a reference that contains two tandem telomere repeats originating from the 
telomere insert of plasmid pBB. Bases that agree with the reference are in grey and substitutions or insertions are represented by the colour base 
substitution that has occurred (A: Red, T: Green, C: Blue, and G Yellow). No base is shown for a deletion. Sequence image was generated using 
Geneious 8.1.5 (Biomatters Ltd., Auckland, New Zealand). 
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7.5.2 Number of telomeric repeats observed on the MinIONTM sequencer from the 
telomere repeat plasmids 
One of our key goals was to determine if the MinIONTM could read tandem telomere repeats, so 
the number of perfect tandem repeats were counted using searches of the data in Geneious v 8.1.5. 
Table 7.5 shows the number of telomere repeats obtained from the plasmid sequencing runs. Many 
more repeats were apparent than observed in the reads on the genomic pull-down libraries, and a 
larger number of consecutive repeats was also observed, with the longest perfect telomere 
sequence containing 6 tandem repeats. It was also noted that there were fewer repeats originating 
from the complementary C-rich strand than that of the G-rich strand. Although this is an 
improvement on the previous runs, it is still much lower than the expected repeat number of 17, 
23 and 266 for pBB, f.pRST1 and pSXneo respectively. These data suggest that the MinIONTM 
can accurately read short tracts of T2AG3 but may have difficulty with long contiguous tracts.  
 
 
Table 7.5. Total number of telomere and complement repeats 
Number of telomere and  
complement repeats Run 1 Run 2 
 pBB f.pRST1 Pooled plasmids 
TTAGGG/ CCCTAA repeat 859 3114 1967 
(TTAGGG)2/ (CCCTAA)2 repeats 72 429 126 
(TTAGGG)3/ (CCCTAA)3 repeats  21 128 28 
(TTAGGG)4/ (CCCTAA)4 repeats 5 38 5 
(TTAGGG)5/ (CCCTAA)5 repeats 2 11 0 










7.5.3 Read-depth of the plasmid sequence data 
The read-depth of the MinIONTM plasmid sequencing data was assessed in Geneious v 8.1.5 
(Figure 7.16). Plasmids pBB and f.pRST1 were found to both have 100% coverage of the reference 
sequence whereas pSXneo only had a 50.7% coverage. Although pBB and f.pRST1 had 100% 
coverage, it was not consistent throughout the plasmid, with the 5’ and 3’ ends of the linearised 
plasmid having the least read coverage. The general trend seen for these two plasmids was that 
the coverage steadily decreased when approaching the telomere insert, and dropped off within the 
insert. pSXneo, on the other hand, had especially poor coverage at the 5’ end where the 1.6 kb the 








Figure 7.16. Coverage of sequence reads for the three plasmids 
The coverage of the linearised plasmids was assessed using LASTZ. Both pBB (A) and f.pRST1 
(B) had a coverage of 100%, whereas pSXneo (C) had only 50.7% coverage. Forward sequences 
are shown in red and reverse in blue, and the base coordinate highlighted in blue above the figure 
indicates the 5’ border of the telomere repeat insert. The read-depth was not consistent throughout 
the plasmids with the 5’ and 3’ ends having the least coverage, with a steady decrease shown when 








Several methods are currently available for measuring telomere length, all with their own strengths 
and limitations. The MinIONTM nanopore sequencer is an emerging NGS sequencing technology 
that has the ability to sequence long reads (> 100 kb) at the single molecule level. We had the 
opportunity to trial this new technology, and sought to establish whether it might prove useful for 
accurately measuring telomere repeats.  
7.6.1 Telomeric pull-down from genomic DNA 
A non-PCR based pull-down approach was established to enrich telomeric DNA from total gDNA 
before using for nanopore sequencing. The preliminary data looked promising with the dot-blot 
confirming that telomeric DNA could be pulled-down using this method. Modifications to the 
initial method were made, leading to a reduction in workflow time from three days to two, and 
improvements in the yield of telomeric DNA that could be pulled-down. 
 
A limitation of this approach was that although there was clearly enrichment of telomeric DNA 
using this pull-down method, it was not possible to quantify the degree of enrichment. The dot-
blot could only provide qualitative data and confirm that the telomeric DNA was present but it did 
not provide any information on the purity of the sample and what proportion of gDNA was 
remaining. If the amount of gDNA was much greater than that of the telomere product then this 
could have swamped the MinIONTM with non-telomeric DNA specific reads to the exclusion of 
telomeric repeat reads. Therefore, future modifications to the pull-down protocol should include 
a method for quantifying the ratio of genomic DNA to telomeric DNA before and after enrichment. 
One approach would be to try and determine the purity of the sample by quantifying or detecting 
the amount of gDNA present. This could be achieved by using another DIG labelled probe that 
identifies ALU repeats present in the gDNA for example, as they are dispersed throughout the 
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genome and would provide a fair estimate of the amount present. An alternative approach would 
be to carry out qPCR analysis on the DNA fractions before and after pull-down using the two-
plate telomere assay to quantify the relative amount of telomeric DNA compared to the single 
copy reference gene. Another way to quantitatively assess the purity of the sample would be to 
analyse the products from the pull-down assay on an alternative next generation sequencing 
platform, such as the MiSeq (Illumina) or Ion Torrent (Life Technologies). This would help clarify 
whether the issue experienced in our MinIONTM analysis was due to lack of telomeric DNA 
enrichment, or poor reading of the repeat regions by the MinIONTM device. 
 
Once the proportion of gDNA remaining in enriched samples was identified, the next steps would 
be to explore ways of reducing this. It is possible that residual, contaminating non-telomeric 
gDNA is non-specifically bound or ‘tangled up’ in the beads. Therefore, another potential 
improvement would be to treat the DNA after one round of capture with frequently cutting 
restriction enzymes. This would digest non-telomeric DNA into short fragments, while leaving 
the repetitive telomeric DNA tracts intact and available for recovery by another round of capture, 
prior to MinIONTM library preparation. 
7.6.2 MinIONTM analysis of telomeric pull-down products  
As few telomeric repeats were observed in the MinIONTM sequence reads, it was surprising that 
there were so few human DNA sequences recognised with the BLAST search and that no sub-
telomeric regions were evident. The data from the most recent sequence analyses of human sub-
telomeric regions [Stong et al. 2014] were in Genbank and would have been included in the 
BLAST analysis of the genomic pull-down reads, but none showed up in the analysis. A total of 
five reads from both pull-down assays showed some alignment to the human genome, and were 
located on chromosomes 17, 14, 4 and 3. Even with the large read lengths generated from the 
sequencing runs, only short segments of less than 50 bases aligned, and it is quite possible that all 
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of these matches were simply by chance. More sophisticated bioinformatic approaches to sequence 
alignment may be worth exploring in order to see if better evidence for presence of human gDNA 
can be obtained from these sequence reads.  
7.6.3 MinIONTM analysis of telomeric repeat plasmids 
For the control plasmids, telomeric repeats of known length were present (verified in Section 
7.2.2) at a high proportion in the MinIONTM data. The MinIONTM sequencing successfully 
identified the plasmid vector and telomeric insert DNA, although these showed only moderate 
similarity to the reference sequence and few perfect tandem telomere repeats were observed. The 
telomeric inserts had a slightly better identity to the reference than the plasmid vector but the 
shorter length of the telomeric insert may have created a bias in these results.   
 
There are several possible explanations for the paucity of tandem telomere repeats observed in 
these sequencing runs. The first involves the device itself. The LASTZ analysis shows that the 
read coverage of the telomeric insert is much lower than that for the plasmid vector, which could 
be attributable to the sequencer not being able to read the repetitive repeats, and perhaps to the 
high GC content. A recent study set out to test whether MinIONTM performance was affected by 
GC content by sequencing three bacterial genomes with varying GC nucleotide compositions 
(28.6%, 50.8% and 70.7%). This report concluded that if there was any trend at all, it was that 
extreme GC content results in lower coverage [Laver et al. 2015]. That said, with a GC content of 
50%, telomeres are not markedly GC rich. However, they do contain a recurring G-triplet which 
has the propensity to form G-quadruplex structures, which will be further discussed below.  
 
It appeared that the MinIONTM had difficulty sequencing telomeric DNA located at either the 5’ 
or 3’end of the plasmids, as coverage for this region was much lower. This may relate to damage 
to full length molecules which could be more likely to happen near the ends, or this could 
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potentially have been some kind of positional effect due to poor sequencing at the beginning and 
ends of the reads. Jain et al., (2005) observed that some 50% of the low sequence depth in their 
M13 gDNA analysis on the MinIONTM was present at the beginning and end of the reference, and 
they attributed this to trimming by the Metrichor software (which is run centrally at ONT, Oxford, 
UK). One way to test this possibility would be to linearise the plasmid using a restriction enzyme 
such that the insert is located in the middle of the read, so there are no ambiguities over whether 
the low read coverage is a positional problem or due to the properties of the insert.  
 
The reduced coverage around the telomeric insert could also occur if the pores were being blocked 
in some way. Telomeric regions are known to be capable of adopting unusual DNA structures 
called G-quadruplexes, which form byHoogsteen bonding between guanine bases, and can assume 
several conformations. At the time of writing this thesis, there was some suggestive evidence that 
G-quadruplexes (G4s) could potentially stall or slow migration of DNA strands through the 
nanopore [Urban et al. 2015], which could explain why so few tandem telomeric repeats were 
evident in my data. Additionally G4s could potentially have interfered with library preparation, a 
process which has yet to be fully optimised. The pull-down products contain a single-stranded G-
rich overhang in which G4s could have formed, especially as it was unknown whether potassium 
– a cation essential for formation of G4 - was present in the buffer used for library preparation 
(not disclosed by ONT). Formation of G4 could potentially inhibit the binding of the hairpin 
adapter or motor protein, thereby contributing to poor sequencing of telomeric regions. 
 
The hypothesis that G-quadruplexes are forming and inhibiting entry or passage of telomere 
repeats through the nanopore could be further explored by trying to inhibit the secondary 
structures from forming and seeing if better sequence reads can be obtained. Deaza-dGTP 
analogues pair weakly with conventional bases and are therefore used to minimise the formation 
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of DNA secondary structures such as G4s in G-rich regions [Seela and Driller 1989, Fernandez-
Rachubinski et al. 1990, Jung et al. 2002]. PCR with 7-deaza-dGTP in place of dGTP could be 
used to generate amplicons of telomeric repeats unable to form G4 structures, and these could be 
tested on the MinIONTM. Another way to reduce potential G4 formation would be to use a running 
buffer that does not include K+, however as the reagents come from a kit of unspecified 
composition, this may not be possible. Furthermore, Urban et al., 2015 suggested that the number 
of “0 moves” in the raw MinIONTM sequence traces might be a good indicator of possible G4 
stalling within the MinIONTM sequencer, which could be further explored in our data. 
 
A final possibility to account for the poor sequence data is that the telomere repeats are present 
and being read on the MinIONTM, but when the raw data are translated into sequence using 
Metrichor software, the algorithms are not accurately calling these repetitive telomeric sequences 
[Jain et al. 2015]. MinIONTM reads can be resubmitted to Metrichor, so as the algorithms for base 
calling improve perhaps it will be worth reanalysing these sequence reads for more accurately 
called telomere repeats at a later date [Urban et al. 2015]. 
 
Not only were there few telomere repeats present in both the pull-down and plasmid reads, but 
there were even less of the complementary C-rich strand reads. Although the C-rich strand itself 
cannot form G4s, the presence of multiple G4s on either strand could conceivably interfere with 
the motor protein or inhibit entry of either single strand into the pore. To resolve this problem, an 
asymmetric PCR [Innis et al. 1988, Liu and Whittier 1995] could be used to preferentially amplify 
the C-rich strand prior to loading on the MinIONTM to establish whether C-rich repeats can be read 
when there is no interference from the G-rich strand[Innis et al. 1988, Liu and Whittier 1995]. 
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7.6.4 MinIONTM sequencing 
The version of the MinIONTM flow cells and kits used for these experiments appeared to be very 
error prone, with a significant number of substitutions and indels occurring, and large regions that 
have no homology to the reference sequence, making alignment difficult. Due to this high error 
rate an early study concluded that the device was unlikely to be of utility especially for genotyping 
applications [Mikheyev and Tin 2014], however, with the advances in sequencing chemistries 
more recent studies have found that SNVs can be called with 97-99% accuracy [Jain et al. 2015]. 
Despite the high error rate, the MinIONTM is able to generate extremely long sequence reads, with 
sequences of > 100 kb that map to the reference genome observed [Urban et al. 2015]. We were 
also able to obtain long sequence reads, although without convincing evidence of homology to 
known human sequence.  
 
The experimental nature of the MinIONTM means that the sequencing chemistry is rapidly 
evolving, with three versions of flow cell (R6, R7 and R7.3) already produced since the MAP 
programme was first established. Modifications have also been made to the library preparation 
kits as well as advances in the algorithms used for base calling [Sovic et al. 2015, Szalay and 
Golovchenko 2015]. These alterations have already resulted in improvements in the performance 
of the device in respect to throughput, accuracy and number of 2D reads generated. This is 
especially evident in the error rate of the 2D sequence reads with identity to the reference 
increasing from 8.9% in the initial study [Mikheyev and Tin 2014] to 66% with the R6 chemistry, 
70% with R7 and more recently up to 85% with R7.3 [Quick et al. 2014, Ashton et al. 2015] [Jain 
et al. 2015]. However, in our hands only an average of 50% identity for telomeric plasmid 
sequences was achieved with the R7 chemistry, although to a degree this poor identity could result 
from the nature of the sequencing template and the repeat region we were trying to sequence. Even 
though MinIONTM accuracy is increasing in regard to 2D reads, the amount of 2D reads that are 
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obtained per run is still highly variable ranging from 8% to 86% [Quick et al. 2014, Jain et al. 
2015, Laver et al. 2015, Urban et al. 2015]. The percentage of reads obtained by Quick et al., of 
86% is an outlier, where the majority of studies report values at the lower end of this range which 
are more comparable to the proportion of 2D reads we observed of 11.2% and 15.3%.  
 
The number of reads obtained from our four sequencing runs ranged from 1,595-19,160 which 
was similar to that of 16, 401 seen by Ashton et al., 2015 [Ashton et al. 2015], but much lower 
than the yield of 43,656 template reads and 23,338 complement reads (R7) and 39,819 template 
reads and 18,889 complement reads (R7.3) produced from Quick et al., 2014 [Quick et al. 2014]. 
This could be attributable to the device itself where variations in the quality of the flow cells have 
been shown to impact on the amount of sequence reads generated [Ashton et al. 2015]. Our flow 
cells did not always perform optimally, often with only a fraction of the potential 512 pores 
available for use, and for some flow cells, a sudden, catastrophic drop-off in performance after the 
first few hours of operation. This drop-off in performance has now been reported by various groups 
in the MinIONTM Access Programme, but has yet to be properly understood or explained by ONT 
(Prof. M. Kennedy, personal communication). It was noted that more sequence reads were 
generated from the plasmid libraries compared to the pull-down product, which could have been 
attributable to the variations in the flow cells used, although of our four sequencing runs, the run 
that produced the most reads was using the earlier of the chemistries (R7 instead of R7.3). 
Alternatively, it may have been because the plasmid DNA was of better quality resulting in a better 
library preparation. 
7.7 Conclusions and future directions 
The pilot work described in this chapter demonstrated that nanopore sensing holds some potential 
as an alternate approach for measuring telomere length, especially as it generated very long 
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sequence reads. The preliminary data obtained from the MinIONTM suggests that some tandem 
repeats can be read but it appears to be very error prone with few perfect telomere repeat sequences 
obtained, and considerable improvements would need to occur to achieve the goal of telomere 
repeat measurement with this device. Key research areas to enable these improvements may be 
further optimisation of the pull-down assay, advances in the sequencing chemistry and flow cells, 
and improvements in the base calling software. Future experiments ought to be carried out using 
the plasmid DNA as a model before further pursuing the pull-down approach. If the MinIONTM 
sequencer could accurately read telomere repeats, the pull-down assay could be implemented for 
high throughput using a 96 well plate format,  and multiple samples could be run together on one 
flow cell by adding index adapters during library preparation. 
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Chapter 8: General discussion 
8.1 Summary of key findings 
Telomere length is a complex trait influenced by multiple factors, and shortened TL is thought to 
be relevant to ageing and age-related disease. The principle aim of this thesis was to explore the 
impact of environmental and genetic factors on TL. Several approaches were used to achieve these 
aims. Considerable effort was put into establishing and validating a telomere length measurement 
assay, using the qPCR platform available in our institution (Lightcycler LC480, Roche). Two 
association studies were then conducted with local longitudinal cohorts that had amassed 
considerable amounts of phenotypic data, in order to thoroughly examine the impact of 
environmental factors on TL, as well as the relevance of TL to current health status. To assess the 
potential impact of rare genetic variation on TL, six subjects from the CHALICE cohort with short 
telomeres underwent whole exome sequencing analysis. Finally, attempts were made to develop 
a novel method for precisely measure telomere length, using the MinIONTM nanopore sequencer. 
8.1.1 Establishment of a qPCR telomere length assay 
In large epidemiological studies, measuring TL by qPCR is the preferred method of measurement 
as it requires less starting material than other methods, is efficient with low cost and high-
throughput. However, when establishing the MMQPCR assay on the qPCR platform available to 
us (Roche LightCycler® 480), a number of technical issues were encountered (Chapter 3). 
Platform specific problems included complexities in the extraction and analysis of the data, as well 
as significant plate position effects due to differential heating across the Peltier block which had a 
marked impact on assay variability. The MMQPCR assay design also had inherent issues, the main 
one involving sensitivity of the assay to choice of hot-start Taq polymerase. Several commercial 
hot-start polymerases were found to have residual activity prior to the activation step, and as the 
telomere-specific primers had the propensity for forming primer dimers, they were very sensitive 
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to this residual activity, thus interfering with successful quantification. Reliable data could only 
be obtained by implementing a modified form of the original Cawthon (2002) “two-plate” method, 
which was validated by comparison with TRF data. 
8.1.2 Association analyses 
The qPCR TL assay (Chapter 3) was applied to two longitudinal cohorts. The first was the CHDS 
(Chapter 4), a birth cohort that has followed participants for over 30 years, and the second was 
CHALICE (Chapter 5), a population sample of 50 year olds. For the CHDS, associations between 
TL and exposure to a wide range of life course stressors, spanning the perinatal period through to 
young adulthood, were examined. No associations between these measures and TL were evident, 
although Māori and Pacific Island participants were found to have a significantly higher average 
LTL than Europeans. For CHALICE, a different approach was taken and the aim was to evaluate 
the individual predictive power of TL as a biomarker of general health. The only significant 
association observed was between TL and gender, suggesting that TL measurements were unlikely 
to provide information of much significance to the individual.  
8.1.3 Impact of rare variants on telomere length 
The detection of highly penetrant rare variants that may influence gene function and impact on TL 
appears be restricted to the study of severe telomeropathies and relatively unexplored in healthy 
subjects from the population. The pilot study conducted in this thesis used whole exome 
sequencing to examine six subjects from the CHALICE study who had the shortest average TL of 
the cohort (Chapter 6). This limited sample size meant that it was not well powered for the de novo 
detection of rare variants and restricted the analysis to a candidate gene approach of 88 genes that 
were involved in telomere biology. The top fifteen variants arising from this analysis were then 
genotyped in the CHALICE cohort to determine if they were over-represented in individuals with 
short telomeres in the population. Two variants reached statistical significance, although they were 
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found to be very rare in this cohort and in the genome databases, with one being a singleton and 
the other only found in two individuals. These missense variants were both in very relevant genes 
(SLX4 and ATM respectively), but would need to be followed up in larger cohort and by laboratory 
studies aimed at assessing impact of the variants on gene function, before any firm conclusion 
could be drawn about their relevance to telomere length.  
 
Although the findings of this pilot study were inconclusive there is merit in continuing the search 
for rare and common variants that may impact on TL, using exome analysis in larger studies. TL 
could also be measured retrospectively in cohorts for which exome sequencing has already been 
performed.   
8.1.4 Development of a novel telomere repeat measurement assay 
There is a clear need for a method that provides a quick, easy and high-throughput way of 
accurately measuring TL. The final chapter (Chapter 7) set out to address this aim by exploring 
the use of the MinIONTM sequencing device as a novel means for accurately measuring TL from 
individual chromosomes. This device is capable of long-read sequencing at the single molecule 
level, and although currently only accessible through involvement in the MinION Access 
Programme run by Oxford Nanopore Technology (Oxford, UK), it is approaching commercial 
release. Preliminary data from the MinIONTM sequencer from both the “pull-down” assay and 
several positive control plasmids, showed that very long sequence reads can be generated with 
reads of many tens of kilobases being obtained. We found that some telomere repeats can be 
detected, but the reads generated appeared to be very error prone with few perfect telomere repeat 
sequences obtained. This pilot work demonstrated that nanopore sensing holds some potential as 
an alternate approach for measuring telomere length but further optimisation of the “pull-down” 
assay is required, and further advances in the sequencing chemistry and flow cells, and base calling 
software will be required to realise this goal.  
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8.2 Association studies and effect sizes 
Since the Nobel Prize was awarded to Elizabeth Blackburn, Carol Greider, and Jack Szostak for 
the discovery of how chromosomes were protected by telomeres and maintained by the enzyme 
telomerase, there has been a lot of excitement around the prospect of telomere length as a 
biomarker of age related morbidity and mortality. This has stimulated many association studies to 
investigate the role of telomeres in health and disease, with mixed outcomes. A key problem with 
genetic association studies, which is also evident in telomere research, is that subsequent to any 
initial primary report there is typically a high rate of non-replication with inconsistent findings 
observed following. These initial reports quite often use relatively small sample sizes and are often 
prone to false positives, and publication bias can often influence the pattern of subsequent studies 
that appear [Ioannidis 2005, Sullivan 2007, Munafo 2009]. Telomere length is a complex trait with 
a considerable amount of inter-individual variation, and it is likely that individual genetic effect 
sizes are generally small, thus requiring studies with large sample sizes for detection [Ioannidis 
2005].  
 
Recently, a number of studies with large sample sizes have found that shortened TL is associated 
with cardiovascular disease (CVD) [Haycock et al. 2014] (n = 43,725), and mortality [Rode et al. 
2015] (n = 64,637), but some have only found modest associations with CVD [Weischer et al. 
2012] (n = 19,838) or small effect sizes [Haver et al. 2015] (n = 3,275), and others have found no 
association with mortality [Weischer et al. 2014] (n = 4,576). Results from these studies are more 
likely to be trustworthy, and probably provide a better picture of the true impact of telomere length 
on human biology than the wealth of much smaller published studies. The small sample sizes in 
our studies most likely limited the power in our associations for detecting factors that impact on 
TL. That said, these smaller studies, particularly once published, can be further analysed in meta-




It is clear that some associations are real with robust associations being made with age, gender and 
ethnicity [Lapham et al. 2015], but only time will tell how many of the other putative associations 
reported are genuine. There is a need for replication of these studies with large sample numbers 
or meta-analyses to resolve these discrepancies.   
8.3 Technical aspects of the assay  
A major factor limiting the assessment of TL as a putative biomarker is the current methodology 
for measuring TL. The precise and sensitive methods that measure individual TL are labour 
intensive, technically challenging and low throughput, and thus more amenable to studies of 
telomere biology. In contrast, large epidemiological studies which require high throughput employ 
methods that provide a relatively imprecise measure of average TL in a population of cells. It is 
unknown whether cellular senescence is induced by the global decrease in TL or the presence of 
a few critically short telomeres, so it is uncertain whether epidemiological studies that measure 
average TL are even measuring the most biologically relevant aspect of the telomere. It is also 
unclear whether a ‘snapshot’ measure of TL from cross-sectional studies is sensitive enough to 
measure the effects of environmental stress, and that measures of TL erosion would provide a 
more comprehensive assessment by comparing TL before and after exposure to stress.  
 
In addition, it is uncertain whether TL is being measured in the correct tissue. The majority of 
studies utilise blood, in which the majority of DNA will be derived from leukocytes. It is assumed 
these cells will reflect the cumulative damage resulting from major determinants of ageing 
including cellular replication, inflammation and oxidative stress, as well as biological stress due 
to organ dysfunction elsewhere in the body [von Zglinicki et al. 2005, Oeseburg et al. 2010]. 
Leukocytes, however, are comprised of a heterogeneous cell population which differ in their 
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turnover rates and degree of telomere shortening, so any fluctuations in these cellular 
subpopulations could affect average TL at a given time-point [Sanders and Newman 2013]. 
Absolute TL has been shown to differ amongst tissues, but there appears to be some synchrony in 
relative TL amongst other somatic tissues from the same individual [Friedrich et al. 2000, Takubo 
et al. 2002, Daniali et al. 2013]. However, the relationship between TL in surrogate tissues and 
those affected by disease as well as the susceptibility to environmental factors affecting TL 
regulation in that specific tissues still need to be fully evaluated [Thomas et al. 2008, Gadalla et 
al. 2010, Bodelon et al. 2014].  
8.3.1 Measurement error for methods assessing average TL 
The overall correlation between the three methods that measure average TL (TRF, qPCR and 
Flow-FISH) is modest (reviewed in section 1.5.7), and there appears to be significant inter-
laboratory technical variation (10% CV for TRF and STELA and > 20% for qPCR). The majority 
of large epidemiological studies (including our own) employ the qPCR methods for TL 
measurement. Although this method is seen as the most efficient method, it tends to have the 
highest measurement error (up to 28%) and provides less consistent results across laboratories 
compared to TRF (< 12%) and STELA [Gardner et al. 2014, Haycock et al. 2014, Martin-Ruiz et 
al. 2014]. For example, some common associations, such as shorter TL amongst males, are evident 
in some qPCR studies but not others, while TRF findings are more consistent [Gardner et al. 2014]. 
This level of technical variation is found to be much larger than that observed between case and 
control groups, further reducing the statistical power of analyses. The precision and reproducibility 
of this method appears to be laboratory dependent, and failure to carry out extensive optimisation 
of this method will exacerbate this issue [Martin-Ruiz et al. 2014].  
 
Furthermore, these large measurement errors are likely to impact longitudinal measures of TL 
erosion. Only small differences in TL have been observed over time, estimated to be around 30-
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100 bp/yr of erosion [Aviv et al. 2006]. Thus, a 2% measurement error has been estimated to be 
equivalent of up to 5 years error rate in TL attrition. Therefore, if TL erosion was assessed, the 
optimal time of follow-up would need to be sufficiently long to enable the impact of environmental 
factors to outweigh those due to measurement error. 
8.3.2 qPCR assays for measuring TL 
There are many methodological differences between laboratories using the qPCR method. The 
basic protocol can be modified in several ways such as the DNA extraction method (sample 
preparation), qPCR platform, reference gene chosen, one or two plate approach, reaction 
components, cycling profiles and data analysis methods. All of these factors are likely to be 
impacting on the accuracy of measurements, and perhaps to differences observed between 
laboratories [Aubert et al. 2012]. The other methodological variations have been relatively 
unexplored, thus there is a clear need for a comprehensive assessment of the technical variation 
arising from the qPCR assays to determine if they alter the T/S ratio. Some steps have already 
been made in this direction ([Martin-Ruiz et al. 2014]. 
 
The qPCR platform has also been found to be a major source of variation in the qPCR assays due 
to the differing temperature uniformity across the block-based thermal cyclers which contribute 
to problems in quantification [Eisenberg et al. 2015]. Several platforms are available for measuring 
TL by qPCR, all of which seem to have their own inherent position effects. The LC480 appears to 
be rarely used for TL measurements, although at the time of writing this thesis, a study of 110,266 
participants was published which used this platform [Lapham et al. 2015] and the original qPCR 
method [Cawthon 2002]. Considerable technical challenges were experienced when attempting to 
establish a reliable MMQPCR method for telomere length measurement on the LC480 platform. 
We assume this was the same for the large study [Lapham et al. 2015] or they would have used 
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that assay as it is much more cost effective, allows for higher throughput and more precise 
measurement as pipetting error is not as evident.  
8.3.3 A potential new method for TL measurement 
Given the above issues, development of improved methods for TL measurement is warranted. 
With further optimisation, the pull-down assay described in this thesis could be valuable as it does 
not require a PCR step, and thus reduces biases that might arrive from PCR. Furthermore, if the 
technical issues which prevented effective reading of telomere repeats on the MinIONTM 
sequencer can be overcome, this could well offer a more precise method of TL measurement in 
various contexts, including in a relatively high throughput fashion by, for example, using indexing 
of samples to allow multiplex analysis. As a direct method of counting telomere repeats, such an 
approach could also be used to accurately calibrate other methods.  
8.4 Concluding remarks and future directions 
Telomeres have been an attractive biomarker for health and ageing since the discovery that they 
shorten with normal cell division. Over the past decade, a vast amount of information has been 
gathered to gain a better understanding of telomere biology including structural features, function, 
maintenance and regulatory mechanisms. The factors influencing TL variation and attrition rates 
have also been extensively studied as well as the impact of both rare and common variants on 
telomere maintenance and length. Shortened telomeres have also been directly implicated in 
several rare inherited progeroid diseases which have arisen from mutations that alter telomere 
biology and accelerate telomere erosion. Despite these advances in the understanding of TL 
dynamics, there are still uncertainties regarding the effect of various factors on telomere 




There are still many gaps in the literature regarding mean TL as it is likely to be a complex trait 
which is influenced by a plethora of factors. TL is highly heritable with considerable variation 
amongst individuals, but it is still unknown what the normal rate of telomere shortening is within 
and between individuals of the same and different populations. There is currently no reference 
range for mean LTL over the course of the human lifespan, and a comprehensive picture of 
telomere dynamics in different tissues/cells in both health and disease is not available. Better 
descriptions of these patterns, using more precise methods, and focusing on longitudinal studies, 
allowing multiple analyses over periods of many years, will enhance our understanding of the 
relationship between TL and the impact of environmental and genetic factors.  
 
Furthermore, the most biologically critical parameters of TL are yet to be elucidated. It is unclear, 
for example, whether measurements of the shortest telomeres, the global decrease in average TL, 
or TL erosion over time, would prove the more informative approach. Additionally, risk factors 
that accelerate TL shortening, as well as potentially protective factors, need to be more accurately 
determined. Only with a more robust understanding of these factors, coupled with more accurate 
measurement methods, will it be possible to determine whether TL is predictive of age-associated 
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Script for converting FASTQ files to VCF through the NeSI pipeline 
 
## FUNCTION: Mapping paired-end reads to generate a sorted, cleaned, realigned, and 
recalibrated BAM file, and call variants from this file 
##    INPUT: A file named SingleSampleInfo.sh defining parameters, files and tools 
##   OUTPUT: BAM and VCF files and their index files; will be named 
ANYNAME.ba[m|i] and ANYNAME.vcf[.idx], and intermediate files 
## 
##   AUTHOR: Klaus 
## MODIFIER: Klaus 
##  VERSION: 12 
##     DATE: 03-09-2013 
## MOD_DATE: 06-05-2014 
# 
#  LL STEPS 0: FCHK1 check all required files 
#           1: ALN01 align fastq reads '1' (bwa aln) 
#           2: ALN02 align fastq reads '2' (bwa aln) 
#           3: SAMPE merge alignments (bwa sampe) 
#           4: S2BAM convert SAM -> BAM (samtools view) 
#           5: COMPR gzip SAM file 
#           6: SORT1 sort BAM (samtools sort), index BAM (samtools index) and get stats 
(samtools flagstat and idxstats) 
#           7: CLEAN clean BAM (picard CleanSam) 
#           8: FXMP1 fix mate pair (picard FixMateInformation) 
#           9: PMDU1 mark duplicates (picard MarkDuplicates); get stats (samtools flagstat and 
idxstats) 
#          10: RALNA realign around known indels (GATK RealignerTargetCreator) 
#          11: RALNB realign around known indels (GATK Indelrealigner) 
#          12: FXMP2 fix mate pair (picard FixMateInformation) 
#          13: PMDU2 mark duplicates (picard MarkDuplicates) 
#          14: BQSRA recalibrate base quality  
#          15: BQSRB recalibrate base quality  
#          16: BQSRC recalibrate base quality and print reads to BAM file 
#          17: HCALL call variants from BAM file 














DNA preparation and next-generation sequencing  
Genomic DNA (gDNA) was submitted to Otogenetics Corporation (Norcross, GA USA) for 
exome capture and sequencing. Briefly, gDNA was subjected to agarose gel and OD ratio tests 
to confirm the purity and concentration prior to Bioruptor (Diagenode, Inc., Denville, NJ USA) 
fragmentation. Fragmented gDNAs were tested for size distribution and concentration using 
an Agilent Tapestation 2200 and Nanodrop. Illumina libraries were made from qualified 
fragmented gDNA using SPRIworks HT Reagent Kit (Beckman Coulter, Inc. Indianapolis, IN 
USA, catalog# B06938) and the resulting libraries were subjected to exome enrichment using 
Agilent SureSelect AV5 (Agilent Technologies, Wilmington, DE USA, catalog# 5190-6213) 
following manufacturer’s instructions. Enriched libraries were tested for enrichment by qPCR 
and for size distribution and concentration by an Agilent Bioanalyzer 2100. The samples were 
then sequenced Illumina HiSeq 2000, using HighOutput v3 chemistry which generated paired-
end reads of 101 nucleotides (nt). Data was analyzed for data quality using FASTQC 
(Babraham Institute, Cambridge, UK). 



















Mapped reads 28,438,093  96.63% 14,470,513  98.33% 13,967,580  94.92%
mapped confidently 27,933,058  94.91% 14,214,509  96.59% 13,718,549  93.22%
mapped repetitively 505,035   1.72% 256,004   1.74% 249,031   1.69%
Reads not mapped 993,127   3.37% 245,097   1.67% 748,030   5.08%
no mapping 119,488   0.41% 61,061   0.41% 58,427   0.40%
low quality 765,060   2.60% 126,811   0.86% 638,249   4.34%
ribosomal RNA 11,769   0.04% 6,129   0.04% 5,640   0.04%
primer 21   0.00% 1   0.00% 20   0.00%
control (phiX-174) 96,463   0.33% 50,966   0.35% 45,497   0.31%
poly-A 129   0.00% 113   0.00% 16   0.00%
poly-C 141   0.00% 4   0.00% 137   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 56   0.00% 12   0.00% 44   0.00%
Total reads 29,431,220 100.00% 14,715,610 100.00% 14,715,610 100.00%









Mapped reads 30,284,102  96.87% 15,397,780  98.50% 14,886,322  95.23%
mapped confidently 29,772,725  95.23% 15,138,549  96.84% 14,634,176  93.62%
mapped repetitively 511,377   1.64% 259,231   1.66% 252,146   1.61%
Reads not mapped 980,112   3.13% 234,327   1.50% 745,785   4.77%
no mapping 106,488   0.34% 54,423   0.35% 52,065   0.33%
low quality 771,658   2.47% 125,808   0.80% 645,850   4.13%
ribosomal RNA 7,186   0.02% 3,711   0.02% 3,475   0.02%
primer 23   0.00% 2   0.00% 21   0.00%
control (phiX-174) 93,366   0.30% 49,495   0.32% 43,871   0.28%
poly-A 885   0.00% 868   0.01% 17   0.00%
poly-C 117   0.00% 4   0.00% 113   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 389   0.00% 16   0.00% 373   0.00%
Total reads 31,264,214 100.00% 15,632,107 100.00% 15,632,107 100.00%
















Mapped reads 31,768,492  96.75% 16,140,255  98.31% 15,628,237  95.19%
mapped confidently 31,195,486  95.01% 15,849,530  96.54% 15,345,956  93.47%
mapped repetitively 573,006   1.75% 290,725   1.77% 282,281   1.72%
Reads not mapped 1,066,338   3.25% 277,160   1.69% 789,178   4.81%
no mapping 154,318   0.47% 79,120   0.48% 75,198   0.46%
low quality 799,390   2.43% 138,205   0.84% 661,185   4.03%
ribosomal RNA 12,861   0.04% 6,655   0.04% 6,206   0.04%
primer 18   0.00% 1   0.00% 17   0.00%
control (phiX-174) 99,142   0.30% 52,869   0.32% 46,273   0.28%
poly-A 287   0.00% 264   0.00% 23   0.00%
poly-C 131   0.00% 7   0.00% 124   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 191   0.00% 39   0.00% 152   0.00%
Total reads 32,834,830 100.00% 16,417,415 100.00% 16,417,415 100.00%









Mapped reads 37,523,112  96.54% 19,067,568  98.12% 18,455,544  94.97%
mapped confidently 36,792,831  94.67% 18,697,792  96.22% 18,095,039  93.11%
mapped repetitively 730,281   1.88% 369,776   1.90% 360,505   1.86%
Reads not mapped 1,343,158   3.46% 365,567   1.88% 977,591   5.03%
no mapping 239,698   0.62% 122,190   0.63% 117,508   0.60%
low quality 959,049   2.47% 167,133   0.86% 791,916   4.08%
ribosomal RNA 17,198   0.04% 8,875   0.05% 8,323   0.04%
primer 49   0.00% 5   0.00% 44   0.00%
control (phiX-174) 126,445   0.33% 67,028   0.34% 59,417   0.31%
poly-A 337   0.00% 320   0.00% 17   0.00%
poly-C 201   0.00% 5   0.00% 196   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 181   0.00% 11   0.00% 170   0.00%
Total reads 38,866,270 100.00% 19,433,135 100.00% 19,433,135 100.00%














Mapped reads 39,524,407  95.58% 19,969,307  96.58% 19,555,100  94.57%
mapped confidently 38,752,608  93.71% 19,581,025  94.70% 19,171,583  92.72%
mapped repetitively 771,799   1.87% 388,282   1.88% 383,517   1.85%
Reads not mapped 1,829,547   4.42% 707,670   3.42% 1,121,877   5.43%
no mapping 585,440   1.42% 348,708   1.69% 236,732   1.14%
low quality 1,134,622   2.74% 323,922   1.57% 810,700   3.92%
ribosomal RNA 15,546   0.04% 7,814   0.04% 7,732   0.04%
primer 41,804   0.10% 5   0.00% 41,799   0.20%
control (phiX-174) 52,109   0.13% 27,209   0.13% 24,900   0.12%
poly-A 16   0.00% 11   0.00% 5   0.00%
poly-C 2   0.00% 0   0.00% 2   0.00%
poly-G 1   0.00% 0   0.00% 1   0.00%
poly-T 7   0.00% 1   0.00% 6   0.00%
Total reads 41,353,954 100.00% 20,676,977 100.00% 20,676,977 100.00%









Mapped reads 38,209,444  96.15% 19,303,321  97.15% 18,906,123  95.15%
mapped confidently 37,449,853  94.24% 18,920,964  95.22% 18,528,889  93.25%
mapped repetitively 759,591   1.91% 382,357   1.92% 377,234   1.90%
Reads not mapped 1,531,444   3.85% 567,123   2.85% 964,321   4.85%
no mapping 408,977   1.03% 250,661   1.26% 158,316   0.80%
low quality 1,037,632   2.61% 286,828   1.44% 750,804   3.78%
ribosomal RNA 8,386   0.02% 4,245   0.02% 4,141   0.02%
primer 27,729   0.07% 0   0.00% 27,729   0.14%
control (phiX-174) 48,707   0.12% 25,385   0.13% 23,322   0.12%
poly-A 6   0.00% 3   0.00% 3   0.00%
poly-C 1   0.00% 1   0.00% 0   0.00%
poly-G 0   0.00% 0   0.00% 0   0.00%
poly-T 6   0.00% 0   0.00% 6   0.00%
Total reads 39,740,888 100.00% 19,870,444 100.00% 19,870,444 100.00%






Plasmid sequences from Addgene 
 
50494: f. pRST1 sequence 


























































53210: pBB sequence 

















































12403: pSXneo 270(T2AG3) 
 
GaaccaCCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
272 
 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA CCCTAA 
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